{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import os\n",
    "os.chdir(\"..\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "\"\"\"\n",
    "Iterate over the PubMED articles that mention infecious diseases from the\n",
    "disease ontology.\n",
    "\"\"\"\n",
    "import rdflib\n",
    "from pylru import lrudecorator\n",
    "import pubcrawler.article as pubcrawler\n",
    "from annotator.keyword_annotator import KeywordAnnotator\n",
    "from annotator.annotator import AnnoDoc\n",
    "import re\n",
    "import json\n",
    "import pymongo"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading disease ontology...\n",
      "disease ontology loaded\n"
     ]
    }
   ],
   "source": [
    "print(\"Loading disease ontology...\")\n",
    "disease_ontology = rdflib.Graph()\n",
    "disease_ontology.parse(\n",
    "    \"http://purl.obolibrary.org/obo/doid.owl\",\n",
    "    format=\"xml\"\n",
    ")\n",
    "print(\"disease ontology loaded\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Graph identifier=Nbda20d900ed74f759fe6397bf8111869 (<class 'rdflib.graph.Graph'>)>"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "disease_ontology"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def get_annotation_keywords():\n",
    "    qres = disease_ontology.query(\"\"\"\n",
    "    prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\n",
    "    prefix obo: <http://purl.obolibrary.org/obo/>\n",
    "    prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "    SELECT ?entity ?label\n",
    "    WHERE {\n",
    "        # only resolve diseases by infectious agent\n",
    "        ?entity rdfs:subClassOf* obo:DOID_0050117\n",
    "        ; oboInOwl:hasNarrowSynonym|oboInOwl:hasRelatedSynonym|oboInOwl:hasExactSynonym|rdfs:label ?label\n",
    "    }\n",
    "    \"\"\")\n",
    "    def remove_parenthetical_notes(label):\n",
    "        label = re.sub(r\"\\s\\(.*\\)\",\"\", label)\n",
    "        label = re.sub(r\"\\s\\[.*\\]\",\"\", label)\n",
    "        assert(len(label) > 0)\n",
    "        return label\n",
    "    return list(set([remove_parenthetical_notes(str(r[1])) for r in qres]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "with open(\"annotation_keywords\", \"w+\") as f:\n",
    "    for item in get_annotation_keywords():\n",
    "        f.write(\"{}\\n\".format(item))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def str_escape(s):\n",
    "    return json.dumps(s)[1:-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "@lrudecorator(500)\n",
    "def resolve_keyword(keyword):\n",
    "    query = \"\"\"\n",
    "    prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\n",
    "    prefix obo: <http://purl.obolibrary.org/obo/>\n",
    "    prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "    SELECT ?entity\n",
    "    WHERE {\n",
    "        # only resolve diseases by infectious agent\n",
    "        ?entity rdfs:subClassOf* obo:DOID_0050117\n",
    "        ; oboInOwl:hasNarrowSynonym|oboInOwl:hasRelatedSynonym|oboInOwl:hasExactSynonym|rdfs:label ?label\n",
    "        FILTER regex(?label, \"^(\"\"\" + str_escape(re.escape(keyword)) + str_escape(\"(\\s[\\[\\(].*[\\]\\)])*\") + \"\"\")$\", \"i\")\n",
    "    }\n",
    "    \"\"\"\n",
    "    qres = list(disease_ontology.query(query))\n",
    "    if len(qres) == 0:\n",
    "        print(\"no match for\", keyword.encode('ascii', 'xmlcharrefreplace'))\n",
    "    elif len(qres) > 1:\n",
    "        print(\"multiple matches for\", keyword.encode('ascii', 'xmlcharrefreplace'))\n",
    "        print(qres)\n",
    "    return qres"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(rdflib.term.URIRef('http://purl.obolibrary.org/obo/DOID_4325'))]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resolve_keyword(\"ebola virus disease\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def iterate_infectious_disease_articles(collection, update_collection = False, no_reannotation = False):\n",
    "    keyword_annotator = KeywordAnnotator(keywords=get_annotation_keywords())\n",
    "    total_article_count = 0\n",
    "    article_with_body_count = 0\n",
    "    infectious_disease_article_count = 0\n",
    "    query = {}\n",
    "    if no_reannotation == False:\n",
    "        query = {\n",
    "            \"articles.\"\n",
    "        }\n",
    "    for article in collection.find():\n",
    "        total_article_count += 1\n",
    "        pc_article = pubcrawler.Article(article)\n",
    "        if pc_article.article_type() == \"research-article\":\n",
    "            body = pc_article.get_text_from_tags('body')\n",
    "            if len(body) > 0:\n",
    "                article_with_body_count += 1\n",
    "                anno_doc = AnnoDoc(body)\n",
    "                anno_doc.add_tier(keyword_annotator)\n",
    "                infectious_diseases = [\n",
    "                    (disease.text, resolve_keyword(disease.text))\n",
    "                    for disease in anno_doc.tiers['keywords'].spans\n",
    "                ]\n",
    "                if len(infectious_diseases) > 0:\n",
    "                    infectious_disease_article_count += 1\n",
    "                    #print(infectious_disease_article_count, \"/\", total_article_count, \",\", article_with_body_count)\n",
    "                    yield article, infectious_diseases"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "db = pymongo.MongoClient('localhost')['pmc']\n",
    "articles = db.articlesubset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 388,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "cursor = articles.find({'meta': {'$exists': False}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 389,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "9966"
      ]
     },
     "execution_count": 389,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cursor.count()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 387,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'_id': 'Clin_Med_Insights_Cardiol_2015_Apr_19_8(Suppl_3)_49-59',\n",
       " 'annotations': {'disease-ontology-keywords': None},\n",
       " 'meta': {'article-ids': {'doi': '10.4137/CMC.S17068',\n",
       "   'pmc': '4405090',\n",
       "   'pmid': '25983559',\n",
       "   'publisher-id': 'cmc-suppl_3-2014-049'},\n",
       "  'article-type': 'review-article',\n",
       "  'keywords': ['myocarditis',\n",
       "   'myocardial infarct',\n",
       "   'inflammasome',\n",
       "   'macrophages',\n",
       "   'autoantibodies',\n",
       "   'sex hormones']},\n",
       " 'nxml': '<!DOCTYPE article PUBLIC \"-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN\" \"JATS-archivearticle1.dtd\">\\n<article xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" article-type=\"review-article\"><?properties open_access?><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">Clin Med Insights Cardiol</journal-id><journal-id journal-id-type=\"iso-abbrev\">Clin Med Insights Cardiol</journal-id><journal-id journal-id-type=\"publisher-id\">Clinical Medicine Insights: Cardiology</journal-id><journal-title-group><journal-title>Clinical Medicine Insights. Cardiology</journal-title></journal-title-group><issn pub-type=\"epub\">1179-5468</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmid\">25983559</article-id><article-id pub-id-type=\"pmc\">4405090</article-id><article-id pub-id-type=\"doi\">10.4137/CMC.S17068</article-id><article-id pub-id-type=\"publisher-id\">cmc-suppl_3-2014-049</article-id><article-categories><subj-group subj-group-type=\"heading\"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Sex Differences in Inflammation During Atherosclerosis</article-title></title-group><contrib-group><contrib contrib-type=\"author\"><name><surname>Fairweather</surname><given-names>DeLisa</given-names></name><xref ref-type=\"corresp\" rid=\"c1-cmc-suppl_3-2014-049\"/></contrib><aff id=\"af1-cmc-suppl_3-2014-049\">Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</aff></contrib-group><author-notes><corresp id=\"c1-cmc-suppl_3-2014-049\">CORRESPONDENCE: <email>dfairweather@jhu.edu</email></corresp></author-notes><pub-date pub-type=\"collection\"><year>2014</year></pub-date><pub-date pub-type=\"epub\"><day>19</day><month>4</month><year>2015</year></pub-date><volume>8</volume><issue>Suppl 3</issue><fpage>49</fpage><lpage>59</lpage><history><date date-type=\"received\"><day>03</day><month>12</month><year>2014</year></date><date date-type=\"rev-recd\"><day>02</day><month>2</month><year>2015</year></date><date date-type=\"accepted\"><day>09</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2014 the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type=\"open-access\"><license-p>This is an open access article published under the Creative Commons CC-BY-NC 3.0 License.</license-p></license></permissions><abstract><p>Atherosclerosis is the leading cause of death in the United States and worldwide, yet more men die from atherosclerosis than women, and at a younger age. Women, on the other hand, mainly develop atherosclerosis following menopause, and particularly if they have one or more autoimmune diseases, suggesting that the immune mechanisms that increase disease in men are different from those in women. The key processes in the pathogenesis of atherosclerosis are vascular inflammation, lipid accumulation, intimal thickening and fibrosis, remodeling, and plaque rupture or erosion leading to myocardial infarction and ischemia. Evidence indicates that sex hormones alter the immune response during atherosclerosis, resulting in different disease phenotypes according to sex. Women, for example, respond to infection and damage with increased antibody and autoantibody responses, while men have elevated innate immune activation. This review describes current knowledge regarding sex differences in the inflammatory immune response during atherosclerosis. Understanding sex differences is critical for improving individualized medicine.</p></abstract><kwd-group><kwd>myocarditis</kwd><kwd>myocardial infarct</kwd><kwd>inflammasome</kwd><kwd>macrophages</kwd><kwd>autoantibodies</kwd><kwd>sex hormones</kwd></kwd-group></article-meta></front><body><sec sec-type=\"intro\"><title>Introduction</title><p>Atherosclerosis is characterized by a buildup of atheromas or fibrofatty plaques in large-to-medium-sized cardiac arteries that may rupture or erode and compromise blood flow to the heart (and other organs), resulting in ischemic heart disease (IHD). The key processes in the pathogenesis of atherosclerosis are vascular inflammation, lipid accumulation, intimal thickening and fibrosis, arterial stiffness, remodeling, and plaque rupture (or erosion), leading to myocardial infarction (MI) and ischemia. Pathology progresses silently for many years or decades before clinical disease becomes apparent. The major consequences of atherosclerosis are MI (a heart attack), cerebral infarction (stroke), aortic aneurysms, and peripheral artery disease. Atherosclerosis is the leading cause of death in men and women in the United States and worldwide.<xref rid=\"b1-cmc-suppl_3-2014-049\" ref-type=\"bibr\">1</xref>,<xref rid=\"b2-cmc-suppl_3-2014-049\" ref-type=\"bibr\">2</xref> Yet more men die from atherosclerosis or coronary artery disease (CAD) than women and at a younger age (40&#x02013;60 years of age).<xref rid=\"b2-cmc-suppl_3-2014-049\" ref-type=\"bibr\">2</xref>&#x02013;<xref rid=\"b4-cmc-suppl_3-2014-049\" ref-type=\"bibr\">4</xref> Women, on the other hand, mainly develop atherosclerosis following menopause, resulting in more women &#x0201c;living&#x0201d; with atherosclerosis than men.<xref rid=\"b5-cmc-suppl_3-2014-049\" ref-type=\"bibr\">5</xref>,<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref> Although women are much less likely to develop atherosclerosis than men, women with an autoimmune disease are at an increased risk of developing CAD.<xref rid=\"b7-cmc-suppl_3-2014-049\" ref-type=\"bibr\">7</xref> Atherosclerosis in women is strongly associated with hypertension, or high blood pressure, and certain autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis,<xref rid=\"b2-cmc-suppl_3-2014-049\" ref-type=\"bibr\">2</xref>,<xref rid=\"b7-cmc-suppl_3-2014-049\" ref-type=\"bibr\">7</xref>,<xref rid=\"b8-cmc-suppl_3-2014-049\" ref-type=\"bibr\">8</xref> suggesting that the immune mechanisms that lead to CAD in men are different from those in women.</p><p>Women are reported to have higher death rates following MI than men.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b9-cmc-suppl_3-2014-049\" ref-type=\"bibr\">9</xref> This higher death rate is due, at least in part, to reasons that are not directly associated with the pathogenesis of atherosclerosis and include more complications following surgery in women,<xref rid=\"b10-cmc-suppl_3-2014-049\" ref-type=\"bibr\">10</xref>,<xref rid=\"b11-cmc-suppl_3-2014-049\" ref-type=\"bibr\">11</xref> drugs that are more effective in men but may not be as effective or have unexpected side effects in women,<xref rid=\"b5-cmc-suppl_3-2014-049\" ref-type=\"bibr\">5</xref>,<xref rid=\"b12-cmc-suppl_3-2014-049\" ref-type=\"bibr\">12</xref> and vascular assist devices (VAD) that may &#x0201c;fit&#x0201d; the chest cavity of men better than women and cause fewer side effects in men.<xref rid=\"b13-cmc-suppl_3-2014-049\" ref-type=\"bibr\">13</xref>,<xref rid=\"b14-cmc-suppl_3-2014-049\" ref-type=\"bibr\">14</xref> Another reason why women die more frequently following MI may be due to misdiagnosis of atherosclerosis and a correspondingly later treatment in women.<xref rid=\"b15-cmc-suppl_3-2014-049\" ref-type=\"bibr\">15</xref> A number of studies confirm that women and men differ in their reported symptoms of CAD.<xref rid=\"b16-cmc-suppl_3-2014-049\" ref-type=\"bibr\">16</xref>,<xref rid=\"b17-cmc-suppl_3-2014-049\" ref-type=\"bibr\">17</xref> Although chest pain is a good predictor of obstructive CAD in men, it is not in women.<xref rid=\"b15-cmc-suppl_3-2014-049\" ref-type=\"bibr\">15</xref>,<xref rid=\"b18-cmc-suppl_3-2014-049\" ref-type=\"bibr\">18</xref> Additionally, atherosclerosis occurs more often in women with apparently &#x0201c;normal&#x0201d; or nonoccluded coronary arteries.<xref rid=\"b3-cmc-suppl_3-2014-049\" ref-type=\"bibr\">3</xref>,<xref rid=\"b19-cmc-suppl_3-2014-049\" ref-type=\"bibr\">19</xref>&#x02013;<xref rid=\"b22-cmc-suppl_3-2014-049\" ref-type=\"bibr\">22</xref> Since atherosclerosis, plaque rupture or erosion, and MI are inflammatory processes, these observations suggest that key differences exist in the inflammatory infiltrate between men and women with CAD. This review highlights current knowledge on sex differences in cardiac inflammation during inflammatory cardiovascular diseases (CVDs) like atherosclerosis.</p></sec><sec><title>Inflammation and Atherosclerosis</title><p>The key processes in the pathogenesis of atherosclerosis are vascular inflammation, lipid accumulation, intimal thickening and fibrosis, remodeling, and plaque rupture or erosion, leading to MI and ischemia.<xref rid=\"b23-cmc-suppl_3-2014-049\" ref-type=\"bibr\">23</xref> Most of our understanding on the role of inflammation in atherosclerosis comes from animal models.<xref rid=\"b24-cmc-suppl_3-2014-049\" ref-type=\"bibr\">24</xref> A number of recent reviews describe the role of inflammatory mediators in the pathogenesis of atherosclerosis.<xref rid=\"b25-cmc-suppl_3-2014-049\" ref-type=\"bibr\">25</xref>&#x02013;<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref> The atherosclerotic plaque is located within the lining of vessel walls and consists primarily of macrophages, mast cells (MCs), T cells, B cells, and dendritic cells (DCs) (<xref ref-type=\"fig\" rid=\"f1-cmc-suppl_3-2014-049\">Fig. 1</xref>). Plaques develop a necrotic core of lipids and a fibrous cap of smooth muscle cells and collagen. In advanced stages of disease, immune cells may also accumulate on the lumen side of the plaque, disrupting blood flow. Elevated levels of circulating cholesterol and apolipoprotein B (ApoB) undergo oxidative modifications to form oxidized low-density lipoprotein (oxLDL) that is internalized by macrophage scavenger receptors to create macrophage foam cells within plaques.<xref rid=\"b31-cmc-suppl_3-2014-049\" ref-type=\"bibr\">31</xref> Most foam cells arise from mononuclear phagocytic cells, but vascular endothelial cells and smooth muscle cells can also contain lipids.<xref rid=\"b25-cmc-suppl_3-2014-049\" ref-type=\"bibr\">25</xref>,<xref rid=\"b32-cmc-suppl_3-2014-049\" ref-type=\"bibr\">32</xref>,<xref rid=\"b33-cmc-suppl_3-2014-049\" ref-type=\"bibr\">33</xref> Internalization of oxLDL results in the formation of cholesterol crystals that activate the inflammasome, leading to secretion of mediators including interleukin (IL)-1, IL-6, IL-18, chemokines, eicosanoids, proteinases, and oxidases that promote plaque inflammation, fibrosis, and remodeling.<xref rid=\"b23-cmc-suppl_3-2014-049\" ref-type=\"bibr\">23</xref>,<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b34-cmc-suppl_3-2014-049\" ref-type=\"bibr\">34</xref> The inflammasome is part of the body&#x02019;s innate pathogen pattern recognition system, which includes nucleotide binding oligomerization domain (NOD)-like receptors and Toll-like receptors (TLRs). TLR4 activation by certain bacteria, viruses, and other agents like cholesterol crystals increases pro-IL-1&#x003b2; and pro-IL-18 levels, which are cleaved by the inflammasome component caspase-1 to the active form of IL-1&#x003b2; and IL&#x02212;18. MCs and macrophages are key immune sites of inflammasome activation.</p><p>Activation of TLR2, TLR4, MyD88, and the inflammasome (ie, NALP3) leads to NF&#x003ba;B activation and the production of IL-1&#x003b2; and IL-18, two proinflammatory cytokines important in the pathogenesis of atherosclerosis.<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b35-cmc-suppl_3-2014-049\" ref-type=\"bibr\">35</xref> Deletion of either of these cytokines in mouse models of atherosclerosis significantly reduces disease. CD4<sup>+</sup> T helper (Th)1-type responses involving IL-18 and interferon (IFN)&#x003b3; increase inflammation in plaques, and both CD4<sup>+</sup> and CD8<sup>+</sup> T cells are present in atherosclerotic plaques of patients.<xref rid=\"b27-cmc-suppl_3-2014-049\" ref-type=\"bibr\">27</xref>&#x02013;<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref> CD8<sup>+</sup> T cells are usually associated with Th1-type immune responses. IL-18 is a strong inducer of IFN&#x003b3; and drives Th1 responses, and so it should be kept in mind that a dominant Th1 response in atherosclerosis could be due to inflammasome activation in addition to the classic IL-12/STAT4-induced IFN&#x003b3; pathway. Contradictory results have been found in animal models regarding the role of Th2 (ie, IL-4, IL-33) and Th17 responses in disease pathogenesis.<xref rid=\"b23-cmc-suppl_3-2014-049\" ref-type=\"bibr\">23</xref>,<xref rid=\"b36-cmc-suppl_3-2014-049\" ref-type=\"bibr\">36</xref> For example, atherosclerosis is promoted in animal models by MCs, eosinophils, and/or IgE responses that require a Th2-type immune response, IL-4 and/or IL-33.<xref rid=\"b37-cmc-suppl_3-2014-049\" ref-type=\"bibr\">37</xref>&#x02013;<xref rid=\"b39-cmc-suppl_3-2014-049\" ref-type=\"bibr\">39</xref> In contrast, injection of mice with IL-13 or helminth antigens to induce a Th2-type immune response associated with alternatively activated M2 macrophages (ie, M2a) reduces atherosclerosis.<xref rid=\"b40-cmc-suppl_3-2014-049\" ref-type=\"bibr\">40</xref>,<xref rid=\"b41-cmc-suppl_3-2014-049\" ref-type=\"bibr\">41</xref></p><sec><title>Macrophages</title><p>Macrophages are the dominant infiltrate within the atherosclerotic plaque and follow a similar nomenclature as Th cells with M1 being driven by Th1- associated cytokines and M2 driven by Th2-associated cytokines.<xref rid=\"b26-cmc-suppl_3-2014-049\" ref-type=\"bibr\">26</xref>,<xref rid=\"b29-cmc-suppl_3-2014-049\" ref-type=\"bibr\">29</xref>,<xref rid=\"b42-cmc-suppl_3-2014-049\" ref-type=\"bibr\">42</xref> Similar to Th cells, in a typical immune response, macrophages shift from M1 to M2 during an acute response in order to regulate inflammation.<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref> Importantly, a number of M2 phenotypes have been identified (ie, M2a, M2b, M2c, M2d, M4) that can be anti-inflammatory (ie, M2a, M2c) or may promote remodeling and fibrosis (ie, M2b).<xref rid=\"b29-cmc-suppl_3-2014-049\" ref-type=\"bibr\">29</xref>,<xref rid=\"b42-cmc-suppl_3-2014-049\" ref-type=\"bibr\">42</xref> Although M1 macrophages are an important component of atherosclerotic plaques in mice and humans, it is important to realize that IFNs and Th1-type immune responses strongly inhibit fibrosis and remodeling by transcriptionally downregulating profibrotic cytokines like IL-4 and transforming growth factor (TGF)&#x003b2;<sub>1</sub> via STAT1.<xref rid=\"b43-cmc-suppl_3-2014-049\" ref-type=\"bibr\">43</xref>,<xref rid=\"b44-cmc-suppl_3-2014-049\" ref-type=\"bibr\">44</xref> Additionally, TLR3, TLR7, and TLR9 signaling, which drive dominant Th1 responses following infection, has been found to decrease atherosclerosis in animal models.<xref rid=\"b45-cmc-suppl_3-2014-049\" ref-type=\"bibr\">45</xref> This means that although M1 macrophages are associated with elevated inflammation they may additionally protect against plaque remodeling, rupture, and MI. Of all of the M2 subtypes, M2b are most closely associated with IFN&#x003b3;/Th1 responses because they express TLR2 and TLR4 and activate the inflammasome releasing IL-18, which elevates IFN&#x003b3; and Th1 responses.<xref rid=\"b29-cmc-suppl_3-2014-049\" ref-type=\"bibr\">29</xref>,<xref rid=\"b42-cmc-suppl_3-2014-049\" ref-type=\"bibr\">42</xref> Thus, macrophage subtypes that express TLR2 and/or TLR4 (ie, M2b) promote remodeling and increase the risk for MI by releasing profibrotic mediators like IL-1&#x003b2; and TGF&#x003b2;<sub>1</sub>. IL-10, which is released from M2 and regulatory T-cell populations, inhibits inflammation but promotes foam cell formation and so its role in atherosclerosis remains somewhat ambiguous although most evidence from animal models suggests that IL-10 protects against atherosclerosis by reducing inflammation.<xref rid=\"b46-cmc-suppl_3-2014-049\" ref-type=\"bibr\">46</xref></p></sec><sec><title>Mast cells</title><p>Mast cells are found in atherosclerotic plaques and increase in number and degranulation at sites of plaque rupture.<xref rid=\"b47-cmc-suppl_3-2014-049\" ref-type=\"bibr\">47</xref>&#x02013;<xref rid=\"b50-cmc-suppl_3-2014-049\" ref-type=\"bibr\">50</xref> Degranulating MCs release profibrotic and prothrombotic factors associated with plaque rupture, thrombosis, and MI such as chymase, tryptase, IL-1&#x003b2;, TGF&#x003b2;<sub>1</sub>, and matrix metalloproteinases (MMPs).<xref rid=\"b38-cmc-suppl_3-2014-049\" ref-type=\"bibr\">38</xref>,<xref rid=\"b44-cmc-suppl_3-2014-049\" ref-type=\"bibr\">44</xref>,<xref rid=\"b51-cmc-suppl_3-2014-049\" ref-type=\"bibr\">51</xref>&#x02013;<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref> MC-deficient mice have been found to have reduced atherosclerosis in animal models, suggesting that MCs promote CAD.<xref rid=\"b37-cmc-suppl_3-2014-049\" ref-type=\"bibr\">37</xref>,<xref rid=\"b38-cmc-suppl_3-2014-049\" ref-type=\"bibr\">38</xref></p><p>Not only do MCs contribute to atherosclerosis by releasing mediators that increase inflammation, promote remodeling, and increase the risk for plaque rupture but they have also been found to release renin and activate the local renin&#x02013;angiotensin system (RAS).<xref rid=\"b54-cmc-suppl_3-2014-049\" ref-type=\"bibr\">54</xref> Circulating levels of angiotensinogen, released to the bloodstream from the kidneys, is converted to biologically inactive angiotensin I (AngI) by the protease renin that is released from the liver and then activated to produce AngII by angiotensin-converting enzyme (ACE) located locally on the vascular endothelium.<xref rid=\"b55-cmc-suppl_3-2014-049\" ref-type=\"bibr\">55</xref> Circulating AngII via its receptors regulates blood pressure, plasma volume, and sympathetic neural activity and increases atherosclerotic plaque instability by altering MMPs among other roles.<xref rid=\"b54-cmc-suppl_3-2014-049\" ref-type=\"bibr\">54</xref>,<xref rid=\"b56-cmc-suppl_3-2014-049\" ref-type=\"bibr\">56</xref>,<xref rid=\"b57-cmc-suppl_3-2014-049\" ref-type=\"bibr\">57</xref> Renin, the rate-limiting step in the RAS, is also produced locally within the heart by cardiac myocytes, fibroblasts, endothelial cells, and MCs.<xref rid=\"b54-cmc-suppl_3-2014-049\" ref-type=\"bibr\">54</xref>,<xref rid=\"b58-cmc-suppl_3-2014-049\" ref-type=\"bibr\">58</xref>&#x02013;<xref rid=\"b60-cmc-suppl_3-2014-049\" ref-type=\"bibr\">60</xref> Mast cells also release chymase and cathepsin-D, which are able to activate AngII.<xref rid=\"b54-cmc-suppl_3-2014-049\" ref-type=\"bibr\">54</xref> Locally released AngII contributes to arrhythmias and acute heart failure by promoting norepinephrine release from cardiac sympathetic nerves. Blocking renin release from MCs using inhibitors or knockout mice decreases arrhythmias in animal models,<xref rid=\"b61-cmc-suppl_3-2014-049\" ref-type=\"bibr\">61</xref>,<xref rid=\"b62-cmc-suppl_3-2014-049\" ref-type=\"bibr\">62</xref> suggesting that MCs play an important role in RAS-mediated promotion of atherosclerosis and heart failure. Thus, MCs are key immune cells capable of promoting multiple stages of the pathogenesis of atherosclerosis that lead to MI and heart failure.</p></sec><sec><title>T cells</title><p>As mentioned previously, atherosclerotic plaques of patients contain T cells.<xref rid=\"b33-cmc-suppl_3-2014-049\" ref-type=\"bibr\">33</xref> In mouse models and patients, CD4<sup>+</sup> T cells predominate over CD8<sup>+</sup> T cells and display a dominant Th1-type immune phenotype.<xref rid=\"b47-cmc-suppl_3-2014-049\" ref-type=\"bibr\">47</xref> Th1- and Th17-type responses have been found to increase atherosclerotic inflammation in animal models.<xref rid=\"b36-cmc-suppl_3-2014-049\" ref-type=\"bibr\">36</xref>,<xref rid=\"b41-cmc-suppl_3-2014-049\" ref-type=\"bibr\">41</xref>,<xref rid=\"b63-cmc-suppl_3-2014-049\" ref-type=\"bibr\">63</xref>,<xref rid=\"b64-cmc-suppl_3-2014-049\" ref-type=\"bibr\">64</xref> In contrast, a Th2-type immune response has been found to reduce atherosclerosis.<xref rid=\"b40-cmc-suppl_3-2014-049\" ref-type=\"bibr\">40</xref> Similar to M2 macrophages, regulatory T cells that release IL-10 and TGF&#x003b2; appear to limit atherosclerotic inflammation.<xref rid=\"b65-cmc-suppl_3-2014-049\" ref-type=\"bibr\">65</xref>,<xref rid=\"b66-cmc-suppl_3-2014-049\" ref-type=\"bibr\">66</xref> These findings highlight the difficulty in determining the role of particular immune cells and cytokines in the pathogenesis of disease, as both M2 and regulatory T cells as well as certain cytokines like IL-4 and TGF&#x003b2; reduce plaque inflammation and also promote remodeling and fibrosis.</p></sec><sec><title>B cells and autoantibodies</title><p>B cells are also present in the atherosclerotic plaques of patients. Similar to autoimmune diseases, atherosclerosis patients have autoantibodies against LDL, oxLDL, collagen, and heat-shock proteins (eg, see Refs<xref rid=\"b67-cmc-suppl_3-2014-049\" ref-type=\"bibr\">67</xref>&#x02013;<xref rid=\"b70-cmc-suppl_3-2014-049\" ref-type=\"bibr\">70</xref>). T-cell clones reactive to LDL have been isolated from human plaques and circulating LDL, and oxLDL autoantibodies are abundant in atherosclerosis patients.<xref rid=\"b23-cmc-suppl_3-2014-049\" ref-type=\"bibr\">23</xref> In one study, autoantibodies against oxLDL discriminated between atherosclerotic and control patients better than other lipoproteins such as total cholesterol or LDL levels.<xref rid=\"b71-cmc-suppl_3-2014-049\" ref-type=\"bibr\">71</xref> A correlation exists between oxLDL autoantibody levels and the extent of atherosclerosis, cardiovascular complications, and the risk of restenosis following angioplasty.<xref rid=\"b67-cmc-suppl_3-2014-049\" ref-type=\"bibr\">67</xref> Elevated oxLDL/&#x003b2;2-glycoprotein-I autoantibody immune complexes (ICs) are associated with more severe CAD and predict a 3.5-fold increased risk for adverse outcomes, including arterial thrombosis.<xref rid=\"b72-cmc-suppl_3-2014-049\" ref-type=\"bibr\">72</xref> Deposition of autoantibodies and/or ICs at the plaque site may precipitate thromboembolism.<xref rid=\"b67-cmc-suppl_3-2014-049\" ref-type=\"bibr\">67</xref>,<xref rid=\"b68-cmc-suppl_3-2014-049\" ref-type=\"bibr\">68</xref> These findings indicate that autoantibodies and autoreactive T and B cells participate in the pathogenesis of atherosclerosis.</p><p>Although collagen-responsive autoreactive T cells have been found to increase Th17 responses during atherosclerosis in patients and mice,<xref rid=\"b70-cmc-suppl_3-2014-049\" ref-type=\"bibr\">70</xref> the role of collagen autoantibodies remain unclear. Collagen epitopes have been found to cross-react with coxsackievirus, and it has been hypothesized that these cross-reactive autoantibody ICs may promote myocarditis and valvular heart disease.<xref rid=\"b73-cmc-suppl_3-2014-049\" ref-type=\"bibr\">73</xref> Another possibility is that autoantibodies against collagen or heat-shock proteins are produced in an attempt to reduce the levels of these proinflammatory and profibrotic mediators, and so may protect and/or inadvertently promote disease. Collagen released during vessel damage or remodeling is known to activate platelets, for example, which may promote thrombosis and MI at plaque sites.<xref rid=\"b74-cmc-suppl_3-2014-049\" ref-type=\"bibr\">74</xref>,<xref rid=\"b75-cmc-suppl_3-2014-049\" ref-type=\"bibr\">75</xref></p><p>Although B cells have been found to promote atherosclerosis in mice,<xref rid=\"b76-cmc-suppl_3-2014-049\" ref-type=\"bibr\">76</xref> recent studies suggest that certain autoantibodies (eg, B1 cells, native ApoB immunoglobulin (Ig)M, and IgG antibodies) protect against atherosclerosis, while others (eg, B2 cells, ox-LDL IgG antibodies) promote disease.<xref rid=\"b47-cmc-suppl_3-2014-049\" ref-type=\"bibr\">47</xref> Regulatory B cells as well as intravenous administration of total IgG (IVIg) have been found to reduce atherosclerosis in mice.<xref rid=\"b65-cmc-suppl_3-2014-049\" ref-type=\"bibr\">65</xref>,<xref rid=\"b67-cmc-suppl_3-2014-049\" ref-type=\"bibr\">67</xref>,<xref rid=\"b77-cmc-suppl_3-2014-049\" ref-type=\"bibr\">77</xref>,<xref rid=\"b78-cmc-suppl_3-2014-049\" ref-type=\"bibr\">78</xref> Thus, some B cells and antibodies/autoantibodies (such as ICs) promote atherosclerosis and thrombosis while others inhibit disease, similar to the duality found for macrophages and T cells.</p></sec></sec><sec><title>Sex Hormones and Cardiac Inflammation</title><p>The higher incidence and severity of atherosclerosis in men than women across all age groups suggests that sex hormones play a major role in the pathogenesis of disease.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b79-cmc-suppl_3-2014-049\" ref-type=\"bibr\">79</xref> Sex differences in the incidence of CVD are also influenced by gender differences in cardiovascular risk factors and presentation of disease.<xref rid=\"b80-cmc-suppl_3-2014-049\" ref-type=\"bibr\">80</xref>,<xref rid=\"b81-cmc-suppl_3-2014-049\" ref-type=\"bibr\">81</xref> That the incidence of CAD increases in women as estrogen declines with age and following menopause suggests a protective role for estrogen in the heart. However, the benefit of estrogen therapy following menopause has been controversial.<xref rid=\"b82-cmc-suppl_3-2014-049\" ref-type=\"bibr\">82</xref>&#x02013;<xref rid=\"b86-cmc-suppl_3-2014-049\" ref-type=\"bibr\">86</xref> Interpreting results from studies has been complicated by the mixture of hormones used for therapy (ie, estrogen and progesterone), their doses, and the age and duration (ie, timing of initiation) of therapy.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b87-cmc-suppl_3-2014-049\" ref-type=\"bibr\">87</xref>,<xref rid=\"b88-cmc-suppl_3-2014-049\" ref-type=\"bibr\">88</xref> If hormone therapy is started during or shortly after menopause, it appears to reduce the risk for CAD,<xref rid=\"b88-cmc-suppl_3-2014-049\" ref-type=\"bibr\">88</xref> although more research is needed.</p><p>Underlying the sex difference in incidence of atherosclerosis is the knowledge that sex differences exist in normal heart physiology and function. For example, men have larger hearts (greater left ventricular mass), cardiac contractility is greater in healthy women than age-matched men, myocardial mass is better preserved in women as they age, cardiac apoptosis is threefold higher in men compared to women as they age, women have smaller coronary vessels than men, and premenopausal women have lower blood pressure but a faster resting heart rate than men.<xref rid=\"b89-cmc-suppl_3-2014-049\" ref-type=\"bibr\">89</xref>&#x02013;<xref rid=\"b91-cmc-suppl_3-2014-049\" ref-type=\"bibr\">91</xref> Sex differences in cardiac pathology also occur with aging. For example, hypertrophy, apoptosis, and fibrosis are greater in the aging male than female heart.<xref rid=\"b92-cmc-suppl_3-2014-049\" ref-type=\"bibr\">92</xref> These underlying sex differences in cardiac physiology directly influence the pathogenesis of atherosclerosis.</p><sec><title>Sex hormones and receptors</title><p>Estrogen, progestin, and androgen hormones act through ligand-dependent, ligand-independent, genomic, and non-genomic mechanisms.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref> The canonical pathway of hormone action involves steroid binding to an intracellular receptor that leads to dimerization and binding of the dimer complex to the regulatory element of the promoter region of specific genes. These are termed estrogen response elements (EREs) and androgen response elements (AREs) and are capable of turning on or off hundreds of genes at a time and behave essentially as ligand-activated transcription factors. This is likely the reason why such large sex differences occur for most inflammatory diseases (ie, 20:1 female to male for thyroiditis and 9:1 for SLE, for example).<xref rid=\"b93-cmc-suppl_3-2014-049\" ref-type=\"bibr\">93</xref> Hormone receptors are also expressed on the surface of immune and other cells, where they mediate rapid signaling.<xref rid=\"b94-cmc-suppl_3-2014-049\" ref-type=\"bibr\">94</xref>&#x02013;<xref rid=\"b96-cmc-suppl_3-2014-049\" ref-type=\"bibr\">96</xref> Estrogen receptors (ERs) include ER&#x003b1;, ER&#x003b2;, and GPR30. Each of these receptors can be found within cells and on the cell surface. ER&#x003b1; and ER&#x003b2; are the product of two difference genes, <italic>ESR1</italic> and <italic>ESR2</italic>, but share a high degree of homology.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref> Interestingly, a single androgen receptor (AR) is transcribed from a gene located on the X chromosome.<xref rid=\"b97-cmc-suppl_3-2014-049\" ref-type=\"bibr\">97</xref></p><p>And not surprisingly, since hormones are essentially growth factors required for normal cell growth and maintenance, ER&#x003b1;/&#x003b2;, progesterone receptors (PRs), AR, and aromatase (the enzyme that converts androgens to estrogens) are expressed on/in vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, and cardiomyocytes in humans and rodents.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b98-cmc-suppl_3-2014-049\" ref-type=\"bibr\">98</xref> Women have higher ER expression in their arteries than men, which decreases with age and menopause.<xref rid=\"b79-cmc-suppl_3-2014-049\" ref-type=\"bibr\">79</xref> Estrogen via ER&#x003b2; signaling has been shown to regulate arterial tone and blood pressure, while ER&#x003b1; protects against vascular injury, remodeling and fibrosis, and atherosclerosis.<xref rid=\"b99-cmc-suppl_3-2014-049\" ref-type=\"bibr\">99</xref>&#x02013;<xref rid=\"b101-cmc-suppl_3-2014-049\" ref-type=\"bibr\">101</xref> Additionally, platelets, which are important for induction of thrombosis, express ER&#x003b2; and the AR and respond to sex steroids.<xref rid=\"b102-cmc-suppl_3-2014-049\" ref-type=\"bibr\">102</xref> And finally, ER&#x003b1;/&#x003b2;, PR, and AR expression has been found to shift in men and women with atherosclerosis as they age (reviewed in Ref.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>).</p></sec><sec><title>Sex hormone effects on immune cells</title><p>Our understanding of sex hormone effects on immune cells comes mainly from cell culture and animal studies of normal, healthy cells or the study of various inflammatory diseases like autoimmune diseases. Very little information exists on the effect of sex hormones on inflammation in atherosclerosis. With this paucity of data in mind, I will briefly discuss what is known generally about the effect of sex hormones on immune cells, what has been discovered about sex differences in cardiac inflammation and remodeling during myocarditis, and propose how these findings may relate to sex differences in inflammation in atherosclerosis.</p><p>Sex steroid hormone receptors like ER&#x003b1;, ER&#x003b2;, and AR are expressed on and within immune cells that are present in atherosclerotic plaques including MCs, macrophages, DCs, T cells, and B cells.<xref rid=\"b102-cmc-suppl_3-2014-049\" ref-type=\"bibr\">102</xref> Human and mouse monocytes and macrophages express ER&#x003b1;, ER&#x003b2;, and AR.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b102-cmc-suppl_3-2014-049\" ref-type=\"bibr\">102</xref> AR expression on human monocytes is higher in men compared to women.<xref rid=\"b103-cmc-suppl_3-2014-049\" ref-type=\"bibr\">103</xref>&#x02013;<xref rid=\"b105-cmc-suppl_3-2014-049\" ref-type=\"bibr\">105</xref> In general, estrogen has been found to have anti-inflammatory effects on macrophages. Estrogen inhibits the TLR2/TLR4 ligand lipopolysaccharide (LPS)-induced gene products like tumor necrosis factor (TNF), IL-1, and IL-6 by down-regulating NF&#x003ba;B signaling (<xref ref-type=\"table\" rid=\"t1-cmc-suppl_3-2014-049\">Table 1</xref>).<xref rid=\"b106-cmc-suppl_3-2014-049\" ref-type=\"bibr\">106</xref>&#x02013;<xref rid=\"b110-cmc-suppl_3-2014-049\" ref-type=\"bibr\">110</xref> Estrogen has also been found to reduce oxidative stress in healthy murine peritoneal macrophages,<xref rid=\"b110-cmc-suppl_3-2014-049\" ref-type=\"bibr\">110</xref> and to skew macrophages to a M2 phenotype.<xref rid=\"b111-cmc-suppl_3-2014-049\" ref-type=\"bibr\">111</xref> In contrast, Rettew et al found that testosterone decreased TLR4 expression in the RAW tumor macrophage cell line (which are male cells),<xref rid=\"b112-cmc-suppl_3-2014-049\" ref-type=\"bibr\">112</xref> while ovariectomy and estrogen replacement in female C57BL/6 mice increased TLR4 expression on macrophages.<xref rid=\"b113-cmc-suppl_3-2014-049\" ref-type=\"bibr\">113</xref> It is possible that the effect of sex hormones on normal healthy immune cells is not always the same as their effect during infection and disease (ie, bacterial LPS, viral infection, myocarditis). In support of this idea, we found that TLR4 expression was higher on male than female macrophages (and MCs) during innate coxsackievirus B3 (CVB3) infection and acute viral myocarditis.<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref> These findings highlight some of the difficulties inherent in studying the effect of sex hormones on immune cells. Evidence that estrogen may promote an anti-atherosclerotic phenotype in macrophages comes from reports that estrogen decreases oxLDL<xref rid=\"b115-cmc-suppl_3-2014-049\" ref-type=\"bibr\">115</xref>,<xref rid=\"b116-cmc-suppl_3-2014-049\" ref-type=\"bibr\">116</xref> and increases ApoE levels<xref rid=\"b117-cmc-suppl_3-2014-049\" ref-type=\"bibr\">117</xref> (<xref ref-type=\"table\" rid=\"t1-cmc-suppl_3-2014-049\">Table 1</xref>). Higher expression of ER&#x003b1; in the vasculature of premenopausal women correlates with a lower incidence of atherosclerosis, further suggesting that ER&#x003b1; protects against atherosclerosis.<xref rid=\"b118-cmc-suppl_3-2014-049\" ref-type=\"bibr\">118</xref>,<xref rid=\"b119-cmc-suppl_3-2014-049\" ref-type=\"bibr\">119</xref></p><p>Women have an increased antibody response to infections and vaccines compared to men.<xref rid=\"b120-cmc-suppl_3-2014-049\" ref-type=\"bibr\">120</xref>,<xref rid=\"b121-cmc-suppl_3-2014-049\" ref-type=\"bibr\">121</xref> This is due to the ability of estrogen to activate B cells, resulting in increased levels of antibodies (and autoantibodies) (<xref ref-type=\"table\" rid=\"t1-cmc-suppl_3-2014-049\">Table 1</xref>), while androgens decrease B-cell maturation reducing B-cell synthesis of antibody in humans.<xref rid=\"b122-cmc-suppl_3-2014-049\" ref-type=\"bibr\">122</xref>&#x02013;<xref rid=\"b124-cmc-suppl_3-2014-049\" ref-type=\"bibr\">124</xref> However, depending on the dose, estrogen can either drive Th1 and/or Th17 responses (low dose) or increase the regulatory arm of the adaptive immune response by enhancing tolerogenic DCs, IL-4-driven Th2 responses, IL-10, TGF&#x003b2;, Treg, and alternatively activated M2 macrophages (high dose) (<xref ref-type=\"table\" rid=\"t1-cmc-suppl_3-2014-049\">Table 1</xref>).<xref rid=\"b7-cmc-suppl_3-2014-049\" ref-type=\"bibr\">7</xref>,<xref rid=\"b122-cmc-suppl_3-2014-049\" ref-type=\"bibr\">122</xref>&#x02013;<xref rid=\"b125-cmc-suppl_3-2014-049\" ref-type=\"bibr\">125</xref></p><p>Far less research has been conducted on the effect of androgens on immune cell function, but in general, androgens are thought to drive cell-mediated and Th1 responses.<xref rid=\"b126-cmc-suppl_3-2014-049\" ref-type=\"bibr\">126</xref>&#x02013;<xref rid=\"b129-cmc-suppl_3-2014-049\" ref-type=\"bibr\">129</xref> One complication in understanding the role of sex hormones like testosterone on immune cells is that most published studies do not interpret data in the context of sex. For example, the sex of cells used in culture experiments is seldom reported.<xref rid=\"b130-cmc-suppl_3-2014-049\" ref-type=\"bibr\">130</xref> Additionally, effects prescribed to testosterone may be due to testosterone or estrogen because of aromatase conversion of testosterone to estrogen.</p></sec><sec><title>Sex hormone effects on myocardial inflammation</title><p>Myocarditis, or inflammation of the myocardium, shares many similarities to atherosclerosis (<xref ref-type=\"table\" rid=\"t2-cmc-suppl_3-2014-049\">Table 2</xref>). The primary difference between the diseases is location; atherosclerotic inflammation is confined to the vascular wall, while myocardial inflammation is present in the heart muscle. The different locations for inflammation produce different disease outcomes (ie, dilated cardiomyopathy vs MI), but otherwise the mechanisms that promote or protect against both diseases are remarkably similar and include the following: TLR2 and TLR4 signaling increase inflammation<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b35-cmc-suppl_3-2014-049\" ref-type=\"bibr\">35</xref>,<xref rid=\"b131-cmc-suppl_3-2014-049\" ref-type=\"bibr\">131</xref>,<xref rid=\"b132-cmc-suppl_3-2014-049\" ref-type=\"bibr\">132</xref>; the inflammasome and IL-1&#x003b2; promote disease<xref rid=\"b23-cmc-suppl_3-2014-049\" ref-type=\"bibr\">23</xref>,<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b34-cmc-suppl_3-2014-049\" ref-type=\"bibr\">34</xref>,<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>; increased inflammation is associated with a Th1-type immune response<xref rid=\"b27-cmc-suppl_3-2014-049\" ref-type=\"bibr\">27</xref>&#x02013;<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b133-cmc-suppl_3-2014-049\" ref-type=\"bibr\">133</xref>,<xref rid=\"b134-cmc-suppl_3-2014-049\" ref-type=\"bibr\">134</xref>; M2b macrophages that express TLR2/TLR4 and release IL-1&#x003b2; and TGF&#x003b2; promote remodeling<xref rid=\"b29-cmc-suppl_3-2014-049\" ref-type=\"bibr\">29</xref>,<xref rid=\"b42-cmc-suppl_3-2014-049\" ref-type=\"bibr\">42</xref>,<xref rid=\"b135-cmc-suppl_3-2014-049\" ref-type=\"bibr\">135</xref>; anti-inflammatory M2a macrophages, Treg and other regulatory T cells, IL-4, and IL-10 reduce inflammation<xref rid=\"b65-cmc-suppl_3-2014-049\" ref-type=\"bibr\">65</xref>,<xref rid=\"b66-cmc-suppl_3-2014-049\" ref-type=\"bibr\">66</xref>,<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref>,<xref rid=\"b135-cmc-suppl_3-2014-049\" ref-type=\"bibr\">135</xref>; MC activation promotes remodeling, thrombosis, and heart failure,<xref rid=\"b38-cmc-suppl_3-2014-049\" ref-type=\"bibr\">38</xref>,<xref rid=\"b44-cmc-suppl_3-2014-049\" ref-type=\"bibr\">44</xref>,<xref rid=\"b51-cmc-suppl_3-2014-049\" ref-type=\"bibr\">51</xref>&#x02013;<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>; and TLR3 signaling protects against disease.<xref rid=\"b45-cmc-suppl_3-2014-049\" ref-type=\"bibr\">45</xref>,<xref rid=\"b136-cmc-suppl_3-2014-049\" ref-type=\"bibr\">136</xref>,<xref rid=\"b137-cmc-suppl_3-2014-049\" ref-type=\"bibr\">137</xref> Although inflammation during atherosclerosis is initially present within the vessel wall, once an MI occurs, the myocardium is damaged and an inflammatory response ensues that is very similar to the pathogenesis of viral myocarditis.</p><p>So what about sex differences in the myocardial immune response? Men (and male mice) are more likely to develop myocarditis and progress to dilated cardiomyopathy (DCM) and heart failure than women,<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref>,<xref rid=\"b138-cmc-suppl_3-2014-049\" ref-type=\"bibr\">138</xref> similar to atherosclerosis. Our understanding of sex differences in cardiac inflammation during myocarditis comes almost exclusively from animal models of disease. Huber and colleagues were the first to describe that male BALB/c mice have increased CVB3-induced myocarditis compared to females.<xref rid=\"b139-cmc-suppl_3-2014-049\" ref-type=\"bibr\">139</xref> Male mice with CVB3 myocarditis develop a predominantly Th1-type adaptive immune response with more Th1-induced IgG2a anti-CVB3 antibodies compared to female mice, who develop a Th2 response and more regulatory T-cell populations.<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref>,<xref rid=\"b134-cmc-suppl_3-2014-049\" ref-type=\"bibr\">134</xref>,<xref rid=\"b140-cmc-suppl_3-2014-049\" ref-type=\"bibr\">140</xref> This Th1 vs Th2 dichotomy, as well as the severity of myocardial inflammation, has been found to be due to testosterone and estradiol, respectively.<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>,<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref>,<xref rid=\"b135-cmc-suppl_3-2014-049\" ref-type=\"bibr\">135</xref>,<xref rid=\"b140-cmc-suppl_3-2014-049\" ref-type=\"bibr\">140</xref>&#x02013;<xref rid=\"b142-cmc-suppl_3-2014-049\" ref-type=\"bibr\">142</xref></p><p>Males also have more MCs and macrophages than females during myocarditis, which express more TLR4 and IL-1&#x003b2;.<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>,<xref rid=\"b114-cmc-suppl_3-2014-049\" ref-type=\"bibr\">114</xref>,<xref rid=\"b135-cmc-suppl_3-2014-049\" ref-type=\"bibr\">135</xref> The predominant Th1 response in male mice with CVB3 myocarditis is not due to classical IL-12/STAT4-induced IFN&#x003b3; production, but TLR4-induced IL-18, a cytokine that strongly induces IFNs.<xref rid=\"b134-cmc-suppl_3-2014-049\" ref-type=\"bibr\">134</xref> Male mice have more classically activated M1 macrophages in the heart during acute CVB3 myocarditis, while females have more inhibitory M2a macrophages.<xref rid=\"b135-cmc-suppl_3-2014-049\" ref-type=\"bibr\">135</xref>,<xref rid=\"b143-cmc-suppl_3-2014-049\" ref-type=\"bibr\">143</xref> TLR4 mRNA expression has been found to be higher in patients with biopsy-proven myocarditis and DCM than controls.<xref rid=\"b144-cmc-suppl_3-2014-049\" ref-type=\"bibr\">144</xref>,<xref rid=\"b145-cmc-suppl_3-2014-049\" ref-type=\"bibr\">145</xref> Although sex differences in TLR4 levels were not examined, &#x0223c;75% of the myocarditis and DCM patients in these studies were men. Testosterone has been found to be responsible for increasing each of these immune mediators in animal models. Additionally, cholesterol uptake in macrophages is associated with increased myocardial inflammation,<xref rid=\"b146-cmc-suppl_3-2014-049\" ref-type=\"bibr\">146</xref>,<xref rid=\"b147-cmc-suppl_3-2014-049\" ref-type=\"bibr\">147</xref> similar to its role in atherosclerosis.</p><p>Evidence that estrogen protects against myocardial inflammation following MI also exists from animal models. ER&#x003b1; knockout mice have more ischemic damage to the myocardium compared to wild-type (WT) mice.<xref rid=\"b148-cmc-suppl_3-2014-049\" ref-type=\"bibr\">148</xref>,<xref rid=\"b149-cmc-suppl_3-2014-049\" ref-type=\"bibr\">149</xref> Also, administration of an ER&#x003b1;-selective agonist or ER&#x003b1; transgenic mice were found to reduce injury and inflammation in an ischemic reperfusion injury model.<xref rid=\"b101-cmc-suppl_3-2014-049\" ref-type=\"bibr\">101</xref>,<xref rid=\"b150-cmc-suppl_3-2014-049\" ref-type=\"bibr\">150</xref>&#x02013;<xref rid=\"b152-cmc-suppl_3-2014-049\" ref-type=\"bibr\">152</xref> Estrogen also protects against hypertension in females in animal models by reducing AngII levels.<xref rid=\"b153-cmc-suppl_3-2014-049\" ref-type=\"bibr\">153</xref> However, hypertension increases in women after menopause when estrogen levels drop.<xref rid=\"b8-cmc-suppl_3-2014-049\" ref-type=\"bibr\">8</xref> This may also be due to smaller vessel sizes in women and other physiological differences as well as changes in blood pressure related to autoimmune diseases like SLE. Overall, these data indicate that estrogen reduces myocardial inflammation while testosterone promotes it.</p></sec><sec><title>Sex hormone effects on cardiac remodeling</title><p>A critical step in the progression from myocarditis to DCM involves extracellular matrix (ECM) remodeling and fibrosis.<xref rid=\"b154-cmc-suppl_3-2014-049\" ref-type=\"bibr\">154</xref> Scar tissue/collagen laid down in the myocardium following myocarditis is due primarily to immune cell release of profibrotic enzymes (ie, collagenases, MMPs), cytokines (ie, TGF&#x003b2;<sub>1</sub>, IL-1&#x003b2;), and other mediators during the peak of acute inflammation.<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref> The immune cells and ECM components involved in this process are virtually identical in myocarditis, atherosclerotic plaques, and post-MI cardiac damage.<xref rid=\"b4-cmc-suppl_3-2014-049\" ref-type=\"bibr\">4</xref>,<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b142-cmc-suppl_3-2014-049\" ref-type=\"bibr\">142</xref> MCs and macrophages are particularly important in regulating the degradation and synthesis of ECM components that form the outer layer of the plaque leading to an MI or that produce myocardial scar tissue and DCM.<xref rid=\"b30-cmc-suppl_3-2014-049\" ref-type=\"bibr\">30</xref>,<xref rid=\"b52-cmc-suppl_3-2014-049\" ref-type=\"bibr\">52</xref>,<xref rid=\"b155-cmc-suppl_3-2014-049\" ref-type=\"bibr\">155</xref> Cytokines associated with Th2-type immune responses like IL-4, TGF&#x003b2;, and IL-1&#x003b2;, certain M2 macrophages (ie, M2b), and MCs are central to the remodeling process. MC activation during myocarditis is associated with increased remodeling, DCM, and heart failure in males.<xref rid=\"b44-cmc-suppl_3-2014-049\" ref-type=\"bibr\">44</xref>,<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref> It is important to realize that remodeling is a cycle of laying down and breaking up ECM products like collagen, so that the same process that lays down collagen to produce DCM also breaks it up to produce an MI.</p><p>Only males of mouse strains that respond to CVB3 infection with a dominant Th2 response, like BALB/c mice, develop fibrosis and DCM following acute myocarditis.<xref rid=\"b44-cmc-suppl_3-2014-049\" ref-type=\"bibr\">44</xref>,<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>,<xref rid=\"b136-cmc-suppl_3-2014-049\" ref-type=\"bibr\">136</xref> These findings highlight the importance of Th2-driven MCs and M2 macrophages that express TLR4 and IL-1&#x003b2; (ie, M2b subtype) in the progression to fibrosis and DCM in males during and following acute myocarditis. This type of Th2-driven immune response appears to be disguised as a classical Th1 response in males due to elevated levels of TLR4-induced IL-18, which increases IFN&#x003b3; production and Th1-type immune cells. Interestingly, macrophage-derived IL-18 has recently been found to increase fibrinogen deposition during vascular remodeling in rats,<xref rid=\"b156-cmc-suppl_3-2014-049\" ref-type=\"bibr\">156</xref> suggesting that the inflammasome is particularly important for plaque remodeling in men with atherosclerosis.</p><p>Several studies report that patients with myocarditis or DCM have a greater induction of ECM proteins and/or fibrosis in the heart compared to women, including increased collagen and MMP production.<xref rid=\"b92-cmc-suppl_3-2014-049\" ref-type=\"bibr\">92</xref>,<xref rid=\"b157-cmc-suppl_3-2014-049\" ref-type=\"bibr\">157</xref>,<xref rid=\"b158-cmc-suppl_3-2014-049\" ref-type=\"bibr\">158</xref> In myocarditis patients, men are 2 times more likely to present with myocardial fibrosis then women by cardiac magnetic resonance imaging (MRI).<xref rid=\"b157-cmc-suppl_3-2014-049\" ref-type=\"bibr\">157</xref> Various animal models of heart disease have shown that testosterone is responsible for adverse cardiac remodeling in males following MI<xref rid=\"b159-cmc-suppl_3-2014-049\" ref-type=\"bibr\">159</xref> and that estrogen signaling via ER&#x003b1;, in particular, prevents cardiac myocyte hypertrophy and fibrosis in females by blocking TGF&#x003b2; and collagen synthesis.<xref rid=\"b99-cmc-suppl_3-2014-049\" ref-type=\"bibr\">99</xref>&#x02013;<xref rid=\"b101-cmc-suppl_3-2014-049\" ref-type=\"bibr\">101</xref> Serpin A3n, also known as &#x003b1;1-anti-chymotrypsin, is an important remodeling enzyme released from MCs, which was found to be upregulated in 11 separate microarray studies of acute DCM patients as well as in male mice with acute CVB3 myocarditis.<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref>,<xref rid=\"b160-cmc-suppl_3-2014-049\" ref-type=\"bibr\">160</xref> Serpin A3n was found to be increased in the heart of male mice by testosterone and IL-1&#x003b2; and to induce cardiac fibrosis by altering MMPs during acute CVB3 myocarditis.<xref rid=\"b53-cmc-suppl_3-2014-049\" ref-type=\"bibr\">53</xref> Overall, these studies suggest that elevated testosterone levels in men increase cardiac inflammation and fibrosis, leading to DCM and heart failure. Although few studies have specifically examined sex differences in remodeling during atherosclerosis, a similar role for sex hormones in the remodeling process would be expected for atherosclerosis.</p></sec><sec><title>Sex hormone effects on inflammation with aging and menopause</title><p>Age-related changes in immune function include an impaired ability to respond to new antigens, unsustained memory responses, chronic low-grade inflammation, and an increasing propensity for autoimmune responses due to antibody and autoantibody levels that increase with age.<xref rid=\"b161-cmc-suppl_3-2014-049\" ref-type=\"bibr\">161</xref>&#x02013;<xref rid=\"b163-cmc-suppl_3-2014-049\" ref-type=\"bibr\">163</xref> Few studies exist examining sex hormone effects on the immune response with aging in atherosclerosis, except for studies on brain inflammation, aging, and stroke.<xref rid=\"b164-cmc-suppl_3-2014-049\" ref-type=\"bibr\">164</xref> Hormone replacement therapy (lifting estrogen levels to a relatively higher dose) decreases antibody levels in menopausal women,<xref rid=\"b165-cmc-suppl_3-2014-049\" ref-type=\"bibr\">165</xref> suggesting that these changes are age-related rather than due to estrogen levels alone. Menopause is defined as the final menstrual period without another menstrual period for 12 months.<xref rid=\"b166-cmc-suppl_3-2014-049\" ref-type=\"bibr\">166</xref>&#x02013;<xref rid=\"b168-cmc-suppl_3-2014-049\" ref-type=\"bibr\">168</xref> The mean age when menopause occurs in Western cultures is between 49 and 52 years.<xref rid=\"b166-cmc-suppl_3-2014-049\" ref-type=\"bibr\">166</xref>,<xref rid=\"b167-cmc-suppl_3-2014-049\" ref-type=\"bibr\">167</xref> Decreases in estrogen (ie, estradiol) occur only in the last six months before menopause and thereafter.<xref rid=\"b168-cmc-suppl_3-2014-049\" ref-type=\"bibr\">168</xref> In contrast, testosterone gradually decreases with age in both sexes.<xref rid=\"b169-cmc-suppl_3-2014-049\" ref-type=\"bibr\">169</xref>&#x02013;<xref rid=\"b171-cmc-suppl_3-2014-049\" ref-type=\"bibr\">171</xref> After menopause, the primary endogenous source of estrogen is estrone, which is synthesized in adipocytes via aromatase.<xref rid=\"b172-cmc-suppl_3-2014-049\" ref-type=\"bibr\">172</xref></p><p>Menopause is also associated with decreases in CD4<sup>+</sup> and CD8<sup>+</sup> T cells and natural killer cell activity.<xref rid=\"b172-cmc-suppl_3-2014-049\" ref-type=\"bibr\">172</xref>&#x02013;<xref rid=\"b174-cmc-suppl_3-2014-049\" ref-type=\"bibr\">174</xref> Additionally, aging and menopause have been associated with an increase in the cytokines IL-1, IL-6 (IL-1&#x003b2; increases IL-6 levels), IL-18, TNF, and C-reactive protein (CRP) levels, which are biomarkers of an inflammatory response and associated with increased risk for heart failure in atherosclerosis patients.<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref>,<xref rid=\"b156-cmc-suppl_3-2014-049\" ref-type=\"bibr\">156</xref>,<xref rid=\"b175-cmc-suppl_3-2014-049\" ref-type=\"bibr\">175</xref>,<xref rid=\"b176-cmc-suppl_3-2014-049\" ref-type=\"bibr\">176</xref> Importantly, these cytokines are derived mainly from innate immune cells like macrophages and MCs at sites of tissue inflammation. That lower estrogen levels during menopause increase these cytokines is consistent with the known ability of higher doses of estrogen to downregulate NF&#x003ba;B, Th1 responses, IL-1, and IL-6 via ER&#x003b1; in various human and murine cell types.<xref rid=\"b107-cmc-suppl_3-2014-049\" ref-type=\"bibr\">107</xref>,<xref rid=\"b109-cmc-suppl_3-2014-049\" ref-type=\"bibr\">109</xref>,<xref rid=\"b177-cmc-suppl_3-2014-049\" ref-type=\"bibr\">177</xref>&#x02013;<xref rid=\"b179-cmc-suppl_3-2014-049\" ref-type=\"bibr\">179</xref> Thus, during menopause the protective role of estrogen in decreasing innate immune cell activation is lost, allowing increased proinflammatory cytokine levels, while, at the same time, autoantibody levels and ICs continue to rise due to continued low levels of estrogen. In contrast, in most men, androgen levels that promote innate immune cell activation and proinflammatory cytokines decline past age 50 without the increase in autoantibodies found in women because of estrogen. This may explain, at least in part, why atherosclerosis and hypertension increase in women following menopause.<xref rid=\"b5-cmc-suppl_3-2014-049\" ref-type=\"bibr\">5</xref>,<xref rid=\"b6-cmc-suppl_3-2014-049\" ref-type=\"bibr\">6</xref></p></sec><sec sec-type=\"discussion\"><title>Implications for sex differences in inflammation during atherosclerosis</title><p>The similarity between immune mechanisms involved in the pathogenesis of myocarditis and atherosclerosis suggests that sex differences in the inflammatory response and cardiac remodeling may also be similar. However, mechanistic studies examining sex differences in inflammation during atherosclerosis have, for the most part, not yet been conducted. A number of key questions need to be addressed. Do sera biomarkers like TNF and IL-6 predict poor outcome in male and female atherosclerosis patients? Or, are they better predictors in males due to the inhibition of these cytokines by estrogen? Do TLR4/inflammasome/IL-1&#x003b2; levels predict MI in males better than females because testosterone increases this signaling pathway? Is the correlation between autoantibodies to oxLDL and CAD more prevalent in females where estrogen increases B-cell and antibody/autoantibody responses? If so, could this partially explain why women are at an increased risk to develop CAD when they have one or more autoimmune diseases? Why is hypertension higher in women with CAD than men after menopause, and does hypertension relate directly to cardiac inflammation? Does AngII activation promote hypertension and arrhythmias more in men because estrogen reduces its expression in women? These are just a few of the questions that need to be answered to gain a better understanding of sex differences in the pathogenesis of atherosclerosis and risk factors for MI.</p><p>If sex differences in inflammation found in myocarditis apply to atherosclerosis, I hypothesize that MCs and M2b TLR4<sup>+</sup> macrophages increase inflammation and foam cell accumulation in the atherosclerotic plaques of men where they promote remodeling resulting in a thrombotic MI (<xref ref-type=\"fig\" rid=\"f2-cmc-suppl_3-2014-049\">Fig. 2</xref>). In contrast, a primary driver of MIs in women could be the result of deposition of autoantibodies against oxLDL and other autoantibodies in the form of ICs (<xref ref-type=\"fig\" rid=\"f2-cmc-suppl_3-2014-049\">Fig. 2</xref>). The presence of ICs coupled with the smaller size of vessels could increase blood pressure in women and promote local inflammation and shearing of the vessel wall to generate an MI. This process would be accelerated after menopause in women as cardioprotective estrogen levels drop but who have elevated autoantibody levels due to the presence of one or more autoimmune diseases.</p></sec></sec><sec sec-type=\"conclusions\"><title>Conclusions</title><p>We currently do not understand how the immune response in women differs from men with atherosclerosis because most clinical studies contain a majority of men, which skews our understanding of the factors important for men, and data are typically not analyzed according to sex (controlling for sex does not adequately reveal sex differences). Additionally, researchers studying atherosclerosis using animal models have not reported sex differences in disease. In order to improve diagnosis and treatment of CAD, the research community needs to understand how the immune response is similar and how it differs in men and women with atherosclerosis.</p></sec></body><back><fn-group><fn id=\"fn1-cmc-suppl_3-2014-049\"><p><bold>ACADEMIC EDITOR:</bold> Thomas E. Vanhecke, Editor in Chief</p></fn><fn id=\"fn2-cmc-suppl_3-2014-049\"><p><bold>FUNDING:</bold> This work was supported by the National Institutes of Health awards from the National Heart, Lung, and Blood Institute (R01 HL111938), the National Institute of Environmental Health Sciences (R21 ES024414), and an American Heart Association Grant-in-Aid (12GRNT12050000). These funding agencies were not involved either in writing the review article or in the decision to submit the article for publication. The author confirms that the funder had no influence over the study design, content of the article, or selection of this journal.</p></fn><fn id=\"fn3-cmc-suppl_3-2014-049\"><p><bold>COMPETING INTERESTS:</bold> Author discloses no potential conflicts of interest.</p></fn><fn id=\"fn4-cmc-suppl_3-2014-049\"><p>Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).</p></fn><fn id=\"fn5-cmc-suppl_3-2014-049\"><p><bold>Author Contributions</bold></p><p>Wrote the manuscript: DF. Developed structure and arguments for the paper: DF. Made critical revisions and approved final version: DF. The author reviewed and approved of the final manuscript.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id=\"b1-cmc-suppl_3-2014-049\"><label>1</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><etal/></person-group><article-title>A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990&#x02013;2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2224</fpage><lpage>60</lpage><pub-id pub-id-type=\"pmid\">23245609</pub-id></element-citation></ref><ref id=\"b2-cmc-suppl_3-2014-049\"><label>2</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics &#x02013; 2011 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2011</year><volume>104</volume><fpage>276</fpage><lpage>308</lpage></element-citation></ref><ref id=\"b3-cmc-suppl_3-2014-049\"><label>3</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shaw</surname><given-names>LJ</given-names></name><name><surname>Bugiardini</surname><given-names>R</given-names></name><name><surname>Merz</surname><given-names>CNB</given-names></name></person-group><article-title>Women and ischemic heart disease: evolving knowledge</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><fpage>1561</fpage><lpage>75</lpage><pub-id pub-id-type=\"pmid\">19833255</pub-id></element-citation></ref><ref id=\"b4-cmc-suppl_3-2014-049\"><label>4</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shih</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Boyle</surname><given-names>AJ</given-names></name></person-group><article-title>The aging heart and post-infarction left ventricular remodeling</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type=\"pmid\">21185495</pub-id></element-citation></ref><ref id=\"b5-cmc-suppl_3-2014-049\"><label>5</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name></person-group><article-title>Therapeutic implications of the gender-specific aspects of cardiovascular disease</article-title><source>Nat Rev Drug Discov</source><year>2006</year><volume>5</volume><fpage>425</fpage><lpage>38</lpage><pub-id pub-id-type=\"pmid\">16672926</pub-id></element-citation></ref><ref id=\"b6-cmc-suppl_3-2014-049\"><label>6</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Villablanca</surname><given-names>AC</given-names></name><name><surname>Jayachandran</surname><given-names>M</given-names></name><name><surname>Banka</surname><given-names>C</given-names></name></person-group><article-title>Atherosclerosis and sex hormones: current concepts</article-title><source>Clin Sci</source><year>2010</year><volume>119</volume><fpage>493</fpage><lpage>513</lpage><pub-id pub-id-type=\"pmid\">20958265</pub-id></element-citation></ref><ref id=\"b7-cmc-suppl_3-2014-049\"><label>7</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Petri</surname><given-names>MA</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Cooper</surname><given-names>LT</given-names><suffix>Jr</suffix></name></person-group><article-title>Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis</article-title><source>Expert Rev Clin Immunol</source><year>2012</year><volume>8</volume><fpage>269</fpage><lpage>84</lpage><pub-id pub-id-type=\"pmid\">22390491</pub-id></element-citation></ref><ref id=\"b8-cmc-suppl_3-2014-049\"><label>8</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Sakao</surname><given-names>S</given-names></name><name><surname>Tanabe</surname><given-names>N</given-names></name><name><surname>Tatsumi</surname><given-names>K</given-names></name></person-group><article-title>The estrogen paradox in pulmonary arterial hypertension</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2010</year><volume>299</volume><fpage>L435</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">20656892</pub-id></element-citation></ref><ref id=\"b9-cmc-suppl_3-2014-049\"><label>9</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Angeja</surname><given-names>BG</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Frederick</surname><given-names>PD</given-names></name><name><surname>Canto</surname><given-names>JG</given-names></name><name><surname>Grady</surname><given-names>D</given-names></name></person-group><article-title>Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women</article-title><source>Circulation</source><year>2001</year><volume>6</volume><fpage>2300</fpage><lpage>4</lpage><pub-id pub-id-type=\"pmid\">11696469</pub-id></element-citation></ref><ref id=\"b10-cmc-suppl_3-2014-049\"><label>10</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Angeja</surname><given-names>BG</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><fpage>1297</fpage><lpage>301</lpage><pub-id pub-id-type=\"pmid\">11691498</pub-id></element-citation></ref><ref id=\"b11-cmc-suppl_3-2014-049\"><label>11</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Othman</surname><given-names>H</given-names></name><name><surname>Kbanbatta</surname><given-names>S</given-names></name><name><surname>Seth</surname><given-names>M</given-names></name><etal/></person-group><article-title>Differences in sex-related bleeding and outcomes after percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) registry</article-title><source>Am Heart J</source><year>2014</year><volume>168</volume><fpage>552</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">25262266</pub-id></element-citation></ref><ref id=\"b12-cmc-suppl_3-2014-049\"><label>12</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Seeland</surname><given-names>U</given-names></name><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name></person-group><article-title>Sex and gender differences in cardiovascular drug therapy</article-title><source>Handb Exp Pharmacol</source><year>2012</year><volume>214</volume><fpage>211</fpage><lpage>36</lpage><pub-id pub-id-type=\"pmid\">23027453</pub-id></element-citation></ref><ref id=\"b13-cmc-suppl_3-2014-049\"><label>13</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Potapov</surname><given-names>E</given-names></name><name><surname>Schveiger</surname><given-names>M</given-names></name><name><surname>Lehmkuhl</surname><given-names>E</given-names></name><etal/></person-group><article-title>Gender differences during mechanical circulatory support</article-title><source>ASAIO J</source><year>2012</year><volume>58</volume><fpage>320</fpage><lpage>5</lpage><pub-id pub-id-type=\"pmid\">22635009</pub-id></element-citation></ref><ref id=\"b14-cmc-suppl_3-2014-049\"><label>14</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Boyle</surname><given-names>AJ</given-names></name><name><surname>Jorde</surname><given-names>UP</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><etal/></person-group><article-title>Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 Heart-Mate II outpatients</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><fpage>880</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">24316083</pub-id></element-citation></ref><ref id=\"b15-cmc-suppl_3-2014-049\"><label>15</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name></person-group><article-title>Sex and gender differences in symptoms of myocardial ischaemia</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>3064</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">21920971</pub-id></element-citation></ref><ref id=\"b16-cmc-suppl_3-2014-049\"><label>16</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Arslanian-Engoren</surname><given-names>C</given-names></name><name><surname>Engoren</surname><given-names>M</given-names></name></person-group><article-title>Physiological and anatomical bases for sex differences in pain and nausea as presenting symptoms of acute coronary syndromes</article-title><source>Heart Lung</source><year>2010</year><volume>39</volume><fpage>386</fpage><lpage>93</lpage><pub-id pub-id-type=\"pmid\">20561860</pub-id></element-citation></ref><ref id=\"b17-cmc-suppl_3-2014-049\"><label>17</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kirchberger</surname><given-names>I</given-names></name><name><surname>Hejer</surname><given-names>M</given-names></name><name><surname>Kuch</surname><given-names>B</given-names></name><name><surname>Wende</surname><given-names>R</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name></person-group><article-title>Sex differences in patient-reported symptoms associated with myocardial infarction (from the population-based MONICA/KORA Myocardial Infarction Registry)</article-title><source>Am J Cardiol</source><year>2011</year><volume>107</volume><fpage>1585</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">21420056</pub-id></element-citation></ref><ref id=\"b18-cmc-suppl_3-2014-049\"><label>18</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lewis</surname><given-names>JF</given-names></name><name><surname>McGorray</surname><given-names>SP</given-names></name><name><surname>Pepine</surname><given-names>CJ</given-names></name></person-group><article-title>Assessment of women with suspected myocardial ischemia: review of findings of the Women&#x02019;s Ischemia Syndrome Evaluation (WISE) Study</article-title><source>Curr Womens Health Rep</source><year>2002</year><volume>2</volume><fpage>110</fpage><lpage>4</lpage><pub-id pub-id-type=\"pmid\">12116599</pub-id></element-citation></ref><ref id=\"b19-cmc-suppl_3-2014-049\"><label>19</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Tamis</surname><given-names>JE</given-names></name><name><surname>Thompson</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global use of strategies to open occluded coronary arteries in acute coronary syndromes IIb investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>226</fpage><lpage>32</lpage><pub-id pub-id-type=\"pmid\">10413734</pub-id></element-citation></ref><ref id=\"b20-cmc-suppl_3-2014-049\"><label>20</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Arbustini</surname><given-names>E</given-names></name><name><surname>Dal Bello</surname><given-names>B</given-names></name><name><surname>Morbini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction</article-title><source>Heart</source><year>1999</year><volume>82</volume><fpage>269</fpage><lpage>72</lpage><pub-id pub-id-type=\"pmid\">10455073</pub-id></element-citation></ref><ref id=\"b21-cmc-suppl_3-2014-049\"><label>21</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bugiardini</surname><given-names>R</given-names></name><name><surname>Manfrini</surname><given-names>O</given-names></name><name><surname>Pizzi</surname><given-names>C</given-names></name><name><surname>Fontana</surname><given-names>F</given-names></name><name><surname>Morgagni</surname><given-names>G</given-names></name></person-group><article-title>Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>2518</fpage><lpage>23</lpage><pub-id pub-id-type=\"pmid\">15136498</pub-id></element-citation></ref><ref id=\"b22-cmc-suppl_3-2014-049\"><label>22</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bugiardini</surname><given-names>R</given-names></name><name><surname>Bairey Merz</surname><given-names>CN</given-names></name></person-group><article-title>Angina with &#x0201c;normal&#x0201d; coronary arteries: a changing philosophy</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>477</fpage><lpage>84</lpage><pub-id pub-id-type=\"pmid\">15671433</pub-id></element-citation></ref><ref id=\"b23-cmc-suppl_3-2014-049\"><label>23</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Hermansson</surname><given-names>A</given-names></name></person-group><article-title>The immune system in atherosclerosis</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>204</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">21321594</pub-id></element-citation></ref><ref id=\"b24-cmc-suppl_3-2014-049\"><label>24</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McNeill</surname><given-names>E</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Greaves</surname><given-names>DR</given-names></name></person-group><article-title>Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications</article-title><source>Clin Sci</source><year>2010</year><volume>118</volume><fpage>641</fpage><lpage>55</lpage><pub-id pub-id-type=\"pmid\">20210786</pub-id></element-citation></ref><ref id=\"b25-cmc-suppl_3-2014-049\"><label>25</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Inflammation in atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2012</year><volume>32</volume><fpage>2045</fpage><lpage>51</lpage><pub-id pub-id-type=\"pmid\">22895665</pub-id></element-citation></ref><ref id=\"b26-cmc-suppl_3-2014-049\"><label>26</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Mahrendorf</surname><given-names>M</given-names></name><name><surname>Swirski</surname><given-names>FK</given-names></name></person-group><article-title>Monocyte heterogeneity in cardiovascular disease</article-title><source>Semin Immunopathol</source><year>2013</year><volume>35</volume><fpage>553</fpage><lpage>62</lpage><pub-id pub-id-type=\"pmid\">23839097</pub-id></element-citation></ref><ref id=\"b27-cmc-suppl_3-2014-049\"><label>27</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Golia</surname><given-names>E</given-names></name><name><surname>Limongelli</surname><given-names>G</given-names></name><name><surname>Natale</surname><given-names>F</given-names></name><etal/></person-group><article-title>Inflammation and cardiovascular disease: from pathogenesis to therapeutic target</article-title><source>Curr Atheroscler Rep</source><year>2014</year><volume>16</volume><fpage>435</fpage><pub-id pub-id-type=\"pmid\">25037581</pub-id></element-citation></ref><ref id=\"b28-cmc-suppl_3-2014-049\"><label>28</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Salisbury</surname><given-names>D</given-names></name><name><surname>Bronas</surname><given-names>U</given-names></name></person-group><article-title>Inflammation and immune system contribution to the etiology of atherosclerosis: mechanisms and methods of assessment</article-title><source>Nursing Res</source><year>2014</year><volume>63</volume><fpage>375</fpage><lpage>85</lpage></element-citation></ref><ref id=\"b29-cmc-suppl_3-2014-049\"><label>29</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Colin</surname><given-names>S</given-names></name><name><surname>Chinetti-Gbaguidi</surname><given-names>G</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>Macrophage phenotypes in atherosclerosis</article-title><source>Immunol Rev</source><year>2014</year><volume>262</volume><fpage>153</fpage><lpage>66</lpage><pub-id pub-id-type=\"pmid\">25319333</pub-id></element-citation></ref><ref id=\"b30-cmc-suppl_3-2014-049\"><label>30</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name><name><surname>Fredman</surname><given-names>G</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name></person-group><article-title>Inflammation and its resolution as determinants of acute coronary syndromes</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>1867</fpage><lpage>79</lpage><pub-id pub-id-type=\"pmid\">24902971</pub-id></element-citation></ref><ref id=\"b31-cmc-suppl_3-2014-049\"><label>31</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hulsmans</surname><given-names>M</given-names></name><name><surname>Holvoet</surname><given-names>P</given-names></name></person-group><article-title>The vicious circle between oxidative stress and inflammation in atherosclerosis</article-title><source>J Cell Mol Med</source><year>2010</year><volume>14</volume><fpage>70</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">19968738</pub-id></element-citation></ref><ref id=\"b32-cmc-suppl_3-2014-049\"><label>32</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Aqel</surname><given-names>NM</given-names></name><name><surname>Ball</surname><given-names>RY</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name><name><surname>Mitchinson</surname><given-names>MJ</given-names></name></person-group><article-title>Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies</article-title><source>J Pathol</source><year>1985</year><volume>146</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type=\"pmid\">3897495</pub-id></element-citation></ref><ref id=\"b33-cmc-suppl_3-2014-049\"><label>33</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jonasson</surname><given-names>L</given-names></name><name><surname>Holm</surname><given-names>J</given-names></name><name><surname>Skalli</surname><given-names>O</given-names></name><name><surname>Bondjers</surname><given-names>G</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque</article-title><source>Arteriosclerosis</source><year>1986</year><volume>6</volume><fpage>131</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">2937395</pub-id></element-citation></ref><ref id=\"b34-cmc-suppl_3-2014-049\"><label>34</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Brevitti</surname><given-names>G</given-names></name><name><surname>Giugliano</surname><given-names>G</given-names></name><name><surname>Brevitti</surname><given-names>L</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name></person-group><article-title>Inflammation in peripheral artery disease</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1862</fpage><lpage>75</lpage><pub-id pub-id-type=\"pmid\">21041698</pub-id></element-citation></ref><ref id=\"b35-cmc-suppl_3-2014-049\"><label>35</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility</article-title><source>Circulation</source><year>2013</year><volume>128</volume><fpage>632</fpage><lpage>42</lpage><pub-id pub-id-type=\"pmid\">23838163</pub-id></element-citation></ref><ref id=\"b36-cmc-suppl_3-2014-049\"><label>36</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Taleb</surname><given-names>S</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name></person-group><article-title>Adaptive T cell immune responses and atherogenesis</article-title><source>Curr Opin Pharmacol</source><year>2010</year><volume>10</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type=\"pmid\">20207195</pub-id></element-citation></ref><ref id=\"b37-cmc-suppl_3-2014-049\"><label>37</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bot</surname><given-names>I</given-names></name><name><surname>de Jager</surname><given-names>SC</given-names></name><name><surname>Zernecke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>2516</fpage><lpage>25</lpage><pub-id pub-id-type=\"pmid\">17470698</pub-id></element-citation></ref><ref id=\"b38-cmc-suppl_3-2014-049\"><label>38</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Mast cells promote atherosclerosis by releasing proinflammatory cytokines</article-title><source>Nat Med</source><year>2007</year><volume>13</volume><fpage>719</fpage><lpage>24</lpage><pub-id pub-id-type=\"pmid\">17546038</pub-id></element-citation></ref><ref id=\"b39-cmc-suppl_3-2014-049\"><label>39</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>MX</given-names></name><etal/></person-group><article-title>IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/-mice</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><fpage>3564</fpage><lpage>77</lpage><pub-id pub-id-type=\"pmid\">21821913</pub-id></element-citation></ref><ref id=\"b40-cmc-suppl_3-2014-049\"><label>40</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Cardilo-Reis</surname><given-names>L</given-names></name><name><surname>Gruber</surname><given-names>S</given-names></name><name><surname>Schreier</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype</article-title><source>EMBO Mol Med</source><year>2012</year><volume>4</volume><fpage>1072</fpage><lpage>86</lpage><pub-id pub-id-type=\"pmid\">23027612</pub-id></element-citation></ref><ref id=\"b41-cmc-suppl_3-2014-049\"><label>41</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wolfs</surname><given-names>IM</given-names></name><name><surname>Stoger</surname><given-names>JL</given-names></name><name><surname>Goossens</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis</article-title><source>FASEB J</source><year>2014</year><volume>28</volume><fpage>288</fpage><lpage>99</lpage><pub-id pub-id-type=\"pmid\">24043262</pub-id></element-citation></ref><ref id=\"b42-cmc-suppl_3-2014-049\"><label>42</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Cihakova</surname><given-names>D</given-names></name></person-group><article-title>Alternatively activated macrophages in infection and autoimmunity</article-title><source>J Autoimmun</source><year>2009</year><volume>33</volume><fpage>222</fpage><lpage>30</lpage><pub-id pub-id-type=\"pmid\">19819674</pub-id></element-citation></ref><ref id=\"b43-cmc-suppl_3-2014-049\"><label>43</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Eickelberg</surname><given-names>O</given-names></name><name><surname>Pansky</surname><given-names>A</given-names></name><name><surname>Koehler</surname><given-names>E</given-names></name><etal/></person-group><article-title>Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts</article-title><source>FASEB J</source><year>2001</year><volume>15</volume><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type=\"pmid\">11259398</pub-id></element-citation></ref><ref id=\"b44-cmc-suppl_3-2014-049\"><label>44</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Frisancho-Kiss</surname><given-names>S</given-names></name><name><surname>Yusung</surname><given-names>SA</given-names></name><etal/></person-group><article-title>IFN-&#x003b3; protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-&#x003b2;<sub>1</sub>, IL-1&#x003b2;, and IL-4 in the heart</article-title><source>Am J Pathol</source><year>2004</year><volume>165</volume><fpage>1883</fpage><lpage>94</lpage><pub-id pub-id-type=\"pmid\">15579433</pub-id></element-citation></ref><ref id=\"b45-cmc-suppl_3-2014-049\"><label>45</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Salagianni</surname><given-names>M</given-names></name><name><surname>Galani</surname><given-names>IE</given-names></name><name><surname>Lundberg</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Toll-like receptor 7 protects from atherosclerosis by constraining &#x0201c;inflammatory&#x0201d; macrophage activation</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>952</fpage><lpage>62</lpage><pub-id pub-id-type=\"pmid\">22787112</pub-id></element-citation></ref><ref id=\"b46-cmc-suppl_3-2014-049\"><label>46</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Boisvert</surname><given-names>WA</given-names></name></person-group><article-title>Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function</article-title><source>Thromb Haemost</source><year>2015</year><volume>113</volume><fpage>505</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">25373619</pub-id></element-citation></ref><ref id=\"b47-cmc-suppl_3-2014-049\"><label>47</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name><name><surname>Habsson</surname><given-names>GK</given-names></name></person-group><article-title>Immune effector mechanisms implicated in atherosclerosis: from mice to humans</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>1092</fpage><lpage>104</lpage><pub-id pub-id-type=\"pmid\">23809160</pub-id></element-citation></ref><ref id=\"b48-cmc-suppl_3-2014-049\"><label>48</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kaartinen</surname><given-names>M</given-names></name><name><surname>Penttila</surname><given-names>A</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas</article-title><source>Arterioscler Thromb</source><year>1994</year><volume>14</volume><fpage>966</fpage><lpage>72</lpage><pub-id pub-id-type=\"pmid\">7515278</pub-id></element-citation></ref><ref id=\"b49-cmc-suppl_3-2014-049\"><label>49</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kaartinen</surname><given-names>M</given-names></name><name><surname>Penttila</surname><given-names>A</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture</article-title><source>Circulation</source><year>1994</year><volume>90</volume><fpage>1669</fpage><lpage>78</lpage><pub-id pub-id-type=\"pmid\">7923651</pub-id></element-citation></ref><ref id=\"b50-cmc-suppl_3-2014-049\"><label>50</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jeziorska</surname><given-names>M</given-names></name><name><surname>McCollum</surname><given-names>C</given-names></name><name><surname>Woolley</surname><given-names>DE</given-names></name></person-group><article-title>Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries</article-title><source>J Pathol</source><year>1997</year><volume>182</volume><fpage>115</fpage><lpage>22</lpage><pub-id pub-id-type=\"pmid\">9227350</pub-id></element-citation></ref><ref id=\"b51-cmc-suppl_3-2014-049\"><label>51</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bankl</surname><given-names>HC</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name></person-group><article-title>Mast cells, thrombosis, and fibrinolysis</article-title><source>Thromb Res</source><year>2002</year><volume>105</volume><fpage>359</fpage><lpage>65</lpage><pub-id pub-id-type=\"pmid\">12031832</pub-id></element-citation></ref><ref id=\"b52-cmc-suppl_3-2014-049\"><label>52</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Frisancho-Kiss</surname><given-names>D</given-names></name></person-group><article-title>Mast cells and inflammatory heart disease: potential drug targets</article-title><source>Cardiovasc Hematol Disord Drug Targets</source><year>2008</year><volume>8</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type=\"pmid\">18336255</pub-id></element-citation></ref><ref id=\"b53-cmc-suppl_3-2014-049\"><label>53</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Brandt</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><etal/></person-group><article-title>Testosterone and interleukin-1&#x003b2; increase cardiac remodeling during acute coxsackievirus B3 myocarditis via serpin A 3n</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2012</year><volume>302</volume><fpage>H1726</fpage><lpage>36</lpage><pub-id pub-id-type=\"pmid\">22328081</pub-id></element-citation></ref><ref id=\"b54-cmc-suppl_3-2014-049\"><label>54</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Reid</surname><given-names>AC</given-names></name><name><surname>Brazin</surname><given-names>JA</given-names></name><name><surname>Morrey</surname><given-names>C</given-names></name><name><surname>Silver</surname><given-names>RB</given-names></name><name><surname>Levi</surname><given-names>R</given-names></name></person-group><article-title>Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system</article-title><source>Curr Pharm Des</source><year>2011</year><volume>17</volume><fpage>3744</fpage><lpage>52</lpage><pub-id pub-id-type=\"pmid\">22103845</pub-id></element-citation></ref><ref id=\"b55-cmc-suppl_3-2014-049\"><label>55</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Campbell</surname><given-names>DJ</given-names></name></person-group><article-title>Circulating and tissue angiotensin systems</article-title><source>J Clin Invest</source><year>1987</year><volume>79</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">3025255</pub-id></element-citation></ref><ref id=\"b56-cmc-suppl_3-2014-049\"><label>56</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Cipollone</surname><given-names>F</given-names></name><name><surname>Fazia</surname><given-names>M</given-names></name><name><surname>Iezzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Blockade of angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E<sub>2</sub>-dependent matrix metalloproteinase activity</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1482</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">15037537</pub-id></element-citation></ref><ref id=\"b57-cmc-suppl_3-2014-049\"><label>57</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Clancy</surname><given-names>P</given-names></name><name><surname>Seto</surname><given-names>S-W</given-names></name><name><surname>Koblar</surname><given-names>SA</given-names></name><name><surname>Gollege</surname><given-names>J</given-names></name></person-group><article-title>Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma</article-title><source>Atherosclerosis</source><year>2013</year><volume>229</volume><fpage>331</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">23880184</pub-id></element-citation></ref><ref id=\"b58-cmc-suppl_3-2014-049\"><label>58</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dostal</surname><given-names>DE</given-names></name><name><surname>Baker</surname><given-names>KM</given-names></name></person-group><article-title>The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?</article-title><source>Circ Res</source><year>1999</year><volume>85</volume><fpage>643</fpage><lpage>50</lpage><pub-id pub-id-type=\"pmid\">10506489</pub-id></element-citation></ref><ref id=\"b59-cmc-suppl_3-2014-049\"><label>59</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Barlucchi</surname><given-names>L</given-names></name><name><surname>Leri</surname><given-names>A</given-names></name><name><surname>Dostal</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure</article-title><source>Circ Res</source><year>2001</year><volume>88</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type=\"pmid\">11179197</pub-id></element-citation></ref><ref id=\"b60-cmc-suppl_3-2014-049\"><label>60</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Silver</surname><given-names>RB</given-names></name><name><surname>Reid</surname><given-names>AC</given-names></name><name><surname>Mackins</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Mast cells: a unique source of renin</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>13607</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">15342908</pub-id></element-citation></ref><ref id=\"b61-cmc-suppl_3-2014-049\"><label>61</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Mackins</surname><given-names>CJ</given-names></name><name><surname>Kano</surname><given-names>S</given-names></name><name><surname>Seyedi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1063</fpage><lpage>70</lpage><pub-id pub-id-type=\"pmid\">16585966</pub-id></element-citation></ref><ref id=\"b62-cmc-suppl_3-2014-049\"><label>62</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Koda</surname><given-names>K</given-names></name><name><surname>Salazar-Rodriguez</surname><given-names>M</given-names></name><name><surname>Corti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release form cardiac mast cells</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>771</fpage><lpage>81</lpage><pub-id pub-id-type=\"pmid\">20697027</pub-id></element-citation></ref><ref id=\"b63-cmc-suppl_3-2014-049\"><label>63</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nicoletti</surname><given-names>A</given-names></name><name><surname>Elhage</surname><given-names>R</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Transfer of CD4(+) T cells aggravates atherosclerosis in immunedeficient apolipoprotein E knockout mice</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>2919</fpage><lpage>22</lpage><pub-id pub-id-type=\"pmid\">11113040</pub-id></element-citation></ref><ref id=\"b64-cmc-suppl_3-2014-049\"><label>64</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Prasad</surname><given-names>KM</given-names></name><name><surname>Butcher</surname><given-names>M</given-names></name><etal/></person-group><article-title>Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice</article-title><source>Circulation</source><year>2010</year><volume>121</volume><fpage>1746</fpage><lpage>55</lpage><pub-id pub-id-type=\"pmid\">20368519</pub-id></element-citation></ref><ref id=\"b65-cmc-suppl_3-2014-049\"><label>65</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Salomon</surname><given-names>BL</given-names></name><name><surname>Potteaux</surname><given-names>S</given-names></name><etal/></person-group><article-title>Natural regulatory T cells control the development of atherosclerosis in mice</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>178</fpage><lpage>80</lpage><pub-id pub-id-type=\"pmid\">16462800</pub-id></element-citation></ref><ref id=\"b66-cmc-suppl_3-2014-049\"><label>66</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Robertson</surname><given-names>AK</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Gorelik</surname><given-names>L</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Disruption of TGF-beta signaling in T cells accelerates atherosclerosis</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>1342</fpage><lpage>50</lpage><pub-id pub-id-type=\"pmid\">14568988</pub-id></element-citation></ref><ref id=\"b67-cmc-suppl_3-2014-049\"><label>67</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Nussinovitch</surname><given-names>U</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><article-title>Autoimmunity and heart diseases: pathogenesis and diagnostic criteria</article-title><source>Arch Immunol Ther Exp</source><year>2009</year><volume>57</volume><fpage>95</fpage><lpage>104</lpage></element-citation></ref><ref id=\"b68-cmc-suppl_3-2014-049\"><label>68</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Laczik</surname><given-names>R</given-names></name><name><surname>Szodoray</surname><given-names>P</given-names></name><name><surname>Veres</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome</article-title><source>Lupus</source><year>2011</year><volume>20</volume><fpage>730</fpage><lpage>5</lpage><pub-id pub-id-type=\"pmid\">21505011</pub-id></element-citation></ref><ref id=\"b69-cmc-suppl_3-2014-049\"><label>69</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shi</surname><given-names>GP</given-names></name></person-group><article-title>Immunomodulation of vascular diseases: atherosclerosis and autoimmunity</article-title><source>Eur J Vasc Endovasc Surg</source><year>2010</year><volume>39</volume><fpage>485</fpage><lpage>94</lpage><pub-id pub-id-type=\"pmid\">20188603</pub-id></element-citation></ref><ref id=\"b70-cmc-suppl_3-2014-049\"><label>70</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dart</surname><given-names>ML</given-names></name><name><surname>Jankowska-Gan</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis</article-title><source>Circ Res</source><year>2010</year><volume>107</volume><fpage>1106</fpage><lpage>16</lpage><pub-id pub-id-type=\"pmid\">20814021</pub-id></element-citation></ref><ref id=\"b71-cmc-suppl_3-2014-049\"><label>71</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bergmark</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><name><surname>Lefvert</surname><given-names>AK</given-names></name><name><surname>Swedenborg</surname><given-names>J</given-names></name></person-group><article-title>Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1995</year><volume>15</volume><fpage>441</fpage><lpage>5</lpage><pub-id pub-id-type=\"pmid\">7749854</pub-id></element-citation></ref><ref id=\"b72-cmc-suppl_3-2014-049\"><label>72</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Greco</surname><given-names>TP</given-names></name><name><surname>Conti-Kelly</surname><given-names>AM</given-names></name><name><surname>Anthony</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Oxidized-LDL/beta(2)- glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes</article-title><source>Am J Clin Pathol</source><year>2010</year><volume>133</volume><fpage>737</fpage><lpage>43</lpage><pub-id pub-id-type=\"pmid\">20395520</pub-id></element-citation></ref><ref id=\"b73-cmc-suppl_3-2014-049\"><label>73</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Root-Bernstein</surname><given-names>R</given-names></name></person-group><article-title>Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and beta1AR as initial targets of disease</article-title><source>Front Pediatr</source><year>2014</year><volume>2</volume><fpage>85</fpage><pub-id pub-id-type=\"pmid\">25191648</pub-id></element-citation></ref><ref id=\"b74-cmc-suppl_3-2014-049\"><label>74</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Schattner</surname><given-names>M</given-names></name></person-group><article-title>Platelets and galectins</article-title><source>Ann Transl Med</source><year>2014</year><volume>2</volume><fpage>85</fpage><pub-id pub-id-type=\"pmid\">25405160</pub-id></element-citation></ref><ref id=\"b75-cmc-suppl_3-2014-049\"><label>75</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>deWitt</surname><given-names>SM</given-names></name><name><surname>Verdoold</surname><given-names>R</given-names></name><name><surname>Cosemans</surname><given-names>JM</given-names></name><name><surname>Heemskerk</surname><given-names>JW</given-names></name></person-group><article-title>Insights into platelet-based control of coagulation</article-title><source>Thromb Res</source><year>2014</year><volume>133</volume><issue>suppl 2</issue><fpage>S139</fpage><lpage>48</lpage><pub-id pub-id-type=\"pmid\">24862135</pub-id></element-citation></ref><ref id=\"b76-cmc-suppl_3-2014-049\"><label>76</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Herbin</surname><given-names>O</given-names></name><name><surname>Bouaziz</surname><given-names>JD</given-names></name><etal/></person-group><article-title>B cell depletion reduces the development of atherosclerosis in mice</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>1579</fpage><lpage>87</lpage><pub-id pub-id-type=\"pmid\">20603314</pub-id></element-citation></ref><ref id=\"b77-cmc-suppl_3-2014-049\"><label>77</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Caligiuri</surname><given-names>G</given-names></name><name><surname>Nicoletti</surname><given-names>A</given-names></name><name><surname>Poirier</surname><given-names>B</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice</article-title><source>J Clin Invest</source><year>2002</year><volume>109</volume><fpage>745</fpage><lpage>53</lpage><pub-id pub-id-type=\"pmid\">11901183</pub-id></element-citation></ref><ref id=\"b78-cmc-suppl_3-2014-049\"><label>78</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Chou</surname><given-names>MY</given-names></name><name><surname>Fogelstrand</surname><given-names>L</given-names></name><etal/></person-group><article-title>Natural antibodies in murine atherosclerosis</article-title><source>Curr Drug Targets</source><year>2008</year><volume>9</volume><fpage>190</fpage><lpage>5</lpage><pub-id pub-id-type=\"pmid\">18336236</pub-id></element-citation></ref><ref id=\"b79-cmc-suppl_3-2014-049\"><label>79</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Rosano</surname><given-names>GMC</given-names></name></person-group><article-title>Gender differences in the cardiovascular effect of sex hormones</article-title><source>Nat Rev Cardiol</source><year>2009</year><volume>6</volume><fpage>532</fpage><lpage>42</lpage><pub-id pub-id-type=\"pmid\">19564884</pub-id></element-citation></ref><ref id=\"b80-cmc-suppl_3-2014-049\"><label>80</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Tan</surname><given-names>YY</given-names></name><name><surname>Gast</surname><given-names>GM</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name></person-group><article-title>Gender differences in risk factors for coronary heart disease</article-title><source>Maturitas</source><year>2010</year><volume>65</volume><fpage>149</fpage><lpage>60</lpage><pub-id pub-id-type=\"pmid\">19897327</pub-id></element-citation></ref><ref id=\"b81-cmc-suppl_3-2014-049\"><label>81</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lee</surname><given-names>LV</given-names></name><name><surname>Foody</surname><given-names>JM</given-names></name></person-group><article-title>Women and heart disease</article-title><source>Cardiol Clin</source><year>2011</year><volume>29</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type=\"pmid\">21257099</pub-id></element-citation></ref><ref id=\"b82-cmc-suppl_3-2014-049\"><label>82</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses&#x02019; health study</article-title><source>N Engl J Med</source><year>1991</year><volume>325</volume><fpage>756</fpage><lpage>62</lpage><pub-id pub-id-type=\"pmid\">1870648</pub-id></element-citation></ref><ref id=\"b83-cmc-suppl_3-2014-049\"><label>83</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Karas</surname><given-names>RH</given-names></name></person-group><article-title>The protective effects of estrogen on the cardiovascular system</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1801</fpage><lpage>11</lpage><pub-id pub-id-type=\"pmid\">10362825</pub-id></element-citation></ref><ref id=\"b84-cmc-suppl_3-2014-049\"><label>84</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hulley</surname><given-names>S</given-names></name><name><surname>Grady</surname><given-names>D</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><etal/></person-group><article-title>Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>605</fpage><lpage>13</lpage><pub-id pub-id-type=\"pmid\">9718051</pub-id></element-citation></ref><ref id=\"b85-cmc-suppl_3-2014-049\"><label>85</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rossouw</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Prentice</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women&#x02019;s health initiative randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>321</fpage><lpage>33</lpage><pub-id pub-id-type=\"pmid\">12117397</pub-id></element-citation></ref><ref id=\"b86-cmc-suppl_3-2014-049\"><label>86</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Limacher</surname><given-names>M</given-names></name><name><surname>Assaf</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women&#x02019;s Health Initiative randomized controlled trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>1701</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">15082697</pub-id></element-citation></ref><ref id=\"b87-cmc-suppl_3-2014-049\"><label>87</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dubey</surname><given-names>RK</given-names></name><name><surname>Imthurn</surname><given-names>B</given-names></name><name><surname>Barton</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>EK</given-names></name></person-group><article-title>Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen</article-title><source>Cardiovasc Res</source><year>2005</year><volume>66</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type=\"pmid\">15820198</pub-id></element-citation></ref><ref id=\"b88-cmc-suppl_3-2014-049\"><label>88</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Grodstein</surname><given-names>F</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name></person-group><article-title>Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation</article-title><source>J Womens Health (Larchmt)</source><year>2006</year><volume>15</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type=\"pmid\">16417416</pub-id></element-citation></ref><ref id=\"b89-cmc-suppl_3-2014-049\"><label>89</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Karas</surname><given-names>RH</given-names></name></person-group><article-title>Molecular and cellular basis of cardiovascular gender differences</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1583</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">15947175</pub-id></element-citation></ref><ref id=\"b90-cmc-suppl_3-2014-049\"><label>90</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Isensee</surname><given-names>J</given-names></name><name><surname>Ruiz Noppinger</surname><given-names>P</given-names></name></person-group><article-title>Sexually dimorphic gene expression in mammalian somatic tissue</article-title><source>Gend Med</source><year>2007</year><volume>4</volume><issue>suppl B</issue><fpage>S75</fpage><lpage>95</lpage><pub-id pub-id-type=\"pmid\">18156105</pub-id></element-citation></ref><ref id=\"b91-cmc-suppl_3-2014-049\"><label>91</label><element-citation publication-type=\"book\"><person-group person-group-type=\"author\"><name><surname>Legato</surname><given-names>MJ</given-names></name><name><surname>Leghe</surname><given-names>JK</given-names></name></person-group><article-title>Gender and the heart: sex-specific differences in the normal myocardial anatomy and physiology</article-title><person-group person-group-type=\"editor\"><name><surname>Legato</surname><given-names>MJ</given-names></name></person-group><source>Principles of Gender-Specific Medicine</source><edition>2nd ed</edition><publisher-loc>Burlington, MA</publisher-loc><publisher-name>Elsevier</publisher-name><year>2010</year><fpage>151</fpage><lpage>61</lpage></element-citation></ref><ref id=\"b92-cmc-suppl_3-2014-049\"><label>92</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name><name><surname>Oertelt-Prignione</surname><given-names>S</given-names></name><name><surname>Seeland</surname><given-names>U</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group><article-title>Sex and gender differences in myocardial hypertrophy and heart failure</article-title><source>Circ J</source><year>2010</year><volume>74</volume><fpage>1265</fpage><lpage>73</lpage><pub-id pub-id-type=\"pmid\">20558892</pub-id></element-citation></ref><ref id=\"b93-cmc-suppl_3-2014-049\"><label>93</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Frisancho-Kiss</surname><given-names>S</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name></person-group><article-title>Sex differences in autoimmune disease from a pathologic perspective</article-title><source>Am J Pathol</source><year>2008</year><volume>173</volume><fpage>600</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">18688037</pub-id></element-citation></ref><ref id=\"b94-cmc-suppl_3-2014-049\"><label>94</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Revankar</surname><given-names>CM</given-names></name><name><surname>Cimino</surname><given-names>DF</given-names></name><name><surname>Sklar</surname><given-names>LA</given-names></name><name><surname>Arterburn</surname><given-names>JB</given-names></name><name><surname>Prossnitz</surname><given-names>ER</given-names></name></person-group><article-title>A transmembrane intracellular estrogen receptor mediates rapid cell signaling</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1625</fpage><lpage>30</lpage><pub-id pub-id-type=\"pmid\">15705806</pub-id></element-citation></ref><ref id=\"b95-cmc-suppl_3-2014-049\"><label>95</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Pedram</surname><given-names>A</given-names></name><name><surname>Razandi</surname><given-names>M</given-names></name><name><surname>Sainson</surname><given-names>RC</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Hughes</surname><given-names>CC</given-names></name><name><surname>Levin</surname><given-names>ER</given-names></name></person-group><article-title>A conserved mechanism for steroid receptor translocation to the plasma membrane</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>22278</fpage><lpage>88</lpage><pub-id pub-id-type=\"pmid\">17535799</pub-id></element-citation></ref><ref id=\"b96-cmc-suppl_3-2014-049\"><label>96</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Filardo</surname><given-names>E</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane</article-title><source>Endocrinology</source><year>2007</year><volume>148</volume><fpage>3236</fpage><lpage>45</lpage><pub-id pub-id-type=\"pmid\">17379646</pub-id></element-citation></ref><ref id=\"b97-cmc-suppl_3-2014-049\"><label>97</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Joseph</surname><given-names>DR</given-names></name><name><surname>Sullivan</surname><given-names>PM</given-names></name><name><surname>Willard</surname><given-names>HF</given-names></name><name><surname>French</surname><given-names>FS</given-names></name><name><surname>Wilson</surname><given-names>EM</given-names></name></person-group><article-title>Cloning of human androgen receptor complementary DNA and localization to the X chromosome</article-title><source>Science</source><year>1988</year><volume>240</volume><fpage>327</fpage><lpage>30</lpage><pub-id pub-id-type=\"pmid\">3353727</pub-id></element-citation></ref><ref id=\"b98-cmc-suppl_3-2014-049\"><label>98</label><element-citation publication-type=\"book\"><person-group person-group-type=\"author\"><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name><name><surname>Becher</surname><given-names>E</given-names></name><name><surname>Mahmoodzadeh</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>C</given-names></name></person-group><article-title>Sex steroid hormones</article-title><person-group person-group-type=\"editor\"><name><surname>Bader</surname><given-names>M</given-names></name></person-group><source>Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics</source><publisher-loc>Weinheim, Germany</publisher-loc><publisher-name>Wiley-Blackwell</publisher-name><year>2008</year><fpage>39</fpage><lpage>64</lpage></element-citation></ref><ref id=\"b99-cmc-suppl_3-2014-049\"><label>99</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hodgin</surname><given-names>JB</given-names></name><name><surname>Krege</surname><given-names>JH</given-names></name><name><surname>Reddick</surname><given-names>RL</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name><name><surname>Smithies</surname><given-names>O</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name></person-group><article-title>Estrogen receptor alpha is a major mediator of 17beta-estradiol&#x02019;s atheroprotective effects on lesion size in Apoe-/- mice</article-title><source>J Clin Invest</source><year>2001</year><volume>107</volume><fpage>333</fpage><lpage>40</lpage><pub-id pub-id-type=\"pmid\">11160157</pub-id></element-citation></ref><ref id=\"b100-cmc-suppl_3-2014-049\"><label>100</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hammes</surname><given-names>SR</given-names></name><name><surname>Levin</surname><given-names>ER</given-names></name></person-group><article-title>Minireview: recent advances in extranuclear steroid receptor actions</article-title><source>Endocrinology</source><year>2011</year><volume>152</volume><fpage>4489</fpage><lpage>95</lpage><pub-id pub-id-type=\"pmid\">22028449</pub-id></element-citation></ref><ref id=\"b101-cmc-suppl_3-2014-049\"><label>101</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Mahmoodzadeh</surname><given-names>S</given-names></name><name><surname>Leber</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cardiomyocyte-specific estrogen receptor alpha increases angiogenesis, lymphangiogenesis and reduces fibrosis in the female mouse heart post-myocardial infarction</article-title><source>J Cell Sci Ther</source><year>2014</year><volume>5</volume><fpage>153</fpage><pub-id pub-id-type=\"pmid\">24977106</pub-id></element-citation></ref><ref id=\"b102-cmc-suppl_3-2014-049\"><label>102</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Gilliver</surname><given-names>SC</given-names></name></person-group><article-title>Sex steroids as inflammatory regulators</article-title><source>J Steroid Biochem Mol Biol</source><year>2010</year><volume>120</volume><fpage>105</fpage><lpage>15</lpage><pub-id pub-id-type=\"pmid\">20045727</pub-id></element-citation></ref><ref id=\"b103-cmc-suppl_3-2014-049\"><label>103</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McCrohon</surname><given-names>JA</given-names></name><name><surname>Death</surname><given-names>AK</given-names></name><name><surname>Nakhla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>224</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">10645914</pub-id></element-citation></ref><ref id=\"b104-cmc-suppl_3-2014-049\"><label>104</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Sader</surname><given-names>MA</given-names></name><name><surname>McGrath</surname><given-names>KC</given-names></name><name><surname>Hill</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis</article-title><source>Clin Endocrinol (Oxf)</source><year>2005</year><volume>62</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type=\"pmid\">15638871</pub-id></element-citation></ref><ref id=\"b105-cmc-suppl_3-2014-049\"><label>105</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Brechenmacher</surname><given-names>SA</given-names></name><name><surname>Bruns</surname><given-names>CJ</given-names></name><name><surname>Van den Engel</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Influence of surgical trauma on the mRNA expression of sex hormone receptors in PBMCs in male and female patients</article-title><source>Langenbecks Arch Surg</source><year>2008</year><volume>393</volume><fpage>871</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">18297304</pub-id></element-citation></ref><ref id=\"b106-cmc-suppl_3-2014-049\"><label>106</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Deshpande</surname><given-names>R</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Pergolizzi</surname><given-names>RG</given-names></name><name><surname>Michael</surname><given-names>SD</given-names></name><name><surname>Change</surname><given-names>MD</given-names></name></person-group><article-title>Estradiol down-regulates LPS-induced cytokine production and NF&#x003ba;B activation in murine macrophages</article-title><source>Am J Reprod Immunol</source><year>1997</year><volume>38</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type=\"pmid\">9266010</pub-id></element-citation></ref><ref id=\"b107-cmc-suppl_3-2014-049\"><label>107</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Evans</surname><given-names>MJ</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name><name><surname>Adelman</surname><given-names>SJ</given-names></name><name><surname>Harnish</surname><given-names>DC</given-names></name></person-group><article-title>Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo</article-title><source>Circ Res</source><year>2001</year><volume>89</volume><fpage>823</fpage><lpage>30</lpage><pub-id pub-id-type=\"pmid\">11679413</pub-id></element-citation></ref><ref id=\"b108-cmc-suppl_3-2014-049\"><label>108</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Chadwick</surname><given-names>CC</given-names></name><name><surname>Chippari</surname><given-names>S</given-names></name><name><surname>Matelan</surname><given-names>E</given-names></name><etal/></person-group><article-title>Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>2543</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">15699342</pub-id></element-citation></ref><ref id=\"b109-cmc-suppl_3-2014-049\"><label>109</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Demyanets</surname><given-names>S</given-names></name><name><surname>Pfaffenberger</surname><given-names>S</given-names></name><name><surname>Kaun</surname><given-names>C</given-names></name><etal/></person-group><article-title>The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway</article-title><source>Thromb Haemost</source><year>2006</year><volume>95</volume><fpage>107</fpage><lpage>16</lpage><pub-id pub-id-type=\"pmid\">16543969</pub-id></element-citation></ref><ref id=\"b110-cmc-suppl_3-2014-049\"><label>110</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Opposing effects of estradiol and progesterone on the oxidative stress-induced production of chemokine and proinflammatory cytokines in murine peritoneal macrophages</article-title><source>J Med Invest</source><year>2008</year><volume>55</volume><fpage>133</fpage><lpage>41</lpage><pub-id pub-id-type=\"pmid\">18319556</pub-id></element-citation></ref><ref id=\"b111-cmc-suppl_3-2014-049\"><label>111</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Okwan-Duodu</surname><given-names>D</given-names></name><name><surname>Umpierrez</surname><given-names>GE</given-names></name><name><surname>Brawley</surname><given-names>OW</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name></person-group><article-title>Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages</article-title><source>Am J Cancer Res</source><year>2013</year><volume>3</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type=\"pmid\">23359288</pub-id></element-citation></ref><ref id=\"b112-cmc-suppl_3-2014-049\"><label>112</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rettew</surname><given-names>JA</given-names></name><name><surname>Huet-Hudson</surname><given-names>YM</given-names></name><name><surname>Marriott</surname><given-names>I</given-names></name></person-group><article-title>Testosterone reduces macrophage expression in the mouse of Toll-like receptor 4, a trigger for inflammation and innate immunity</article-title><source>Biol Reprod</source><year>2008</year><volume>78</volume><fpage>432</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">18003947</pub-id></element-citation></ref><ref id=\"b113-cmc-suppl_3-2014-049\"><label>113</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rettew</surname><given-names>JA</given-names></name><name><surname>Huet</surname><given-names>YM</given-names></name><name><surname>Marriott</surname><given-names>I</given-names></name></person-group><article-title>Estrogens augment cell surface TLR4 expression on murine macrophages and regulate sepsis susceptibility in vivo</article-title><source>Endocrinology</source><year>2009</year><volume>150</volume><fpage>3877</fpage><lpage>84</lpage><pub-id pub-id-type=\"pmid\">19406943</pub-id></element-citation></ref><ref id=\"b114-cmc-suppl_3-2014-049\"><label>114</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Frisancho-Kiss</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>SE</given-names></name><name><surname>Nyland</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>6710</fpage><lpage>4</lpage><pub-id pub-id-type=\"pmid\">17513715</pub-id></element-citation></ref><ref id=\"b115-cmc-suppl_3-2014-049\"><label>115</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rifici</surname><given-names>VA</given-names></name><name><surname>Khachadurian</surname><given-names>AK</given-names></name></person-group><article-title>The inhibition of low-density lipoprotein oxidation by 17-beta estradiol</article-title><source>Metabolism</source><year>1992</year><volume>41</volume><fpage>1110</fpage><lpage>4</lpage><pub-id pub-id-type=\"pmid\">1328822</pub-id></element-citation></ref><ref id=\"b116-cmc-suppl_3-2014-049\"><label>116</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Sack</surname><given-names>MN</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Cannon</surname><given-names>RO</given-names><suffix>3rd</suffix></name></person-group><article-title>Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>269</fpage><lpage>70</lpage><pub-id pub-id-type=\"pmid\">7905101</pub-id></element-citation></ref><ref id=\"b117-cmc-suppl_3-2014-049\"><label>117</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Irwin</surname><given-names>RW</given-names></name><name><surname>Brinton</surname><given-names>RD</given-names></name></person-group><article-title>Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>16983</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">17077142</pub-id></element-citation></ref><ref id=\"b118-cmc-suppl_3-2014-049\"><label>118</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Losordo</surname><given-names>DW</given-names></name><name><surname>Kearney</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>EA</given-names></name><name><surname>Jekanowski</surname><given-names>J</given-names></name><name><surname>Isner</surname><given-names>JM</given-names></name></person-group><article-title>Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women</article-title><source>Circulation</source><year>1994</year><volume>89</volume><fpage>1501</fpage><lpage>10</lpage><pub-id pub-id-type=\"pmid\">8149515</pub-id></element-citation></ref><ref id=\"b119-cmc-suppl_3-2014-049\"><label>119</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Post</surname><given-names>WS</given-names></name><name><surname>Godschmidt-Clermont</surname><given-names>PJ</given-names></name><name><surname>Wilhide</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system</article-title><source>Cardiovasc Res</source><year>1999</year><volume>43</volume><fpage>985</fpage><lpage>91</lpage><pub-id pub-id-type=\"pmid\">10615426</pub-id></element-citation></ref><ref id=\"b120-cmc-suppl_3-2014-049\"><label>120</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Cook</surname><given-names>IF</given-names></name></person-group><article-title>Sexual dimorphism of humoral immunity with vaccines</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3551</fpage><lpage>5</lpage><pub-id pub-id-type=\"pmid\">18524433</pub-id></element-citation></ref><ref id=\"b121-cmc-suppl_3-2014-049\"><label>121</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name></person-group><article-title>Sex-based biology and the rational design of influenza vaccination strategies</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>suppl 3</issue><fpage>S114</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">24966191</pub-id></element-citation></ref><ref id=\"b122-cmc-suppl_3-2014-049\"><label>122</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Straub</surname><given-names>RH</given-names></name></person-group><article-title>The complex role of estrogens in inflammation</article-title><source>Endocrine Rev</source><year>2007</year><volume>28</volume><fpage>521</fpage><lpage>74</lpage><pub-id pub-id-type=\"pmid\">17640948</pub-id></element-citation></ref><ref id=\"b123-cmc-suppl_3-2014-049\"><label>123</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rubtsov</surname><given-names>A</given-names></name><name><surname>Rubtsova</surname><given-names>K</given-names></name><name><surname>Kappler</surname><given-names>JW</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name></person-group><article-title>Genetic and hormonal factors in female-biased autoimmunity</article-title><source>Autoimm Rev</source><year>2010</year><volume>9</volume><fpage>494</fpage><lpage>8</lpage></element-citation></ref><ref id=\"b124-cmc-suppl_3-2014-049\"><label>124</label><element-citation publication-type=\"book\"><person-group person-group-type=\"author\"><name><surname>Lahita</surname><given-names>RG</given-names></name></person-group><article-title>Sex hormones and immune function</article-title><person-group person-group-type=\"editor\"><name><surname>Legato</surname><given-names>MJ</given-names></name></person-group><source>Principles of Gender-Specific Medicine</source><edition>2nd ed</edition><publisher-loc>Burlington, MA</publisher-loc><publisher-name>Elsevier</publisher-name><year>2010</year><fpage>615</fpage><lpage>26</lpage></element-citation></ref><ref id=\"b125-cmc-suppl_3-2014-049\"><label>125</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Papenfuss</surname><given-names>TL</given-names></name><name><surname>Powell</surname><given-names>ND</given-names></name><name><surname>McClain</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Estriol generates tolergenic dendritic cells in vivo that protect against autoimmunity</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><fpage>3346</fpage><lpage>55</lpage><pub-id pub-id-type=\"pmid\">21317386</pub-id></element-citation></ref><ref id=\"b126-cmc-suppl_3-2014-049\"><label>126</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Giron-Gonzalez</surname><given-names>JA</given-names></name><name><surname>Moral</surname><given-names>FJ</given-names></name><name><surname>Elvira</surname><given-names>J</given-names></name><etal/></person-group><article-title>Consistent production of a higher Th1:Th2 cytokine ratio by stimulated T cells in men compared with women</article-title><source>Eur J Endocrinol</source><year>2000</year><volume>143</volume><fpage>31</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">10870028</pub-id></element-citation></ref><ref id=\"b127-cmc-suppl_3-2014-049\"><label>127</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Giltay</surname><given-names>EJ</given-names></name><name><surname>Fonk</surname><given-names>JC</given-names></name><name><surname>von Blomberg</surname><given-names>BM</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name><name><surname>Schalkwijk</surname><given-names>C</given-names></name><name><surname>Gooren</surname><given-names>LJ</given-names></name></person-group><article-title>In vivo effects of sex steroids in lymphocyte responsiveness and immunoglobulin levels in humans</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>1648</fpage><lpage>57</lpage><pub-id pub-id-type=\"pmid\">10770211</pub-id></element-citation></ref><ref id=\"b128-cmc-suppl_3-2014-049\"><label>128</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Loria</surname><given-names>RM</given-names></name></person-group><article-title>Immune up-regulation and tumor apoptosis by androstene steroids</article-title><source>Steroids</source><year>2002</year><volume>67</volume><fpage>953</fpage><lpage>66</lpage><pub-id pub-id-type=\"pmid\">12398992</pub-id></element-citation></ref><ref id=\"b129-cmc-suppl_3-2014-049\"><label>129</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Desai</surname><given-names>KV</given-names></name><name><surname>Michalowska</surname><given-names>AM</given-names></name><name><surname>Kondaiah</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Shih</surname><given-names>JH</given-names></name><name><surname>Green</surname><given-names>JE</given-names></name></person-group><article-title>Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate</article-title><source>Mol Endocriniol</source><year>2004</year><volume>18</volume><fpage>2895</fpage><lpage>907</lpage></element-citation></ref><ref id=\"b130-cmc-suppl_3-2014-049\"><label>130</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Miller</surname><given-names>VM</given-names></name></person-group><article-title>Why are sex and gender important to basic physiology, translational and individualized medicine?</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2014</year><volume>306</volume><fpage>H781</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">24414073</pub-id></element-citation></ref><ref id=\"b131-cmc-suppl_3-2014-049\"><label>131</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Yusung</surname><given-names>S</given-names></name><name><surname>Frisancho</surname><given-names>S</given-names></name><etal/></person-group><article-title>IL-12R&#x003b2;1 and TLR4 increase IL-1&#x003b2; and IL-18-associated myocarditis and coxsackievirus replication</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>4731</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">12707353</pub-id></element-citation></ref><ref id=\"b132-cmc-suppl_3-2014-049\"><label>132</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Roberts</surname><given-names>BJ</given-names></name><name><surname>Moussawi</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>SA</given-names></name></person-group><article-title>Sex differences in TLR2 and TLR4 expression and their effect on coxsackievirus-induced autoimmune myocarditis</article-title><source>Exp Mol Pathol</source><year>2013</year><volume>94</volume><fpage>58</fpage><lpage>94</lpage><pub-id pub-id-type=\"pmid\">22750431</pub-id></element-citation></ref><ref id=\"b133-cmc-suppl_3-2014-049\"><label>133</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Huber</surname><given-names>SA</given-names></name><name><surname>Pfaeffle</surname><given-names>B</given-names></name></person-group><article-title>Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3</article-title><source>J Virol</source><year>1994</year><volume>68</volume><fpage>5126</fpage><lpage>32</lpage><pub-id pub-id-type=\"pmid\">8035512</pub-id></element-citation></ref><ref id=\"b134-cmc-suppl_3-2014-049\"><label>134</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Frisancho-Kiss</surname><given-names>S</given-names></name><name><surname>Nyland</surname><given-names>JF</given-names></name><name><surname>Davis</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Sex differences in coxsackievirus B3-induced myocarditis: IL-12R&#x003b2;1 signaling and IFN-&#x003b3; increase inflammation in males independent from STAT4</article-title><source>Brain Res</source><year>2006</year><volume>1126</volume><fpage>139</fpage><lpage>47</lpage><pub-id pub-id-type=\"pmid\">16949558</pub-id></element-citation></ref><ref id=\"b135-cmc-suppl_3-2014-049\"><label>135</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Frisancho-Kiss</surname><given-names>S</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Frisancho</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Gonadectomy of male BALB/c mice increases Tim-3<sup>+</sup> alternatively activated M2 macrophages, Tim-3<sup>+</sup> T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis</article-title><source>Brain Behav Immun</source><year>2009</year><volume>23</volume><fpage>649</fpage><lpage>57</lpage><pub-id pub-id-type=\"pmid\">19126426</pub-id></element-citation></ref><ref id=\"b136-cmc-suppl_3-2014-049\"><label>136</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Abston</surname><given-names>ED</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Bucek</surname><given-names>A</given-names></name><etal/></person-group><article-title>Th2 regulation of viral myocarditis in mice: different roles for TLR3 vs. TRIF in progression to chronic disease</article-title><source>Clin Dev Immunol</source><year>2012</year><volume>2012</volume><fpage>129486</fpage><pub-id pub-id-type=\"pmid\">22013485</pub-id></element-citation></ref><ref id=\"b137-cmc-suppl_3-2014-049\"><label>137</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Abston</surname><given-names>ED</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Bucek</surname><given-names>A</given-names></name><etal/></person-group><article-title>TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL&#x02212;4</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2013</year><volume>304</volume><fpage>R267</fpage><lpage>77</lpage><pub-id pub-id-type=\"pmid\">23255589</pub-id></element-citation></ref><ref id=\"b138-cmc-suppl_3-2014-049\"><label>138</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McNamara</surname><given-names>DM</given-names></name><name><surname>Starling</surname><given-names>RC</given-names></name><name><surname>Cooper</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><fpage>1112</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">21884947</pub-id></element-citation></ref><ref id=\"b139-cmc-suppl_3-2014-049\"><label>139</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lyden</surname><given-names>DC</given-names></name><name><surname>Olszewski</surname><given-names>J</given-names></name><name><surname>Feran</surname><given-names>M</given-names></name><name><surname>Job</surname><given-names>LP</given-names></name><name><surname>Huber</surname><given-names>SA</given-names></name></person-group><article-title>Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes</article-title><source>Am J Pathol</source><year>1987</year><volume>126</volume><fpage>432</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">3030117</pub-id></element-citation></ref><ref id=\"b140-cmc-suppl_3-2014-049\"><label>140</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Huber</surname><given-names>SA</given-names></name></person-group><article-title>Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells</article-title><source>Virology</source><year>2008</year><volume>378</volume><fpage>292</fpage><lpage>8</lpage><pub-id pub-id-type=\"pmid\">18586295</pub-id></element-citation></ref><ref id=\"b141-cmc-suppl_3-2014-049\"><label>141</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Huber</surname><given-names>SA</given-names></name><name><surname>Kupperman</surname><given-names>J</given-names></name><name><surname>Newell</surname><given-names>MK</given-names></name></person-group><article-title>Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression</article-title><source>Lupus</source><year>1999</year><volume>8</volume><fpage>384</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">10455518</pub-id></element-citation></ref><ref id=\"b142-cmc-suppl_3-2014-049\"><label>142</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>LT</given-names><suffix>Jr</suffix></name><name><surname>Blauwet</surname><given-names>LA</given-names></name></person-group><article-title>Sex and gender differences in myocarditis and dilated cardiomyopathy</article-title><source>Curr Probl Cardiol</source><year>2013</year><volume>38</volume><fpage>7</fpage><lpage>46</lpage><pub-id pub-id-type=\"pmid\">23158412</pub-id></element-citation></ref><ref id=\"b143-cmc-suppl_3-2014-049\"><label>143</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis</article-title><source>Circ Res</source><year>2009</year><volume>105</volume><fpage>353</fpage><lpage>64</lpage><pub-id pub-id-type=\"pmid\">19608981</pub-id></element-citation></ref><ref id=\"b144-cmc-suppl_3-2014-049\"><label>144</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Akatsu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis</article-title><source>Clin Sci</source><year>2003</year><volume>104</volume><fpage>577</fpage><lpage>84</lpage><pub-id pub-id-type=\"pmid\">12589705</pub-id></element-citation></ref><ref id=\"b145-cmc-suppl_3-2014-049\"><label>145</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Akatsu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Toll-like receptor 4 is expressed with enteroviral replication in myocardium form patients with dilated cardiomyopathy</article-title><source>Lab Invest</source><year>2004</year><volume>84</volume><fpage>173</fpage><lpage>81</lpage><pub-id pub-id-type=\"pmid\">14688801</pub-id></element-citation></ref><ref id=\"b146-cmc-suppl_3-2014-049\"><label>146</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Onyimba</surname><given-names>JA</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Garton</surname><given-names>AE</given-names></name><etal/></person-group><article-title>The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice</article-title><source>Biol Sex Differ</source><year>2011</year><volume>2</volume><fpage>2</fpage><pub-id pub-id-type=\"pmid\">21338512</pub-id></element-citation></ref><ref id=\"b147-cmc-suppl_3-2014-049\"><label>147</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Coronado</surname><given-names>MJ</given-names></name><name><surname>Garton</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Sex differences in translocator protein 18 kDa (TSPO) in the heart: implications for imaging myocardial inflammation</article-title><source>J Cardiovasc Trans Res</source><year>2014</year><volume>7</volume><fpage>192</fpage><lpage>202</lpage></element-citation></ref><ref id=\"b148-cmc-suppl_3-2014-049\"><label>148</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Zhai</surname><given-names>P</given-names></name><name><surname>Eurell</surname><given-names>TE</given-names></name><name><surname>Cooke</surname><given-names>PS</given-names></name><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Gross</surname><given-names>DR</given-names></name></person-group><article-title>Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2000</year><volume>278</volume><fpage>H1640</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">10775144</pub-id></element-citation></ref><ref id=\"b149-cmc-suppl_3-2014-049\"><label>149</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Crisostomo</surname><given-names>P</given-names></name><name><surname>Wairiuko</surname><given-names>GM</given-names></name><name><surname>Meldrum</surname><given-names>DR</given-names></name></person-group><article-title>Estrogen receptor-alpha mediates acute myocardial protection in females</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>290</volume><fpage>H2204</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">16415070</pub-id></element-citation></ref><ref id=\"b150-cmc-suppl_3-2014-049\"><label>150</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Booth</surname><given-names>EA</given-names></name><name><surname>Marchesi</surname><given-names>M</given-names></name><name><surname>Knittel</surname><given-names>AK</given-names></name><name><surname>Kilbourne</surname><given-names>EJ</given-names></name><name><surname>Lucchesi</surname><given-names>BR</given-names></name></person-group><article-title>The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism</article-title><source>J Cardiovasc Pharmacol</source><year>2007</year><volume>49</volume><fpage>401</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">17577105</pub-id></element-citation></ref><ref id=\"b151-cmc-suppl_3-2014-049\"><label>151</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jeanes</surname><given-names>HL</given-names></name><name><surname>Tabor</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>D</given-names></name><name><surname>Ederveen</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>GA</given-names></name></person-group><article-title>Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER) alpha agonist and unaffected by an ER beta antagonist</article-title><source>J Endocrinol</source><year>2008</year><volume>197</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type=\"pmid\">18492815</pub-id></element-citation></ref><ref id=\"b152-cmc-suppl_3-2014-049\"><label>152</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vornehm</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Abarbanell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery</article-title><source>Surgery</source><year>2009</year><volume>146</volume><fpage>145</fpage><lpage>54</lpage><pub-id pub-id-type=\"pmid\">19628068</pub-id></element-citation></ref><ref id=\"b153-cmc-suppl_3-2014-049\"><label>153</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Sandberg</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Hay</surname><given-names>M</given-names></name></person-group><article-title>Sex-specific immune modulation of primary hypertension</article-title><source>Cell Immunol</source><year>2014</year><volume>pii:S0008&#x02013;8749</volume><issue>14</issue><fpage>00178</fpage><lpage>6</lpage></element-citation></ref><ref id=\"b154-cmc-suppl_3-2014-049\"><label>154</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kania</surname><given-names>G</given-names></name><name><surname>Blyszczuk</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>U</given-names></name></person-group><article-title>Mechanisms of cardiac fibrosis in inflammatory heart disease</article-title><source>Trends Cardiovasc Med</source><year>2009</year><volume>19</volume><fpage>247</fpage><lpage>52</lpage><pub-id pub-id-type=\"pmid\">20447565</pub-id></element-citation></ref><ref id=\"b155-cmc-suppl_3-2014-049\"><label>155</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Levick</surname><given-names>SP</given-names></name><name><surname>Melendez</surname><given-names>GC</given-names></name><name><surname>Plante</surname><given-names>E</given-names></name><name><surname>McLarty</surname><given-names>JL</given-names></name><name><surname>Brower</surname><given-names>GL</given-names></name><name><surname>Janicki</surname><given-names>JS</given-names></name></person-group><article-title>Cardiac mast cells: the centrepiece in adverse myocardial remodeling</article-title><source>Cardiovasc Res</source><year>2011</year><volume>89</volume><fpage>12</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">20736239</pub-id></element-citation></ref><ref id=\"b156-cmc-suppl_3-2014-049\"><label>156</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rodriguez-Menocal</surname><given-names>L</given-names></name><name><surname>Faridi</surname><given-names>MH</given-names></name><name><surname>Martinez</surname><given-names>L</given-names></name><etal/></person-group><article-title>Macrophage-derived IL-18 and increased fibrinogen deposition are age-related inflammatory signatures of vascular remodeling</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2014</year><volume>306</volume><fpage>H641</fpage><lpage>53</lpage><pub-id pub-id-type=\"pmid\">24414074</pub-id></element-citation></ref><ref id=\"b157-cmc-suppl_3-2014-049\"><label>157</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Cocker</surname><given-names>MS</given-names></name><name><surname>Abdel-Aty</surname><given-names>H</given-names></name><name><surname>Strohm</surname><given-names>O</given-names></name><name><surname>Friedrich</surname><given-names>MG</given-names></name></person-group><article-title>Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study</article-title><source>Heart</source><year>2009</year><volume>95</volume><fpage>1925</fpage><lpage>30</lpage><pub-id pub-id-type=\"pmid\">19710029</pub-id></element-citation></ref><ref id=\"b158-cmc-suppl_3-2014-049\"><label>158</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Haddad</surname><given-names>GE</given-names></name><name><surname>Saunders</surname><given-names>LJ</given-names></name><name><surname>Crosby</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences</article-title><source>Physiol Genomics</source><year>2008</year><volume>33</volume><fpage>267</fpage><lpage>77</lpage><pub-id pub-id-type=\"pmid\">18303083</pub-id></element-citation></ref><ref id=\"b159-cmc-suppl_3-2014-049\"><label>159</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Cavasin</surname><given-names>MA</given-names></name><name><surname>Tao</surname><given-names>Z-Y</given-names></name><name><surname>Yu</surname><given-names>A-L</given-names></name><name><surname>Yang</surname><given-names>X-P</given-names></name></person-group><article-title>Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>290</volume><fpage>H2043</fpage><lpage>50</lpage><pub-id pub-id-type=\"pmid\">16361364</pub-id></element-citation></ref><ref id=\"b160-cmc-suppl_3-2014-049\"><label>160</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Asakura</surname><given-names>M</given-names></name><name><surname>Kitakaze</surname><given-names>M</given-names></name></person-group><article-title>Global gene expression profiling in the failing myocardium</article-title><source>Circ J</source><year>2009</year><volume>73</volume><fpage>1568</fpage><lpage>76</lpage><pub-id pub-id-type=\"pmid\">19638707</pub-id></element-citation></ref><ref id=\"b161-cmc-suppl_3-2014-049\"><label>161</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Weinberger</surname><given-names>B</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name></person-group><article-title>The aging of the immune system</article-title><source>Transpl Int</source><year>2009</year><volume>22</volume><fpage>1041</fpage><lpage>50</lpage><pub-id pub-id-type=\"pmid\">19624493</pub-id></element-citation></ref><ref id=\"b162-cmc-suppl_3-2014-049\"><label>162</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Gameiro</surname><given-names>CM</given-names></name><name><surname>Romao</surname><given-names>F</given-names></name><name><surname>Castelo-Branco</surname><given-names>C</given-names></name></person-group><article-title>Menopause and aging: changes in the immune system &#x02013; a review</article-title><source>Maturitas</source><year>2010</year><volume>67</volume><fpage>316</fpage><lpage>20</lpage><pub-id pub-id-type=\"pmid\">20813470</pub-id></element-citation></ref><ref id=\"b163-cmc-suppl_3-2014-049\"><label>163</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Goronzy</surname><given-names>JJ</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name></person-group><article-title>Understanding immunosenescence to improve responses to vaccines</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><fpage>428</fpage><lpage>36</lpage><pub-id pub-id-type=\"pmid\">23598398</pub-id></element-citation></ref><ref id=\"b164-cmc-suppl_3-2014-049\"><label>164</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>McCullough</surname><given-names>LD</given-names></name></person-group><article-title>Interactions between age, sex, and hormones in experimental ischemic stroke</article-title><source>Neurochem Inter</source><year>2012</year><volume>61</volume><fpage>1255</fpage><lpage>65</lpage></element-citation></ref><ref id=\"b165-cmc-suppl_3-2014-049\"><label>165</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Zacharovich</surname><given-names>D</given-names></name><name><surname>Pery</surname><given-names>J</given-names></name><name><surname>Kitai</surname><given-names>E</given-names></name></person-group><article-title>Lowering effect of estrogen replacement treatment on immunoglobulins in menopausal women</article-title><source>Rev Fr Gynecol Obstet</source><year>1990</year><volume>85</volume><fpage>207</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">2367798</pub-id></element-citation></ref><ref id=\"b166-cmc-suppl_3-2014-049\"><label>166</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kato</surname><given-names>I</given-names></name><name><surname>Toniolo</surname><given-names>P</given-names></name><name><surname>Akhmedkhanov</surname><given-names>A</given-names></name><name><surname>Koenig</surname><given-names>KL</given-names></name><name><surname>Shore</surname><given-names>R</given-names></name><name><surname>Zeleniuch-Jacquotte</surname><given-names>A</given-names></name></person-group><article-title>Prospective study of factors influencing the onset of natural menopause</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1271</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">10086819</pub-id></element-citation></ref><ref id=\"b167-cmc-suppl_3-2014-049\"><label>167</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jacobsen</surname><given-names>BK</given-names></name><name><surname>Heuch</surname><given-names>I</given-names></name><name><surname>Kvale</surname><given-names>G</given-names></name></person-group><article-title>Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women</article-title><source>Am J Epidemiol</source><year>2003</year><volume>157</volume><fpage>923</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">12746245</pub-id></element-citation></ref><ref id=\"b168-cmc-suppl_3-2014-049\"><label>168</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Harlow</surname><given-names>SD</given-names></name><name><surname>Gass</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><fpage>1159</fpage><lpage>68</lpage><pub-id pub-id-type=\"pmid\">22344196</pub-id></element-citation></ref><ref id=\"b169-cmc-suppl_3-2014-049\"><label>169</label><element-citation publication-type=\"book\"><person-group person-group-type=\"author\"><name><surname>Vermeulen</surname><given-names>A</given-names></name></person-group><article-title>Declining androgens with age: an overview</article-title><person-group person-group-type=\"editor\"><name><surname>Vermeulien</surname><given-names>A</given-names></name><name><surname>Oddens</surname><given-names>BJ</given-names></name></person-group><source>Androgens and the Aging Male</source><publisher-loc>New York</publisher-loc><publisher-name>Parthenon Publishing</publisher-name><year>1996</year><fpage>3</fpage><lpage>14</lpage></element-citation></ref><ref id=\"b170-cmc-suppl_3-2014-049\"><label>170</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Pines</surname><given-names>A</given-names></name></person-group><article-title>Male menopause: is it a real clinical syndrome?</article-title><source>Climacteric</source><year>2011</year><volume>14</volume><fpage>15</fpage><lpage>7</lpage><pub-id pub-id-type=\"pmid\">20670200</pub-id></element-citation></ref><ref id=\"b171-cmc-suppl_3-2014-049\"><label>171</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Davison</surname><given-names>SL</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Donath</surname><given-names>S</given-names></name><name><surname>Montalto</surname><given-names>JG</given-names></name><name><surname>Davis</surname><given-names>SR</given-names></name></person-group><article-title>Androgen levels in adult females: changes with age, menopause, and oophorectomy</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>3847</fpage><lpage>53</lpage><pub-id pub-id-type=\"pmid\">15827095</pub-id></element-citation></ref><ref id=\"b172-cmc-suppl_3-2014-049\"><label>172</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bove</surname><given-names>R</given-names></name></person-group><article-title>Autoimmune diseases and reproductive aging</article-title><source>Clin Immunol</source><year>2013</year><volume>149</volume><fpage>251</fpage><lpage>64</lpage><pub-id pub-id-type=\"pmid\">23522436</pub-id></element-citation></ref><ref id=\"b173-cmc-suppl_3-2014-049\"><label>173</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>White</surname><given-names>HD</given-names></name><name><surname>Crassi</surname><given-names>KM</given-names></name><name><surname>Givan</surname><given-names>AL</given-names></name><etal/></person-group><article-title>CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>3017</fpage><lpage>27</lpage><pub-id pub-id-type=\"pmid\">9058841</pub-id></element-citation></ref><ref id=\"b174-cmc-suppl_3-2014-049\"><label>174</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shakhar</surname><given-names>K</given-names></name><name><surname>Shakhar</surname><given-names>G</given-names></name><name><surname>Rosenne</surname><given-names>E</given-names></name><name><surname>Ben-Eliyahu</surname><given-names>S</given-names></name></person-group><article-title>Timing within the menstrual cycle, sex and the use of oral contraceptives determine adrenergic suppression of NK cell activity</article-title><source>Br J Cancer</source><year>2000</year><volume>83</volume><fpage>1630</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">11104557</pub-id></element-citation></ref><ref id=\"b175-cmc-suppl_3-2014-049\"><label>175</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kalogeropoulos</surname><given-names>A</given-names></name><name><surname>Georgiopoulou</surname><given-names>V</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Inflammatory markers and incident heart failure risk in older adults: the health ABC (health, aging, and body composition) study</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><fpage>2129</fpage><lpage>37</lpage><pub-id pub-id-type=\"pmid\">20447537</pub-id></element-citation></ref><ref id=\"b176-cmc-suppl_3-2014-049\"><label>176</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Medenwald</surname><given-names>D</given-names></name><name><surname>Kors</surname><given-names>JA</given-names></name><name><surname>Loppnow</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inflammation and prolonged QT time: results from the cardiovascular disease, living and ageing in Halle (CARLA) study</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e95994</fpage><pub-id pub-id-type=\"pmid\">24770373</pub-id></element-citation></ref><ref id=\"b177-cmc-suppl_3-2014-049\"><label>177</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Feldman</surname><given-names>I</given-names></name><name><surname>Feldman</surname><given-names>GM</given-names></name><name><surname>Mobarak</surname><given-names>C</given-names></name><name><surname>Dunkelberg</surname><given-names>JC</given-names></name><name><surname>Leslie</surname><given-names>KK</given-names></name></person-group><article-title>Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha</article-title><source>Am J Obstet Gynecol</source><year>2007</year><volume>196</volume><fpage>394.e1</fpage><lpage>394.e11</lpage><pub-id pub-id-type=\"pmid\">17403432</pub-id></element-citation></ref><ref id=\"b178-cmc-suppl_3-2014-049\"><label>178</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Paimela</surname><given-names>T</given-names></name><name><surname>Ryhanen</surname><given-names>T</given-names></name><name><surname>Mannermaa</surname><given-names>E</given-names></name><etal/></person-group><article-title>The effect of 17beta-estradiol on IL-6 secretion and NF-kappaB DNA-binding activity in human retinal pigment epithelial cells</article-title><source>Immunol Lett</source><year>2007</year><volume>110</volume><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type=\"pmid\">17532054</pub-id></element-citation></ref><ref id=\"b179-cmc-suppl_3-2014-049\"><label>179</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Liu</surname><given-names>H-B</given-names></name><name><surname>Loo</surname><given-names>KK</given-names></name><name><surname>Palaszynski</surname><given-names>I</given-names></name><name><surname>Ashouri</surname><given-names>J</given-names></name><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Voskuhl</surname><given-names>RR</given-names></name></person-group><article-title>Estrogen receptor &#x003b1; mediates estrogen&#x02019;s immune protection in autoimmune disease</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>6936</fpage><lpage>40</lpage><pub-id pub-id-type=\"pmid\">14662901</pub-id></element-citation></ref></ref-list></back><floats-group><fig id=\"f1-cmc-suppl_3-2014-049\" position=\"float\"><label>Figure 1</label><caption><p>Role of inflammation in an atherosclerotic plaque. Inflammation within the vessel wall of an atherosclerotic plaque consists primarily of macrophages, mast cells, T cells (Th1, Th2, and Th17), B cells, and dendritic cells (not shown). Plaques develop a necrotic core of lipids and a fibrous cap of smooth muscle cells and collagen. In advanced stages of disease, immune cells may also accumulate on the lumen side of the plaque, disrupting blood flow and contributing to clot formation. Elevated levels of circulating cholesterol and apolipoprotein B undergo oxidative modifications to form oxidized low-density lipoprotein that is internalized by macrophage scavenger receptors to create macrophage foam cells within plaques. Internalization of oxLDL results in the formation of cholesterol crystals that activate TLR4 and the inflammasome, leading to secretion of mediators including proinflammatory and profibrotic cytokines, chemokines, eicosanoids, proteinases, and oxidases that promote plaque inflammation, remodeling, and the eventual formation of a thrombus leading to a MI. Autoantibodies against oxidized lipids (ox) may further promote disease.</p></caption><graphic xlink:href=\"cmc-suppl_3-2014-049f1\"/></fig><fig id=\"f2-cmc-suppl_3-2014-049\" position=\"float\"><label>Figure 2</label><caption><p>Atherosclerotic inflammation leading to MI in men vs women. Testosterone increases the number and activation of mast cells (MCs) and macrophages (Mac), leading to the development of TLR2<sup>+</sup>/TLR4<sup>+</sup>/M2b macrophages and foam cells within atherosclerotic plaques (upraised area of inflammation). Cytokines, enzymes, and other mediators like MMPs released from MCs and Mac allow remodeling of the vessel wall, resulting in thrombus formation and MI in men. In contrast, estrogen promotes more antibodies and autoantibodies (AutoAbs) against oxLDL, for example. Deposition of ICs on narrow vessel walls activates complement and leads to shear stress from higher blood pressure in females, thrombus formation, and MI in women.</p></caption><graphic xlink:href=\"cmc-suppl_3-2014-049f2\"/></fig><table-wrap id=\"t1-cmc-suppl_3-2014-049\" position=\"float\"><label>Table 1</label><caption><p>Effect of estrogen on the immune response.</p></caption><table frame=\"box\" rules=\"rows\"><tbody><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Activates B cells resulting in increased antibodies and autoantibodies</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Increases DC differentiation</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Low dose/after menopause: increases Th1/Th17-type immune responses</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">High dose/pregnancy: increases Th2-type immune responses</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Increases anti-inflammatory M2 macrophages, Treg, IL-4, IL-10, and TGF&#x003b2;</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Inhibits TNF, IL-1, and IL-6 by downregulating NF&#x003ba;B</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Increases atheroprotective ApoE</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Decreases atherogenic oxLDL and angiotensin II</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Decreases remodeling and fibrosis by reducing collagen and TGF&#x003b2;</td></tr></tbody></table></table-wrap><table-wrap id=\"t2-cmc-suppl_3-2014-049\" position=\"float\"><label>Table 2</label><caption><p>Similar mechanisms between myocarditis and atherosclerosis.</p></caption><table frame=\"box\" rules=\"rows\"><tbody><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">TLR2 and TLR4 signaling increase disease</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">The inflammasome, IL-1&#x003b2;, and IL-6 increase disease</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Increased inflammation is associated with a Th1-type immune response</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">M2b macrophages that release IL-1&#x003b2; and TGF&#x003b2; increase disease</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Anti-inflammatory M2a macrophages, Treg, IL-4, and IL-10 reduce inflammation</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">MC activation and remodeling lead to heart failure</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">The presence of clots worsens disease outcome (large mural thrombi in myocarditis, small thrombi occluding vessels leading to MI in atherosclerosis)</td></tr><tr><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">TLR3 signaling decreases disease</td></tr></tbody></table></table-wrap></floats-group></article>'}"
      ]
     },
     "execution_count": 387,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cursor.next()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "keyword_annotator = KeywordAnnotator(keywords=get_annotation_keywords())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 305,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def annotated_keyword_list_to_dict(keyword_list):\n",
    "    keyword_dict = {}\n",
    "    for keyword_entity in keyword_list:\n",
    "        keyword, uri = keyword_entity\n",
    "        if keyword in keyword_dict:\n",
    "            continue\n",
    "        else:\n",
    "            keyword_dict[keyword] = uri[0].entity.toPython()\n",
    "    return(keyword_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 356,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def write_article_meta_to_mongo(article):\n",
    "    pc_article = pubcrawler.Article(article)\n",
    "    anno_doc = AnnoDoc(pc_article.body)\n",
    "    anno_doc.add_tier(keyword_annotator)\n",
    "    infectious_diseases = [\n",
    "        (disease.text, resolve_keyword(disease.text))\n",
    "        for disease in anno_doc.tiers['keywords'].spans\n",
    "    ]\n",
    "    disease_ontology_keywords = None if len(infectious_diseases) == 0 else annotated_keyword_list_to_dict(infectious_diseases)\n",
    "    print(disease_ontology_keywords)\n",
    "    articles.update_one({'_id': 'test'},\n",
    "                        {\n",
    "                        '$set':\n",
    "                            {\n",
    "                            'meta':\n",
    "                                {\n",
    "                                'article-ids': pc_article.pub_ids(),\n",
    "                                'article-type': pc_article.article_type(),\n",
    "                                # 'pub-dates': pc_article.pub_dates()\n",
    "                                # Need to fix stuff with dates in Mongo\n",
    "                                'keywords': pc_article.keywords()\n",
    "                                },\n",
    "                            'annotations':\n",
    "                                {\n",
    "                                'disease-ontology-keywords': disease_ontology_keywords\n",
    "                                }\n",
    "                            },\n",
    "                        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 364,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<pymongo.results.InsertOneResult at 0x11af04bd0>"
      ]
     },
     "execution_count": 364,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x = cursor.next()\n",
    "x['_id'] = \"test\"\n",
    "articles.delete_one({'_id': \"test\"})\n",
    "articles.insert_one(x)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 365,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'_id': 'test',\n",
       " 'nxml': '<!DOCTYPE article PUBLIC \"-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN\" \"JATS-archivearticle1.dtd\">\\n<article xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" article-type=\"research-article\"><?properties open_access?><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">J Pathol</journal-id><journal-id journal-id-type=\"publisher-id\">path</journal-id><journal-title-group><journal-title>The Journal of Pathology</journal-title></journal-title-group><issn pub-type=\"ppub\">0022-3417</issn><issn pub-type=\"epub\">1096-9896</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmid\">20229506</article-id><article-id pub-id-type=\"pmc\">3262968</article-id><article-id pub-id-type=\"doi\">10.1002/path.2696</article-id><article-categories><subj-group subj-group-type=\"heading\"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Driver mutations in <italic>TP53</italic> are ubiquitous in high grade serous carcinoma of the ovary</article-title></title-group><contrib-group><contrib contrib-type=\"author\"><name><surname>Ahmed</surname><given-names>Ahmed Ashour</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Etemadmoghadam</surname><given-names>Dariush</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref></contrib><contrib contrib-type=\"author\"><name><surname>Temple</surname><given-names>Jillian</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Lynch</surname><given-names>Andy G</given-names></name><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Riad</surname><given-names>Mohamed</given-names></name><xref ref-type=\"aff\" rid=\"au4\">4</xref></contrib><contrib contrib-type=\"author\"><name><surname>Sharma</surname><given-names>Raghwa</given-names></name><xref ref-type=\"aff\" rid=\"au5\">5</xref></contrib><contrib contrib-type=\"author\"><name><surname>Stewart</surname><given-names>Colin</given-names></name><xref ref-type=\"aff\" rid=\"au6\">6</xref></contrib><contrib contrib-type=\"author\"><name><surname>Fereday</surname><given-names>Sian</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref></contrib><contrib contrib-type=\"author\"><name><surname>Caldas</surname><given-names>Carlos</given-names></name><xref ref-type=\"aff\" rid=\"au2\">2</xref><xref ref-type=\"aff\" rid=\"au7\">7</xref></contrib><contrib contrib-type=\"author\"><name><surname>deFazio</surname><given-names>Anna</given-names></name><xref ref-type=\"aff\" rid=\"au8\">8</xref></contrib><contrib contrib-type=\"author\"><name><surname>Bowtell</surname><given-names>David</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref><xref ref-type=\"aff\" rid=\"au9\">9</xref><xref ref-type=\"corresp\" rid=\"cor1\">*</xref></contrib><contrib contrib-type=\"author\"><name><surname>Brenton</surname><given-names>James D</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref><xref ref-type=\"corresp\" rid=\"cor2\">*</xref></contrib></contrib-group><aff id=\"au1\"><label>1</label><institution>Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre</institution><addr-line>Robinson Way, Cambridge, CB2 0RE, UK</addr-line></aff><aff id=\"au2\"><label>2</label><institution>Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre</institution><addr-line>Hills Road, Cambridge, CB2 0XZ, UK</addr-line></aff><aff id=\"au3\"><label>3</label><institution>Peter MacCallum Cancer Centre</institution><addr-line>Melbourne, Victoria, Australia</addr-line></aff><aff id=\"au4\"><label>4</label><institution>Department of Obstetrics and Gynaecology, El-Galaa Maternity Teaching Hospital</institution><addr-line>41 July 26th Street, Cairo 11511, Egypt</addr-line></aff><aff id=\"au5\"><label>5</label><institution>Department of Anatomical Pathology, University of Sydney and University of Western Sydney at Westmead Hospital</institution><addr-line>Sydney, Australia</addr-line></aff><aff id=\"au6\"><label>6</label><institution>Department of Pathology, King Edward Memorial Hospital</institution><addr-line>Western Australia, Australia</addr-line></aff><aff id=\"au7\"><label>7</label><institution>Functional Genomics of Breast Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre</institution><addr-line>Robinson Way, Cambridge, CB2 0RE, UK</addr-line></aff><aff id=\"au8\"><label>8</label><institution>Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital</institution><addr-line>New South Wales, Australia</addr-line></aff><aff id=\"au9\"><label>9</label><institution>Department of Biochemistry and Molecular Biology, University of Melbourne</institution><addr-line>Parkville, Victoria, Australia</addr-line></aff><author-notes><corresp id=\"cor1\">*Correspondence to: Professor David Bowtell, Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A\\'Beckett Street, Melbourne, 8006, Victoria, Australia. e-mail: <email>d.bowtell@petermac.org</email></corresp><corresp id=\"cor2\">*Correspondence to: Dr James D Brenton, Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. e-mail: <email>james.brenton@cancer.org.uk</email></corresp><fn><p>No conflicts of interest were declared.</p></fn></author-notes><pub-date pub-type=\"ppub\"><month>5</month><year>2010</year></pub-date><volume>221</volume><issue>1</issue><fpage>49</fpage><lpage>56</lpage><history><date date-type=\"received\"><day>09</day><month>12</month><year>2009</year></date><date date-type=\"rev-recd\"><day>24</day><month>1</month><year>2010</year></date><date date-type=\"accepted\"><day>26</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley &#x00026; Sons, Ltd.</copyright-statement><copyright-year>2010</copyright-year><license license-type=\"open-access\" xlink:href=\"http://creativecommons.org/licenses/by/2.5/\"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p>Numerous studies have tested the association between <italic>TP53</italic> mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of <italic>TP53</italic> mutations in HGPSC, we sequenced exons 2&#x02013;11 and intron&#x02013;exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic <italic>TP53</italic> mutations were identified in 96.7% (<italic>n</italic> = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of <italic>MDM2</italic> or <italic>MDM4</italic>, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between <italic>TP53</italic> mutation and progression-free or overall survival was found. From this first comprehensive mapping of <italic>TP53</italic> mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant <italic>TP53</italic> is a driver mutation in the pathogenesis of HGPSC cancers. Because <italic>TP53</italic> mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. Copyright &#x000a9; 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley &#x00026; Sons, Ltd.</p></abstract><kwd-group><kwd>p53</kwd><kwd>high-grade pelvic serous carcinoma</kwd><kwd>ovarian cancer</kwd><kwd>DNA sequence analysis</kwd><kwd>array-based genomic hybridization</kwd><kwd>histopathology</kwd><kwd>clinical outcome</kwd><kwd>BRCA</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The gene <italic>TP53</italic> that encodes the tumour suppressor protein p53 is amongst the most commonly mutated genes in human cancer [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. The frequent presence of <italic>TP53</italic> mutations in ovarian cancer has been suggested for almost two decades [<xref ref-type=\"bibr\" rid=\"b2\">2</xref>,<xref ref-type=\"bibr\" rid=\"b3\">3</xref>] and during this time, approximately 70 publications have described the relationship between <italic>TP53</italic> mutation status and clinical outcome [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>]. For such an intensively studied question, there is a surprising degree of inconsistency in the published data for both the prevalence of mutation and association with prognosis or chemotherapy response.</p><p>A recent analysis of 64 publications reporting the relationship of <italic>TP53</italic> mutation to clinical outcome found that only six studies fulfilled minimum quality criteria for the method of detecting mutations or assignment of clinical response [<xref ref-type=\"bibr\" rid=\"b5\">5</xref>]. One of the most consistent limitations of previous p53 studies is a reliance on p53 immunostaining as a surrogate marker for <italic>TP53</italic> mutation [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>], even though this leads to an unacceptable number of misclassifications [<xref ref-type=\"bibr\" rid=\"b6\">6</xref>]. Sequencing of tumour DNA is the gold standard to detect different types of mutation and relate these to clinical outcome. However, a recent review of 12 studies that sequenced <italic>TP53</italic> in ovarian cancer found variable mutation frequencies of 15&#x02013;80% [<xref ref-type=\"bibr\" rid=\"b5\">5</xref>]. Inconsistencies between these studies may relate to whether the whole gene was or only the most commonly mutated exons were sequenced. Additionally, most studies were confounded by the inclusion of cases with different histological types, stages, and grades of tumours [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>].</p><p>Determining the true prevalence of <italic>TP53</italic> mutation is critical for understanding the pathogenesis of high-grade serous cancers arising as ovarian, Fallopian tube or primary peritoneal cancer. Although previously assumed to arise from the ovary, pathological examination of the Fallopian tube from carriers with <italic>BRCA1</italic> or <italic>BRCA2</italic> mutation has demonstrated that tubal intraepithelial carcinomas (TICs) arising from secretory epithelial cells in the fimbria are the early invasive lesion in high-grade serous (HGS) carcinoma [<xref ref-type=\"bibr\" rid=\"b7\">7</xref>,<xref ref-type=\"bibr\" rid=\"b8\">8</xref>]. In addition, TICs are found in patients without evidence of germline <italic>BRCA1</italic> or <italic>BRCA2</italic> lesions and show concomitant <italic>TP53</italic> mutations in the tube and in pelvic metastases, further supporting the model that TIC represents the origin of HGS carcinoma. HGS cancers may also arise from the peritoneum and although these may have different epidemiological risk factor profiles [<xref ref-type=\"bibr\" rid=\"b9\">9</xref>], they exist in a clinical continuum with ovarian and Fallopian tube cancers. Hence we use the term high-grade pelvic serous carcinoma (HGPSC) [<xref ref-type=\"bibr\" rid=\"b10\">10</xref>] to recognize the frequent lack of clarity regarding primary site in ovarian/Fallopian tube/peritoneal cancers and their overall biological and clinical similarity.</p><p>To address the limitations of previous studies and determine accurately the relationship between <italic>TP53</italic> mutation and HGPSC, we designed pilot and validation studies to measure the mutation frequency in a homogeneous group of advanced stage HGPSC cancers from a large population-based cohort.</p></sec><sec sec-type=\"materials|methods\"><title>Materials and methods</title><sec><title>Samples and study design</title><p>The results of this study are presented in accordance with reporting recommendations for tumour marker prognostic studies (REMARK) criteria [<xref ref-type=\"bibr\" rid=\"b11\">11</xref>]. Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD3\">Figure 1</xref> (Supporting information) summarizes the flow of patients through the pilot and validation study, including the number of patients included in each stage of the analysis and reasons for exclusion. Patients (<italic>n</italic> = 123) were selected from the Australian Ovarian Cancer Study (AOCS), a population-based, multicentre translational study that comprised prospective collection of bio-specimens and clinical and epidemiological data from patients with primary epithelial ovarian, primary peritoneal, and Fallopian tube cancer diagnosed between 2001 and 2005. Patients treated at Westmead Hospital, Sydney between 1992 and 2002 (<italic>n</italic> = 22) were also included in the pilot cohort, making an overall sample size of 145 HGPSCs. All women in the pilot cohort received first-line platinum-based chemotherapy (cisplatin or carboplatin) with (<italic>n</italic> = 39) or without (<italic>n</italic> = 6) the taxane paclitaxel. Similarly, the majority of patients in the validation set received combination platinum&#x02013;taxane treatment (<italic>n</italic> = 93) or platinum monotherapy (<italic>n</italic> = 4). Three patients (<italic>n</italic> = 3) did not receive any chemotherapy, including one patient with stage I cancer who declined treatment and two patients who were too ill to receive chemotherapy. All patients were prospectively consented using a protocol approved by the human research ethics committees at multiple participating clinical and research centres. Further details of the AOCS cohort can be found at <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.aocstudy.org\">http://www.aocstudy.org</ext-link>. Statistical design and power calculations are described in the Supporting information, Supplementary methods.</p></sec><sec><title><italic>TP53</italic> sequencing</title><p>Coding <italic>TP53</italic> exons 2&#x02013;11 were amplified using primers that encompassed the entire exon and exon&#x02013;intron boundaries. Purified PCR products were se- quenced using an ABI 3100 genetic analyser (Applied Biosystems, Warrington, UK). Sequencing reactions were performed in forward and reverse directions. Mutational analysis was performed using SeqScape&#x000ae; Software v2.6 (Applied Biosystems). Sequence traces were aligned against the <italic>TP53</italic> reference sequence NC_000017. Independent, blinded sequencing of cases from the pilot study was performed by the CR-UK Mutation Detection Facility, Clinical Sciences Building, Level 6, St James\\'s University Hospital, Leeds, UK.</p></sec><sec><title>Characterization of mutation-negative HGPSC cancers</title><p>For single nucleotide polymorphism (SNP) mapping assay, SNP microarray data analysis, quantitative PCR (qPCR), and immunohistochemistry, the reader is referred to the Supporting information, Supplementary methods.</p></sec><sec><title>aCGH data</title><p>Raw data files from aCGH experiments are available from the Gene Expression Omnibus <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.ncbi.nlm.nih.gov/geo/\">http://www.ncbi.nlm.nih.gov/geo/</ext-link> (Accession number GSE19416).</p></sec></sec><sec><title>Results</title><sec><title>Both treatment-responsive and primary resistant HGPSCs have a high frequency of <italic>TP53</italic> mutation</title><p>To estimate the number of samples required to detect a significant association between <italic>TP53</italic> mutations and survival, we performed a pilot study with 45 HGPSCs (ovarian, Fallopian tube, and primary peritoneal). The cohort included 20 chemotherapy-resistant patients who had tumour progression within 6 months of completion of treatment and 25 responsive patients who did not progress for at least 9 months. The two groups showed no statistically significant differences in age, tumour stage, residual disease or type of chemotherapy (<xref ref-type=\"table\" rid=\"tbl1\">Table 1</xref>). Review of pathology reports showed one patient with low-grade serous (LGS) carcinoma (case 450) and this case was excluded from further analysis. Unexpectedly, pathogenic <italic>TP53</italic> mutations were identified in 43 out of 44 patients included in the study (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref> and Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD3\">Figure 1</xref>). Mutations were compared to Release 13 of the IARC <italic>TP53</italic> mutation database [<xref ref-type=\"bibr\" rid=\"b12\">12</xref>] and 20 cases had rare <italic>TP53</italic> mutations, defined as less than ten occurrences (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). From these, 12 were randomly selected and independently confirmed by a clinical reference laboratory blinded to our results (data not shown). Further analysis of mutations is described below.</p><table-wrap id=\"tbl1\" position=\"float\"><label>Table 1</label><caption><p>A comparison between the clinical characteristics of the chemotherapy-resistant and -responsive patients in the pilot study</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\"/><th align=\"center\" rowspan=\"1\" colspan=\"1\">Resistant (<italic>n</italic> = 20)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Responsive (<italic>n</italic> = 25)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\"><italic>p</italic> (test)</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">PFS (months)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">10.2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">23.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x0003c; 0.001 (log rank)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">OS (months)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">21.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">57.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x0003c; 0.001 (log rank)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Age (years)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">58.26</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">58.7</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.7 (Wilcoxon rank sum)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Range</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">22.9&#x02013;78</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">38.1&#x02013;77.7</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Stage (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;III</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">20</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">23</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.5 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;IV</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">&#x02014;</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">2</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Chemotherapy (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">19</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.4 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Neo-adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Residual disease (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;No residual disease</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.2 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x02264;1 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">11</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">8</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 1 cm and &#x02264;2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">6</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">TP53 (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Wild type</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.4 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Mutant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">19</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td><td rowspan=\"1\" colspan=\"1\"/></tr></tbody></table><table-wrap-foot><fn><p>OS = overall survival; PFS = progression-free survival, defined as the period from diagnosis to the date of documented progression. Six samples (2 resistant, 4 responsive) did not have precise values for size &#x0003c; 2 cm.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Confirmation of high frequency of <italic>TP53</italic> mutation in an unselected population-based cohort of serous cancers</title><p>To exclude the possibility that the high rate of <italic>TP53</italic> mutations was biased by the selection criteria used in the pilot study, we obtained additional serous cancer cases that were a representative subset of a large population-based series (<xref ref-type=\"table\" rid=\"tbl2\">Table 2</xref>). Mutations were detected in 76/82 advanced-stage HGPSCs from these cases, with no significant difference between the percentage of mutations in the matched validation study compared with the pilot study (<italic>p</italic> = 0.3; Fisher exact test).</p><table-wrap id=\"tbl2\" position=\"float\"><label>Table 2</label><caption><p>Clinical characteristics of the validation study patients</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\"/><th align=\"center\" rowspan=\"1\" colspan=\"1\">Validation set (<italic>n</italic> = 82</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">PFS (months)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">13.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">OS (months)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">34</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Age (years)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">61.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Range</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">40.4&#x02013;79.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Stage (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;III</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">73</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;IV</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">9</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Grade (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">18</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;3</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">63</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Chemotherapy (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">71</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Neo-adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">11</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Residual disease (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;No residual disease</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">16</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x02264;1 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">26</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 1 cm and &#x02264;2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">10</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">TP53 (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Wild type</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">6</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Mutant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">76</td></tr></tbody></table><table-wrap-foot><fn><p>OS = overall survival; PFS = progression-free survival.</p></fn></table-wrap-foot></table-wrap></sec><sec><title><italic>TP53</italic> mutations arise at high frequency in exons 2&#x02013;4 and 9&#x02013;11 in HGPSC carcinoma</title><p>We analysed the 119 mutations found in 126 HGPSC cases from the pilot and validation set (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). As expected, the majority of <italic>TP53</italic> mutations were missense mutations (56.3%, <italic>n</italic> = 67/119) occurring in exons 4&#x02013;8 (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The most frequently mutated codon was 273 (<italic>n</italic> = 9/67 cases, 13.4%) comprising R273C, R273H, and R273L mutants. Analysis of exon and splice sites for exons 2&#x02013;4 and 9&#x02013;11, outside the DNA binding domain, showed 12 (10.1%) and 10 (8.4%) mutations, respectively, which taken together comprised 18.5% (<italic>n</italic> = 22/119) of all mutations in our series. Of note, a total of eight mutations affected exon 10 (6.7%) in the tetramerization domain (codons 324&#x02013;356) and all were predicted to cause truncation of the protein. Four of these mutations occurred at g.16915 (codon 342). In 717 serous sub-type ovarian, Fallopian, and primary peritoneal cancer cases in Release 13 of the IARC <italic>TP53</italic> database, 30 (4.2%) had mutations in exons 2&#x02013;4, 18 had mutations affecting exon 10 alone (2.5%), and 20 (2.8%) had mutations in exons 9&#x02013;11. Twenty-two mutations from our series (<italic>n</italic> = 22/119, 18.5%) were not present in the IARC database. With the exception of one, all were insertions or deletions (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The remaining novel mutation in case 434 was at position g.11602_11603GC &#x0003e; AA, creating a unique tandem nonsense mutation.</p></sec><sec><title>Low-stage HGPSC cases have a high frequency of <italic>TP53</italic> mutations</title><p>The very high prevalence of mutation in high-stage cases suggested that <italic>TP53</italic> was an early event in the pathogenesis of HGPSC. From the validation set, 15 cases were stage 1 or 2 HGPSC and 13/15 (86.7%) had <italic>TP53</italic> mutation (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The negative cases 41307 and 60111 had mixed endometrioid/HGS or grade 1 pathology, respectively. As for high-stage cases, the majority of mutations (<italic>n</italic> = 10/13; 76.9%) were missense mutations in exons 5&#x02013;8. There was one nonsense mutation in exon 10 (7.7%) and two splice junction mutations (15.4%).</p></sec><sec><title>Mutation-negative cases have alternative mechanisms of p53 dysfunction</title><p>We considered the possibility that <italic>TP53</italic> mutations in the seven mutation-negative samples (pilot <italic>n</italic> = 1, validation <italic>n</italic> = 6) were missed because of contamination with normal DNA. Although all samples with significant stroma were needle-dissected prior to sequencing, pathological review of the mutation-negative cases indicated that they did not have increased stroma compared with mutation-positive cases (data not shown). Additionally, array-based comparative genomic hybridization (aCGH) showed that all mutation-negative cases had DNA copy number abnormalities (DCNAs), and the least aberrant, case 533, had distinct loss of chromosome arm 1p (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1A</xref>). No samples showed evidence of homozygous deletion of the <italic>TP53</italic> locus (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1</xref>B).</p><fig id=\"fig01\" position=\"float\"><label>Figure 1</label><caption><p>Characterization of <italic>TP53</italic> mutation-negative cancer samples. (A) Summary plots of whole genome DNA copy number data for seven mutation-negative samples. Red indicates chromosomal gain and blue shows regions of chromosomal loss. (B) High-resolution DNA copy number analysis of <italic>MDM2, MDM4</italic>, and <italic>TP53</italic> loci in each sample. The dotted line indicates the position of the gene within the region. Samples with chromosomal gain or loss are marked with a red or blue asterisk, respectively. (C) Confirmation of <italic>MDM2</italic> and <italic>MDM4</italic> copy number gain using quantitative PCR of tumour DNA. Samples with gain are indicated in red. (D) Immunohistochemical staining of p53 protein in the following selected mutation-negative cases: case 41358; case 60258 (<italic>MDM2</italic> gain); case 22029 (<italic>MDM4</italic> gain); and case 60049 (<italic>MDM4</italic> gain).</p></caption><graphic xlink:href=\"path0221-0049-f1\"/></fig><p>Pathology review of the mutation-negative cases resulted in the re-classification of case 60214 as LGS carcinoma, case 23221 as high-grade carcinoma of uncertain primary site, and case 533 as mixed LGS/HGS type (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD2\">Table 2</xref>). Furthermore, aCGH analysis of cases 533 and 60214 did not show high-frequency DCNAs that are typical of HGPSC [<xref ref-type=\"bibr\" rid=\"b11\">11</xref>]. The original diagnosis of HGPSC was confirmed in the remaining four cases (22029, 41358, 60049, and 60258). To further exclude the possibility of pathological misclassification of endometrioid, clear cell or LGS tumours in the mutation-negative cases, we also tested for mutations commonly associated with these subtypes in <italic>KRAS</italic> (exon 2), <italic>BRAF</italic> (exon 15), <italic>CTNNB1</italic> (exon 3), and <italic>PIK3CA</italic> (exons 10 and 21). Case 60214 had a missense mutation (G12C) in exon 2 of <italic>KRAS</italic>, consistent with LGS origin. No other mutations were detected (data not shown).</p><p>Other mutation-independent mechanisms of inactivation of the p53 pathway were investigated. p53 is targeted for degradation through the activity of MDM2 protein and is also regulated by the related MDM4 protein [<xref ref-type=\"bibr\" rid=\"b13\">13</xref>,<xref ref-type=\"bibr\" rid=\"b14\">14</xref>]. Amplification of <italic>MDM2</italic> is associated with loss of p53 activity in some solid tumours [<xref ref-type=\"bibr\" rid=\"b15\">15</xref>,<xref ref-type=\"bibr\" rid=\"b16\">16</xref>]. aCGH analysis of the remaining four cases showed copy number gain of <italic>MDM4</italic> in cases 22029 and 60049, and of <italic>MDM2</italic> in case 60258 (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1B</xref>). These observations were confirmed by qPCR (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1C</xref>). Interestingly, both cases with <italic>MDM4</italic> gain showed heterogeneous p53 immunostaining, including cytoplasmic staining (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>). Case 60258 with <italic>MDM2</italic> gain showed strong nuclear staining for p53 protein (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>). Interestingly, the remaining case with no MDM2 or MDM4 gain (41358) showed strong nuclear p53 immunostaining (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>).</p><p>In summary, the overall <italic>TP53</italic> mutation rate for selected HGPSC cases in the pilot and validation cohorts was 94.4% (<italic>n</italic> = 119/126). After removing the three mutation-negative cases with atypical or LGS histology, the adjusted overall rate was 96.7% (<italic>n</italic> = 119/123). In the remaining four mutation-negative HGPSC cases, three showed evidence of p53 dysfunction with increased p53 nuclear staining or cytoplasmic mislocalization that was correlated with gains at the <italic>MDM2/4</italic> loci.</p></sec><sec><title><italic>TP53</italic> mutation type is not prognostic in HGPSC</title><p>It has been previously reported that the type of <italic>TP53</italic> mutation may predict outcome in ovarian cancer [<xref ref-type=\"bibr\" rid=\"b17\">17</xref>]. Although our study was not adequately powered to detect small effects, we tested for trends in the data. For this analysis, we used all presumed HGPSC cases from the pilot study and the validation cohort (<italic>n</italic> = 127, <italic>n</italic> = 120 had <italic>TP53</italic> mutation; <xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was no indication of significant association between the frequency of <italic>TP53</italic> mutation or the type of mutation (missense versus not) and progression-free survival or overall survival. Similarly, whether or not the missense mutation affected the DNA binding motifs formed by the L2 and L3 loops (codons 164&#x02013;194 and 237&#x02013;250, respectively) or the LSH motifs (codons 119&#x02013;135 and 272&#x02013;287) [<xref ref-type=\"bibr\" rid=\"b18\">18</xref>] had no significant effect on progression-free survival or overall survival (<xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was also no effect of codon 72 polymorphism (Arg, Pro or heterozygous) on prognosis in any of the HGPSCs with mutations (data not shown) or in tumours with missense mutations (<xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was no significant interaction between the type of missense mutation (DNA binding or not) and codon 72 polymorphism (data not shown).</p><table-wrap id=\"tbl3\" position=\"float\"><label>Table 3</label><caption><p>The type of <italic>TP53</italic> mutation does not influence progression-free survival</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" rowspan=\"1\" colspan=\"1\">Index category (<italic>n</italic>)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Comparison (<italic>n</italic>)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Hazard ratio</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">CI</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Log-rank <italic>p</italic> value</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mutant (120)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Wild type (7)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;3.1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.5</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Not missense (52)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Missense (68)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.9</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;1.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.8</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">DBM (44)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">NDBM (24)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;1.7</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr></tbody></table><table-wrap-foot><fn><p>DBM = DNA binding mutations; NDBM = non-DNA binding mutations.</p></fn></table-wrap-foot></table-wrap><table-wrap id=\"tbl4\" position=\"float\"><label>Table 4</label><caption><p>The type of <italic>TP53</italic> mutation does not influence overall survival</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" rowspan=\"1\" colspan=\"1\">Index category (<italic>n</italic>)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Comparison (<italic>n</italic>)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Hazard ratio</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">CI</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Log-rank <italic>p</italic> value</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mutant (120)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Wild type (7)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.7</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;4.6</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Not missense (52)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Missense (68)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.7&#x02013;1.6</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">DBM (44)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">NDBM (24)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.3</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.7&#x02013;2.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.4</td></tr></tbody></table><table-wrap-foot><fn><p>DBM = DNA binding mutations; NDBM = non-DNA binding mutations.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>By addressing the limitations of numerous other studies of <italic>TP53</italic> mutation in ovarian cancer, we have demonstrated for the first time that HGPSCs have the highest frequency of p53 mutation of any solid cancer. Approximately two-thirds of mutations occurred in exons 5&#x02013;8, known to be mutation hotspots for <italic>TP53</italic>. By sequencing exons 2&#x02013;4 and 9&#x02013;11, we identified 22 mutations (<italic>n</italic> = 22/126, 17.5%) that would not have otherwise been identified in our series and are poorly represented in previous reports. The previously unreported mutations that we have discovered are mostly insertions/deletions predicted to result in truncated proteins, but it is notable that HGPSC cases have frequent involvement of exon 10 and specifically involvement of position g.16915 (codon 342) in the oligomerization domain of p53. This region also contains a putative nuclear export signal for p53 and a recent study of a novel missense mutation at codon 351 has shown that K351N results in significant loss of p53 tetramerization, reduced BAX activation, and reduced nuclear export of p53 [<xref ref-type=\"bibr\" rid=\"b19\">19</xref>]. Cytosolic export of p53 is required for cisplatin-induced apoptosis in A2780 cells, suggesting that combined loss of tetramerization and nuclear export is critical for platinum resistance.</p><p>Of the mutation-negative cases, approximately half were reclassified on pathological review as unrepresentative of HGPSC, including two tumours that were LGS and associated with borderline tumour. Serous cancers may follow two distinct routes to malignancy [<xref ref-type=\"bibr\" rid=\"b20\">20</xref>]. A minority of so-called type I tumours progress from borderline tumours, whereas the majority of HGS (type II) tumours arise with no evidence of LGS or borderline tumours. Borderline serous tumours and their type I invasive counterparts are generally low grade, have relatively limited genomic DNA copy number change, have frequent activating RAS pathway mutations, and have substantially lower rates of <italic>TP53</italic> mutation compared with type II tumours [<xref ref-type=\"bibr\" rid=\"b20\">20</xref>&#x02013;<xref ref-type=\"bibr\" rid=\"b23\">23</xref>]. Detailed analysis of six cases of HGPSC arising from LGS and borderline tumours showed no <italic>TP53</italic> mutation [<xref ref-type=\"bibr\" rid=\"b24\">24</xref>]. Consistent with this model, mutation-negative case 533 had both LGS and HGS components and a bland aCGH profile.</p><p>Exclusion of LGS cases and mixed high-grade serous cases increased the <italic>TP53</italic> mutation frequency to approximately 97% of HGPSCs. Of the remaining mutation-negative cases, three may have had inactivation of the p53 pathway through chromosomal gain at the <italic>MDM2</italic> or <italic>MDM4</italic> loci or potentially other genes that alter p53 function in <italic>trans</italic> such as <italic>RFWD2</italic> and <italic>RCHY1</italic> [<xref ref-type=\"bibr\" rid=\"b25\">25</xref>,<xref ref-type=\"bibr\" rid=\"b26\">26</xref>].</p><p>We are aware of over 70 publications that have sought to relate <italic>TP53</italic> mutation with clinical outcome in ovarian cancer, with conflicting conclusions about the importance of <italic>TP53</italic> mutations for tumour aggressiveness, response to treatment, and survival. There is no sign that a conclusion is at hand: since 2008, there have been a number of papers relating <italic>TP53</italic> mutation and clinical outcome [<xref ref-type=\"bibr\" rid=\"b27\">27</xref>&#x02013;<xref ref-type=\"bibr\" rid=\"b30\">30</xref>], with evidence presented for [<xref ref-type=\"bibr\" rid=\"b29\">29</xref>] and against [<xref ref-type=\"bibr\" rid=\"b28\">28</xref>] mutation being a significant prognostic factor. A recent meta-analysis of 62 studies concluded that <italic>TP53</italic> mutation had a modest impact on survival in ovarian cancer but the effect was insufficient to support clinical application [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>]. Whilst meta-analyses such as that of de Graeff <italic>et al</italic> [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>] have the potential to detect subtle trends that may be missed in all but the largest individual studies, they are confounded if there is a substantial false-negative rate, as our findings indicate. Given the near ubiquitous occurrence of <italic>TP53</italic> mutation, it difficult to conclude that it can be of significant prognostic or predictive significance in HGPSC. We have not, however, excluded the possibility that specific mutations can influence prognosis or response to therapy, an important consideration given the mounting evidence that some <italic>TP53</italic> mutations have specific neomorphic functions [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. It is thought that inactivation of the p53 pathway is a common, perhaps mandatory, event in all solid cancers [<xref ref-type=\"bibr\" rid=\"b31\">31</xref>]. What is particularly unusual about HGPSC is an almost total reliance on mutation <italic>TP53</italic> itself for pathway inactivation, perhaps reflecting the requirement of certain tissues for neomorphic mutations for their transformation [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. Future work will need to address interactions between specific mutations and other loci such as <italic>PTEN</italic> and <italic>CDKN2A</italic> [<xref ref-type=\"bibr\" rid=\"b32\">32</xref>,<xref ref-type=\"bibr\" rid=\"b33\">33</xref>].</p><p>Our findings have important implications for the new understanding of the pathogenesis of HGPSC. p53 immunostaining and mutation appear to be a feature of early-stage Fallopian tube lesions from <italic>BRCA1/2</italic> mutation carriers [<xref ref-type=\"bibr\" rid=\"b7\">7</xref>], suggesting that p53 dysfunction is essential for early tumourigenesis of HGPSC. The notion that <italic>TP53</italic> mutation is required to allow survival of <italic>BRCA</italic>-deficient ovarian precursor lesions is consistent with the extremely high rates of <italic>TP53</italic> mutation in breast cancers arising in <italic>BRCA1</italic> mutant women [<xref ref-type=\"bibr\" rid=\"b34\">34</xref>,<xref ref-type=\"bibr\" rid=\"b35\">35</xref>]. BRCA dysfunction may also occur in sporadic HGPSC via a variety of inactivating mechanisms but the very high rate of <italic>TP53</italic> mutation in our series of sporadic HGPSC cases suggests that most are &#x02018;BRCA-like&#x02019; with deficiencies for <italic>BRCA</italic> or closely related DNA repair pathways [<xref ref-type=\"bibr\" rid=\"b36\">36</xref>].</p><p>It has become increasingly clear that ovarian cancer is a series of distinctly different diseases with different aetiologies [<xref ref-type=\"bibr\" rid=\"b23\">23</xref>,<xref ref-type=\"bibr\" rid=\"b37\">37</xref>] and that the development of reliable biomarkers must be subtype-specific [<xref ref-type=\"bibr\" rid=\"b38\">38</xref>]. For example, several biomarkers that appeared to be prognostic in a cohort of all major subtypes of ovarian cancer were not informative within homogeneous subtypes. Our findings provide another example of the importance of refining the analysis of ovarian biomarkers by focusing on the most clinically significant group, HGPSC.</p><p>The key oncogenic and tumour suppressor genes for HGPSC have not been identified and as it has high rates of genomic instability, many of the alterations described may be passenger mutations. Our results for the prevalence of <italic>TP53</italic> mutation may be conservative as our prospectively determined selection criteria excluded low-stage HGPSC cases (<italic>n</italic> = 15). This was because true low-stage HGPSC is a rare entity and often suggests misdiagnosis of LGS histiotype. However, 13/15 of these cases had <italic>TP53</italic> mutation. Our data are therefore consistent with mutant <italic>TP53</italic> being an essential driver mutation early in the pathogenesis of HGPSC. Future studies will need to focus on studying the biological significance of the different types of <italic>TP53</italic> mutation in HGPSC and developing p53 synthetic-lethal therapies for patients with this disease.</p></sec></body><back><ack><p>We thank Sarah Hyland, Philip Chambers, Christian Bourne, and Nik Matthews for expert technical assistance. We acknowledge the support of the University of Cambridge, NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and Hutchison Whampoa Ltd. AAA holds a CR-UK Clinician Scientist Fellowship. D Bowtell, G Chenevix-Trench, A deFazio, A Green, D Gertig, and P Webb&#x02014;The AOCS Management Group&#x02014;gratefully acknowledge the contributions of the full AOCS Study Group, listed on <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.aocstudy.org\">http://www.aocstudy.org</ext-link>, and express their gratitude to all women who participated in the study. The AOCS was supported by the US Army Medical Research and Material Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the NH&#x00026;MRC. We also gratefully acknowledge Catherine Emmanuel, Catherine Kennedy, and Yoke-Eng Chiew for samples, and data from the Westmead Gynaecological Oncology Tissue Bank, a member of the Australasian Biospecimens Network-Oncology group funded by the NH&#x00026;MRC. This work was funded by Cancer Research UK (CR-UK), the Medical Research Council (MRC), and the National Health and Medical Research Council of Australia (NHMRC).</p></ack><ref-list><title>References</title><p>Note: References 39&#x02013;50 are cited in the Supporting information to this article.</p><ref id=\"b1\"><label>1</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Brosh</surname><given-names>R</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name></person-group><article-title>When mutants gain new powers: news from the mutant p53 field</article-title><source>Nature Rev Cancer</source><year>2009</year><volume>9</volume><fpage>701</fpage><lpage>713</lpage><pub-id pub-id-type=\"pmid\">19693097</pub-id></element-citation></ref><ref id=\"b2\"><label>2</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Davidoff</surname><given-names>AM</given-names></name><name><surname>Kerns</surname><given-names>BJ</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Pence</surname><given-names>JC</given-names></name><name><surname>Dodge</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Overexpression and mutation of p53 in epithelial ovarian cancer</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>2979</fpage><lpage>2984</lpage><pub-id pub-id-type=\"pmid\">2032235</pub-id></element-citation></ref><ref id=\"b3\"><label>3</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Okamoto</surname><given-names>A</given-names></name><name><surname>Sameshima</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Terashima</surname><given-names>Y</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Frequent allelic losses and mutations of the p53 gene in human ovarian cancer</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>5171</fpage><lpage>5176</lpage><pub-id pub-id-type=\"pmid\">1680546</pub-id></element-citation></ref><ref id=\"b4\"><label>4</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>de Graeff</surname><given-names>P</given-names></name><name><surname>Crijns</surname><given-names>AP</given-names></name><name><surname>de Jong</surname><given-names>S</given-names></name><name><surname>Boezen</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>WJ</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis</article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type=\"pmid\">19513073</pub-id></element-citation></ref><ref id=\"b5\"><label>5</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group><article-title>Critical evaluation of p53 as a prognostic marker in ovarian cancer</article-title><source>Expert Rev Mol Med</source><year>2004</year><volume>6</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type=\"pmid\">15147608</pub-id></element-citation></ref><ref id=\"b6\"><label>6</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Ishioka</surname><given-names>C</given-names></name><name><surname>Claustres</surname><given-names>M</given-names></name><name><surname>Beroud</surname><given-names>C</given-names></name></person-group><article-title>Locus-specific mutation databases: pitfalls and good practice based on the p53 experience</article-title><source>Nature Rev Cancer</source><year>2006</year><volume>6</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type=\"pmid\">16397528</pub-id></element-citation></ref><ref id=\"b7\"><label>7</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Nucci</surname><given-names>MR</given-names></name><name><surname>Medeiros</surname><given-names>F</given-names></name><name><surname>Saleemuddin</surname><given-names>A</given-names></name><etal/></person-group><article-title>A candidate precursor to serous carcinoma that originates in the distal Fallopian tube</article-title><source>J Pathol</source><year>2007</year><volume>211</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type=\"pmid\">17117391</pub-id></element-citation></ref><ref id=\"b8\"><label>8</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Ince</surname><given-names>TA</given-names></name><name><surname>Muto</surname><given-names>M</given-names></name><name><surname>Kindelberger</surname><given-names>DW</given-names></name><etal/></person-group><article-title>The distal Fallopian tube: a new model for pelvic serous carcinogenesis</article-title><source>Curr Opin Obstet Gynecol</source><year>2007</year><volume>19</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">17218844</pub-id></element-citation></ref><ref id=\"b9\"><label>9</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jordan</surname><given-names>SJ</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>Whiteman</surname><given-names>DC</given-names></name><name><surname>Moore</surname><given-names>SP</given-names></name><name><surname>Bain</surname><given-names>CJ</given-names></name><name><surname>Gertig</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Serous ovarian, Fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>1598</fpage><lpage>1603</lpage><pub-id pub-id-type=\"pmid\">18058817</pub-id></element-citation></ref><ref id=\"b10\"><label>10</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Herrington</surname><given-names>CS</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name></person-group><article-title>The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis</article-title><source>J Pathol</source><year>2007</year><volume>220</volume><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">19882674</pub-id></element-citation></ref><ref id=\"b11\"><label>11</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name></person-group><article-title>Reporting recommendations for tumor marker prognostic studies (REMARK)</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type=\"pmid\">16106022</pub-id></element-citation></ref><ref id=\"b12\"><label>12</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Petitjean</surname><given-names>A</given-names></name><name><surname>Marcel</surname><given-names>V</given-names></name><name><surname>Petre</surname><given-names>A</given-names></name><name><surname>Mounawar</surname><given-names>M</given-names></name><name><surname>Plymoth</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recent advances in p53 research: an interdisciplinary perspective</article-title><source>Cancer Gene Ther</source><year>2009</year><volume>16</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">18802452</pub-id></element-citation></ref><ref id=\"b13\"><label>13</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Montes de Oca Luna</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>DS</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type=\"pmid\">7477326</pub-id></element-citation></ref><ref id=\"b14\"><label>14</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Parant</surname><given-names>J</given-names></name><name><surname>Chavez-Reyes</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>NA</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Reinke</surname><given-names>V</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53</article-title><source>Nature Genet</source><year>2001</year><volume>29</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type=\"pmid\">11528400</pub-id></element-citation></ref><ref id=\"b15\"><label>15</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Oliner</surname><given-names>JD</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>George</surname><given-names>DL</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Amplification of a gene encoding a p53-associated protein in human sarcomas</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>80</fpage><lpage>83</lpage><pub-id pub-id-type=\"pmid\">1614537</pub-id></element-citation></ref><ref id=\"b16\"><label>16</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McCann</surname><given-names>AH</given-names></name><name><surname>Kirley</surname><given-names>A</given-names></name><name><surname>Carney</surname><given-names>DN</given-names></name><name><surname>Corbally</surname><given-names>N</given-names></name><name><surname>Magee</surname><given-names>HM</given-names></name><name><surname>Keating</surname><given-names>G</given-names></name><etal/></person-group><article-title>Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type=\"pmid\">7734324</pub-id></element-citation></ref><ref id=\"b17\"><label>17</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shahin</surname><given-names>MS</given-names></name><name><surname>Hughes</surname><given-names>JH</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name></person-group><article-title>The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>2006</fpage><lpage>2017</lpage><pub-id pub-id-type=\"pmid\">11064359</pub-id></element-citation></ref><ref id=\"b18\"><label>18</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Carrieri</surname><given-names>P</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Klaar</surname><given-names>S</given-names></name><name><surname>Eyfjord</surname><given-names>J</given-names></name><etal/></person-group><article-title>The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type=\"pmid\">16489069</pub-id></element-citation></ref><ref id=\"b19\"><label>19</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Muscolini</surname><given-names>M</given-names></name><name><surname>Montagni</surname><given-names>E</given-names></name><name><surname>Caristi</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Kamada</surname><given-names>R</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>3396</fpage><lpage>3405</lpage><pub-id pub-id-type=\"pmid\">19806023</pub-id></element-citation></ref><ref id=\"b20\"><label>20</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vang</surname><given-names>R</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems</article-title><source>Adv Anat Pathol</source><year>2009</year><volume>16</volume><fpage>267</fpage><lpage>282</lpage><pub-id pub-id-type=\"pmid\">19700937</pub-id></element-citation></ref><ref id=\"b21\"><label>21</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>7273</fpage><lpage>7279</lpage><pub-id pub-id-type=\"pmid\">16243797</pub-id></element-citation></ref><ref id=\"b22\"><label>22</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Meinhold-Heerlein</surname><given-names>I</given-names></name><name><surname>Bauerschlag</surname><given-names>D</given-names></name><name><surname>Hilpert</surname><given-names>F</given-names></name><name><surname>Dimitrov</surname><given-names>P</given-names></name><name><surname>Sapinoso</surname><given-names>LM</given-names></name><name><surname>Orlowska-Volk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>1053</fpage><lpage>1065</lpage><pub-id pub-id-type=\"pmid\">15558012</pub-id></element-citation></ref><ref id=\"b23\"><label>23</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Salani</surname><given-names>R</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Giuntoli</surname><given-names>R</given-names><suffix>2nd</suffix></name><name><surname>Gardner</surname><given-names>G</given-names></name><name><surname>Bristow</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance</article-title><source>Int J Gynecol Cancer</source><year>2008</year><volume>18</volume><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type=\"pmid\">17692090</pub-id></element-citation></ref><ref id=\"b24\"><label>24</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dehari</surname><given-names>R</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Logani</surname><given-names>S</given-names></name><name><surname>Shih</surname><given-names>IeM</given-names></name></person-group><article-title>The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis</article-title><source>Am J Surg Pathol</source><year>2007</year><volume>31</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type=\"pmid\">17592266</pub-id></element-citation></ref><ref id=\"b25\"><label>25</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Leng</surname><given-names>RP</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lemmers</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type=\"pmid\">12654245</pub-id></element-citation></ref><ref id=\"b26\"><label>26</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dornan</surname><given-names>D</given-names></name><name><surname>Wertz</surname><given-names>I</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Arnott</surname><given-names>D</given-names></name><name><surname>Frantz</surname><given-names>GD</given-names></name><name><surname>Dowd</surname><given-names>P</given-names></name><etal/></person-group><article-title>The ubiquitin ligase COP1 is a critical negative regulator of p53</article-title><source>Nature</source><year>2004</year><volume>429</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type=\"pmid\">15103385</pub-id></element-citation></ref><ref id=\"b27\"><label>27</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bartel</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Bohnke</surname><given-names>A</given-names></name><name><surname>Gradhand</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name><name><surname>Thomssen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type=\"pmid\">18172257</pub-id></element-citation></ref><ref id=\"b28\"><label>28</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Darcy</surname><given-names>KM</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>McBroom</surname><given-names>JW</given-names></name><name><surname>Bell</surname><given-names>JG</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><etal/></person-group><article-title>Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers. A Gynecologic Oncology Group study</article-title><source>Gynecol Oncol</source><year>2008</year><volume>111</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type=\"pmid\">18834621</pub-id></element-citation></ref><ref id=\"b29\"><label>29</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hogdall</surname><given-names>EV</given-names></name><name><surname>Christensen</surname><given-names>L</given-names></name><name><surname>Hogdall</surname><given-names>CK</given-names></name><name><surname>Frederiksen</surname><given-names>K</given-names></name><name><surname>Gayther</surname><given-names>S</given-names></name><name><surname>Blaakaer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas</article-title><source>APMIS</source><year>2008</year><volume>116</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type=\"pmid\">18452430</pub-id></element-citation></ref><ref id=\"b30\"><label>30</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Kraszewska</surname><given-names>E</given-names></name><name><surname>Ziolkowska-Seta</surname><given-names>I</given-names></name><name><surname>Madry</surname><given-names>R</given-names></name><name><surname>Timorek</surname><given-names>A</given-names></name><name><surname>Markowska</surname><given-names>J</given-names></name><etal/></person-group><article-title>TP53 status and taxane&#x02013;platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study</article-title><source>BMC Cancer</source><year>2008</year><volume>8</volume><fpage>27</fpage><pub-id pub-id-type=\"pmid\">18230133</pub-id></element-citation></ref><ref id=\"b31\"><label>31</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Harvey</surname><given-names>M</given-names></name><name><surname>Slagle</surname><given-names>BL</given-names></name><name><surname>McArthur</surname><given-names>MJ</given-names></name><name><surname>Montgomery</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Butel</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type=\"pmid\">1552940</pub-id></element-citation></ref><ref id=\"b32\"><label>32</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Terzian</surname><given-names>T</given-names></name><name><surname>Suh</surname><given-names>YA</given-names></name><name><surname>Iwakuma</surname><given-names>T</given-names></name><name><surname>Post</surname><given-names>SM</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>GA</given-names></name><etal/></person-group><article-title>The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss</article-title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type=\"pmid\">18483220</pub-id></element-citation></ref><ref id=\"b33\"><label>33</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guessous</surname><given-names>F</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Ibidapo</surname><given-names>O</given-names></name><name><surname>Fuller</surname><given-names>L</given-names></name><etal/></person-group><article-title>PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>1723</fpage><lpage>1731</lpage><pub-id pub-id-type=\"pmid\">18339852</pub-id></element-citation></ref><ref id=\"b34\"><label>34</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Phillips</surname><given-names>KA</given-names></name><name><surname>Nichol</surname><given-names>K</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Knight</surname><given-names>J</given-names></name><name><surname>Done</surname><given-names>SJ</given-names></name><name><surname>Goodwin</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>469</fpage><lpage>473</lpage><pub-id pub-id-type=\"pmid\">10070948</pub-id></element-citation></ref><ref id=\"b35\"><label>35</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Holstege</surname><given-names>H</given-names></name><name><surname>Joosse</surname><given-names>SA</given-names></name><name><surname>van Oostrom</surname><given-names>CT</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name><name><surname>de Vries</surname><given-names>A</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name></person-group><article-title>High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>3625</fpage><lpage>3633</lpage><pub-id pub-id-type=\"pmid\">19336573</pub-id></element-citation></ref><ref id=\"b36\"><label>36</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Hallmarks of &#x02018;BRCAness&#x02019; in sporadic cancers</article-title><source>Nature Rev Cancer</source><year>2004</year><volume>4</volume><fpage>814</fpage><lpage>819</lpage><pub-id pub-id-type=\"pmid\">15510162</pub-id></element-citation></ref><ref id=\"b37\"><label>37</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Zorn</surname><given-names>KK</given-names></name><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Gangi</surname><given-names>L</given-names></name><name><surname>Chandramouli</surname><given-names>GV</given-names></name><name><surname>Awtrey</surname><given-names>CS</given-names></name><name><surname>Gardner</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6422</fpage><lpage>6430</lpage><pub-id pub-id-type=\"pmid\">16166416</pub-id></element-citation></ref><ref id=\"b38\"><label>38</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Palmer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ovarian carcinoma subtypes are different diseases: implications for biomarker studies</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e232</fpage><pub-id pub-id-type=\"pmid\">19053170</pub-id></element-citation></ref><ref id=\"b39\"><label>39</label><element-citation publication-type=\"journal\"><collab>ICON</collab><article-title>Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type=\"pmid\">12241653</pub-id></element-citation></ref><ref id=\"b40\"><label>40</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Etemadmoghadam</surname><given-names>D</given-names></name><name><surname>de Fazio</surname><given-names>A</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Mermel</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1417</fpage><lpage>1427</lpage><pub-id pub-id-type=\"pmid\">19193619</pub-id></element-citation></ref><ref id=\"b41\"><label>41</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Nelstrop</surname><given-names>AE</given-names></name><name><surname>McClean</surname><given-names>P</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>1545</fpage><lpage>1551</lpage><pub-id pub-id-type=\"pmid\">8622070</pub-id></element-citation></ref><ref id=\"b42\"><label>42</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1534</fpage><lpage>1535</lpage><pub-id pub-id-type=\"pmid\">10995813</pub-id></element-citation></ref><ref id=\"b43\"><label>43</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Thor</surname><given-names>AD</given-names></name><name><surname>Beauchamp</surname><given-names>R</given-names></name><name><surname>Merritt</surname><given-names>V</given-names></name><name><surname>Edgerton</surname><given-names>SM</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name><etal/></person-group><article-title>p53 gene mutations and protein accumulation in human ovarian cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>4961</fpage><lpage>4965</lpage><pub-id pub-id-type=\"pmid\">8506342</pub-id></element-citation></ref><ref id=\"b44\"><label>44</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Kamoi</surname><given-names>S</given-names></name><name><surname>Amada</surname><given-names>S</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Silverberg</surname><given-names>SG</given-names></name></person-group><article-title>Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up</article-title><source>Cancer</source><year>1998</year><volume>82</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type=\"pmid\">9486579</pub-id></element-citation></ref><ref id=\"b45\"><label>45</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Angenendt</surname><given-names>P</given-names></name><etal/></person-group><article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>1807</fpage><lpage>1812</lpage><pub-id pub-id-type=\"pmid\">18772396</pub-id></element-citation></ref><ref id=\"b46\"><label>46</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kuo</surname><given-names>KT</given-names></name><name><surname>Mao</surname><given-names>TL</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Veras</surname><given-names>E</given-names></name><name><surname>Ayhan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma</article-title><source>Am J Pathol</source><year>2009</year><volume>174</volume><fpage>1597</fpage><lpage>1601</lpage><pub-id pub-id-type=\"pmid\">19349352</pub-id></element-citation></ref><ref id=\"b47\"><label>47</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bengtsson</surname><given-names>H</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>B</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Estimation and assessment of raw copy numbers at the single locus level</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type=\"pmid\">18204055</pub-id></element-citation></ref><ref id=\"b48\"><label>48</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rozen</surname><given-names>S</given-names></name><name><surname>Skaletsky</surname><given-names>H</given-names></name></person-group><article-title>Primer3 on the WWW for general users and for biologist programmers</article-title><source>Methods Mol Biol</source><year>2000</year><volume>132</volume><fpage>365</fpage><lpage>386</lpage><pub-id pub-id-type=\"pmid\">10547847</pub-id></element-citation></ref><ref id=\"b49\"><label>49</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Riemenschneider</surname><given-names>MJ</given-names></name><name><surname>Buschges</surname><given-names>R</given-names></name><name><surname>Wolter</surname><given-names>M</given-names></name><name><surname>Reifenberger</surname><given-names>J</given-names></name><name><surname>Bostrom</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>6091</fpage><lpage>6096</lpage><pub-id pub-id-type=\"pmid\">10626796</pub-id></element-citation></ref><ref id=\"b50\"><label>50</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wang</surname><given-names>TL</given-names></name><name><surname>Maierhofer</surname><given-names>C</given-names></name><name><surname>Speicher</surname><given-names>MR</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Digital karyotyping</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>16156</fpage><lpage>16161</lpage><pub-id pub-id-type=\"pmid\">12461184</pub-id></element-citation></ref></ref-list><sec sec-type=\"supplementary-material\"><title>SUPPORTING INFORMATION ON THE INTERNET</title><p>The following supporting information may be found in the online version of this article.</p><p><bold>Supplementary experimental procedures.</bold></p><p><bold>Table S1.</bold> Samples listed by AOCS number with results of somatic <italic>TP53</italic> sequencing.</p><supplementary-material content-type=\"local-data\" id=\"SD1\"><media xlink:href=\"path0221-0049-SD1.pdf\" xlink:type=\"simple\" id=\"d32e3668\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/></supplementary-material><p><bold>Table S2.</bold> Summary of clinical, pathology and molecular review of mutation-negative serous carcinomas.</p><supplementary-material content-type=\"local-data\" id=\"SD2\"><media xlink:href=\"path0221-0049-SD2.pdf\" xlink:type=\"simple\" id=\"d32e3674\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/></supplementary-material><p><bold>Figure S1.</bold> Summary of all cases included in the pilot and validation sets.</p><supplementary-material content-type=\"local-data\" id=\"SD3\"><media xlink:href=\"path0221-0049-SD3.pdf\" xlink:type=\"simple\" id=\"d32e3680\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/><media xlink:href=\"path0221-0049-SD4.doc\" xlink:type=\"simple\" id=\"d32e3681\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"msword\"/></supplementary-material></sec></back></article>'}"
      ]
     },
     "execution_count": 365,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x = articles.find_one({'_id': 'test'})\n",
    "x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 366,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None\n"
     ]
    }
   ],
   "source": [
    "write_article_meta_to_mongo(x)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 367,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'_id': 'test',\n",
       " 'annotations': {'disease-ontology-keywords': None},\n",
       " 'meta': {'article-ids': {'doi': '10.1002/path.2696',\n",
       "   'pmc': '3262968',\n",
       "   'pmid': '20229506'},\n",
       "  'article-type': 'research-article',\n",
       "  'keywords': ['p53',\n",
       "   'high-grade pelvic serous carcinoma',\n",
       "   'ovarian cancer',\n",
       "   'DNA sequence analysis',\n",
       "   'array-based genomic hybridization',\n",
       "   'histopathology',\n",
       "   'clinical outcome',\n",
       "   'BRCA']},\n",
       " 'nxml': '<!DOCTYPE article PUBLIC \"-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN\" \"JATS-archivearticle1.dtd\">\\n<article xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" article-type=\"research-article\"><?properties open_access?><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">J Pathol</journal-id><journal-id journal-id-type=\"publisher-id\">path</journal-id><journal-title-group><journal-title>The Journal of Pathology</journal-title></journal-title-group><issn pub-type=\"ppub\">0022-3417</issn><issn pub-type=\"epub\">1096-9896</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmid\">20229506</article-id><article-id pub-id-type=\"pmc\">3262968</article-id><article-id pub-id-type=\"doi\">10.1002/path.2696</article-id><article-categories><subj-group subj-group-type=\"heading\"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Driver mutations in <italic>TP53</italic> are ubiquitous in high grade serous carcinoma of the ovary</article-title></title-group><contrib-group><contrib contrib-type=\"author\"><name><surname>Ahmed</surname><given-names>Ahmed Ashour</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Etemadmoghadam</surname><given-names>Dariush</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref></contrib><contrib contrib-type=\"author\"><name><surname>Temple</surname><given-names>Jillian</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Lynch</surname><given-names>Andy G</given-names></name><xref ref-type=\"aff\" rid=\"au2\">2</xref></contrib><contrib contrib-type=\"author\"><name><surname>Riad</surname><given-names>Mohamed</given-names></name><xref ref-type=\"aff\" rid=\"au4\">4</xref></contrib><contrib contrib-type=\"author\"><name><surname>Sharma</surname><given-names>Raghwa</given-names></name><xref ref-type=\"aff\" rid=\"au5\">5</xref></contrib><contrib contrib-type=\"author\"><name><surname>Stewart</surname><given-names>Colin</given-names></name><xref ref-type=\"aff\" rid=\"au6\">6</xref></contrib><contrib contrib-type=\"author\"><name><surname>Fereday</surname><given-names>Sian</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref></contrib><contrib contrib-type=\"author\"><name><surname>Caldas</surname><given-names>Carlos</given-names></name><xref ref-type=\"aff\" rid=\"au2\">2</xref><xref ref-type=\"aff\" rid=\"au7\">7</xref></contrib><contrib contrib-type=\"author\"><name><surname>deFazio</surname><given-names>Anna</given-names></name><xref ref-type=\"aff\" rid=\"au8\">8</xref></contrib><contrib contrib-type=\"author\"><name><surname>Bowtell</surname><given-names>David</given-names></name><xref ref-type=\"aff\" rid=\"au3\">3</xref><xref ref-type=\"aff\" rid=\"au9\">9</xref><xref ref-type=\"corresp\" rid=\"cor1\">*</xref></contrib><contrib contrib-type=\"author\"><name><surname>Brenton</surname><given-names>James D</given-names></name><xref ref-type=\"aff\" rid=\"au1\">1</xref><xref ref-type=\"aff\" rid=\"au2\">2</xref><xref ref-type=\"corresp\" rid=\"cor2\">*</xref></contrib></contrib-group><aff id=\"au1\"><label>1</label><institution>Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre</institution><addr-line>Robinson Way, Cambridge, CB2 0RE, UK</addr-line></aff><aff id=\"au2\"><label>2</label><institution>Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre</institution><addr-line>Hills Road, Cambridge, CB2 0XZ, UK</addr-line></aff><aff id=\"au3\"><label>3</label><institution>Peter MacCallum Cancer Centre</institution><addr-line>Melbourne, Victoria, Australia</addr-line></aff><aff id=\"au4\"><label>4</label><institution>Department of Obstetrics and Gynaecology, El-Galaa Maternity Teaching Hospital</institution><addr-line>41 July 26th Street, Cairo 11511, Egypt</addr-line></aff><aff id=\"au5\"><label>5</label><institution>Department of Anatomical Pathology, University of Sydney and University of Western Sydney at Westmead Hospital</institution><addr-line>Sydney, Australia</addr-line></aff><aff id=\"au6\"><label>6</label><institution>Department of Pathology, King Edward Memorial Hospital</institution><addr-line>Western Australia, Australia</addr-line></aff><aff id=\"au7\"><label>7</label><institution>Functional Genomics of Breast Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre</institution><addr-line>Robinson Way, Cambridge, CB2 0RE, UK</addr-line></aff><aff id=\"au8\"><label>8</label><institution>Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital</institution><addr-line>New South Wales, Australia</addr-line></aff><aff id=\"au9\"><label>9</label><institution>Department of Biochemistry and Molecular Biology, University of Melbourne</institution><addr-line>Parkville, Victoria, Australia</addr-line></aff><author-notes><corresp id=\"cor1\">*Correspondence to: Professor David Bowtell, Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A\\'Beckett Street, Melbourne, 8006, Victoria, Australia. e-mail: <email>d.bowtell@petermac.org</email></corresp><corresp id=\"cor2\">*Correspondence to: Dr James D Brenton, Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. e-mail: <email>james.brenton@cancer.org.uk</email></corresp><fn><p>No conflicts of interest were declared.</p></fn></author-notes><pub-date pub-type=\"ppub\"><month>5</month><year>2010</year></pub-date><volume>221</volume><issue>1</issue><fpage>49</fpage><lpage>56</lpage><history><date date-type=\"received\"><day>09</day><month>12</month><year>2009</year></date><date date-type=\"rev-recd\"><day>24</day><month>1</month><year>2010</year></date><date date-type=\"accepted\"><day>26</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley &#x00026; Sons, Ltd.</copyright-statement><copyright-year>2010</copyright-year><license license-type=\"open-access\" xlink:href=\"http://creativecommons.org/licenses/by/2.5/\"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p>Numerous studies have tested the association between <italic>TP53</italic> mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of <italic>TP53</italic> mutations in HGPSC, we sequenced exons 2&#x02013;11 and intron&#x02013;exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic <italic>TP53</italic> mutations were identified in 96.7% (<italic>n</italic> = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative cases showed evidence of p53 dysfunction associated with copy number gain of <italic>MDM2</italic> or <italic>MDM4</italic>, or indicated the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between <italic>TP53</italic> mutation and progression-free or overall survival was found. From this first comprehensive mapping of <italic>TP53</italic> mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant <italic>TP53</italic> is a driver mutation in the pathogenesis of HGPSC cancers. Because <italic>TP53</italic> mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. Copyright &#x000a9; 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley &#x00026; Sons, Ltd.</p></abstract><kwd-group><kwd>p53</kwd><kwd>high-grade pelvic serous carcinoma</kwd><kwd>ovarian cancer</kwd><kwd>DNA sequence analysis</kwd><kwd>array-based genomic hybridization</kwd><kwd>histopathology</kwd><kwd>clinical outcome</kwd><kwd>BRCA</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The gene <italic>TP53</italic> that encodes the tumour suppressor protein p53 is amongst the most commonly mutated genes in human cancer [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. The frequent presence of <italic>TP53</italic> mutations in ovarian cancer has been suggested for almost two decades [<xref ref-type=\"bibr\" rid=\"b2\">2</xref>,<xref ref-type=\"bibr\" rid=\"b3\">3</xref>] and during this time, approximately 70 publications have described the relationship between <italic>TP53</italic> mutation status and clinical outcome [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>]. For such an intensively studied question, there is a surprising degree of inconsistency in the published data for both the prevalence of mutation and association with prognosis or chemotherapy response.</p><p>A recent analysis of 64 publications reporting the relationship of <italic>TP53</italic> mutation to clinical outcome found that only six studies fulfilled minimum quality criteria for the method of detecting mutations or assignment of clinical response [<xref ref-type=\"bibr\" rid=\"b5\">5</xref>]. One of the most consistent limitations of previous p53 studies is a reliance on p53 immunostaining as a surrogate marker for <italic>TP53</italic> mutation [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>], even though this leads to an unacceptable number of misclassifications [<xref ref-type=\"bibr\" rid=\"b6\">6</xref>]. Sequencing of tumour DNA is the gold standard to detect different types of mutation and relate these to clinical outcome. However, a recent review of 12 studies that sequenced <italic>TP53</italic> in ovarian cancer found variable mutation frequencies of 15&#x02013;80% [<xref ref-type=\"bibr\" rid=\"b5\">5</xref>]. Inconsistencies between these studies may relate to whether the whole gene was or only the most commonly mutated exons were sequenced. Additionally, most studies were confounded by the inclusion of cases with different histological types, stages, and grades of tumours [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>].</p><p>Determining the true prevalence of <italic>TP53</italic> mutation is critical for understanding the pathogenesis of high-grade serous cancers arising as ovarian, Fallopian tube or primary peritoneal cancer. Although previously assumed to arise from the ovary, pathological examination of the Fallopian tube from carriers with <italic>BRCA1</italic> or <italic>BRCA2</italic> mutation has demonstrated that tubal intraepithelial carcinomas (TICs) arising from secretory epithelial cells in the fimbria are the early invasive lesion in high-grade serous (HGS) carcinoma [<xref ref-type=\"bibr\" rid=\"b7\">7</xref>,<xref ref-type=\"bibr\" rid=\"b8\">8</xref>]. In addition, TICs are found in patients without evidence of germline <italic>BRCA1</italic> or <italic>BRCA2</italic> lesions and show concomitant <italic>TP53</italic> mutations in the tube and in pelvic metastases, further supporting the model that TIC represents the origin of HGS carcinoma. HGS cancers may also arise from the peritoneum and although these may have different epidemiological risk factor profiles [<xref ref-type=\"bibr\" rid=\"b9\">9</xref>], they exist in a clinical continuum with ovarian and Fallopian tube cancers. Hence we use the term high-grade pelvic serous carcinoma (HGPSC) [<xref ref-type=\"bibr\" rid=\"b10\">10</xref>] to recognize the frequent lack of clarity regarding primary site in ovarian/Fallopian tube/peritoneal cancers and their overall biological and clinical similarity.</p><p>To address the limitations of previous studies and determine accurately the relationship between <italic>TP53</italic> mutation and HGPSC, we designed pilot and validation studies to measure the mutation frequency in a homogeneous group of advanced stage HGPSC cancers from a large population-based cohort.</p></sec><sec sec-type=\"materials|methods\"><title>Materials and methods</title><sec><title>Samples and study design</title><p>The results of this study are presented in accordance with reporting recommendations for tumour marker prognostic studies (REMARK) criteria [<xref ref-type=\"bibr\" rid=\"b11\">11</xref>]. Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD3\">Figure 1</xref> (Supporting information) summarizes the flow of patients through the pilot and validation study, including the number of patients included in each stage of the analysis and reasons for exclusion. Patients (<italic>n</italic> = 123) were selected from the Australian Ovarian Cancer Study (AOCS), a population-based, multicentre translational study that comprised prospective collection of bio-specimens and clinical and epidemiological data from patients with primary epithelial ovarian, primary peritoneal, and Fallopian tube cancer diagnosed between 2001 and 2005. Patients treated at Westmead Hospital, Sydney between 1992 and 2002 (<italic>n</italic> = 22) were also included in the pilot cohort, making an overall sample size of 145 HGPSCs. All women in the pilot cohort received first-line platinum-based chemotherapy (cisplatin or carboplatin) with (<italic>n</italic> = 39) or without (<italic>n</italic> = 6) the taxane paclitaxel. Similarly, the majority of patients in the validation set received combination platinum&#x02013;taxane treatment (<italic>n</italic> = 93) or platinum monotherapy (<italic>n</italic> = 4). Three patients (<italic>n</italic> = 3) did not receive any chemotherapy, including one patient with stage I cancer who declined treatment and two patients who were too ill to receive chemotherapy. All patients were prospectively consented using a protocol approved by the human research ethics committees at multiple participating clinical and research centres. Further details of the AOCS cohort can be found at <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.aocstudy.org\">http://www.aocstudy.org</ext-link>. Statistical design and power calculations are described in the Supporting information, Supplementary methods.</p></sec><sec><title><italic>TP53</italic> sequencing</title><p>Coding <italic>TP53</italic> exons 2&#x02013;11 were amplified using primers that encompassed the entire exon and exon&#x02013;intron boundaries. Purified PCR products were se- quenced using an ABI 3100 genetic analyser (Applied Biosystems, Warrington, UK). Sequencing reactions were performed in forward and reverse directions. Mutational analysis was performed using SeqScape&#x000ae; Software v2.6 (Applied Biosystems). Sequence traces were aligned against the <italic>TP53</italic> reference sequence NC_000017. Independent, blinded sequencing of cases from the pilot study was performed by the CR-UK Mutation Detection Facility, Clinical Sciences Building, Level 6, St James\\'s University Hospital, Leeds, UK.</p></sec><sec><title>Characterization of mutation-negative HGPSC cancers</title><p>For single nucleotide polymorphism (SNP) mapping assay, SNP microarray data analysis, quantitative PCR (qPCR), and immunohistochemistry, the reader is referred to the Supporting information, Supplementary methods.</p></sec><sec><title>aCGH data</title><p>Raw data files from aCGH experiments are available from the Gene Expression Omnibus <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.ncbi.nlm.nih.gov/geo/\">http://www.ncbi.nlm.nih.gov/geo/</ext-link> (Accession number GSE19416).</p></sec></sec><sec><title>Results</title><sec><title>Both treatment-responsive and primary resistant HGPSCs have a high frequency of <italic>TP53</italic> mutation</title><p>To estimate the number of samples required to detect a significant association between <italic>TP53</italic> mutations and survival, we performed a pilot study with 45 HGPSCs (ovarian, Fallopian tube, and primary peritoneal). The cohort included 20 chemotherapy-resistant patients who had tumour progression within 6 months of completion of treatment and 25 responsive patients who did not progress for at least 9 months. The two groups showed no statistically significant differences in age, tumour stage, residual disease or type of chemotherapy (<xref ref-type=\"table\" rid=\"tbl1\">Table 1</xref>). Review of pathology reports showed one patient with low-grade serous (LGS) carcinoma (case 450) and this case was excluded from further analysis. Unexpectedly, pathogenic <italic>TP53</italic> mutations were identified in 43 out of 44 patients included in the study (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref> and Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD3\">Figure 1</xref>). Mutations were compared to Release 13 of the IARC <italic>TP53</italic> mutation database [<xref ref-type=\"bibr\" rid=\"b12\">12</xref>] and 20 cases had rare <italic>TP53</italic> mutations, defined as less than ten occurrences (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). From these, 12 were randomly selected and independently confirmed by a clinical reference laboratory blinded to our results (data not shown). Further analysis of mutations is described below.</p><table-wrap id=\"tbl1\" position=\"float\"><label>Table 1</label><caption><p>A comparison between the clinical characteristics of the chemotherapy-resistant and -responsive patients in the pilot study</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\"/><th align=\"center\" rowspan=\"1\" colspan=\"1\">Resistant (<italic>n</italic> = 20)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Responsive (<italic>n</italic> = 25)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\"><italic>p</italic> (test)</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">PFS (months)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">10.2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">23.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x0003c; 0.001 (log rank)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">OS (months)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">21.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">57.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x0003c; 0.001 (log rank)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Age (years)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">58.26</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">58.7</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.7 (Wilcoxon rank sum)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Range</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">22.9&#x02013;78</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">38.1&#x02013;77.7</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Stage (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;III</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">20</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">23</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.5 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;IV</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">&#x02014;</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">2</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Chemotherapy (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">19</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.4 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Neo-adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Residual disease (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;No residual disease</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.2 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x02264;1 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">11</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">8</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 1 cm and &#x02264;2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">6</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">TP53 (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Wild type</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.4 (Fisher)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Mutant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">19</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td><td rowspan=\"1\" colspan=\"1\"/></tr></tbody></table><table-wrap-foot><fn><p>OS = overall survival; PFS = progression-free survival, defined as the period from diagnosis to the date of documented progression. Six samples (2 resistant, 4 responsive) did not have precise values for size &#x0003c; 2 cm.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Confirmation of high frequency of <italic>TP53</italic> mutation in an unselected population-based cohort of serous cancers</title><p>To exclude the possibility that the high rate of <italic>TP53</italic> mutations was biased by the selection criteria used in the pilot study, we obtained additional serous cancer cases that were a representative subset of a large population-based series (<xref ref-type=\"table\" rid=\"tbl2\">Table 2</xref>). Mutations were detected in 76/82 advanced-stage HGPSCs from these cases, with no significant difference between the percentage of mutations in the matched validation study compared with the pilot study (<italic>p</italic> = 0.3; Fisher exact test).</p><table-wrap id=\"tbl2\" position=\"float\"><label>Table 2</label><caption><p>Clinical characteristics of the validation study patients</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\"/><th align=\"center\" rowspan=\"1\" colspan=\"1\">Validation set (<italic>n</italic> = 82</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">PFS (months)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">13.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">OS (months)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">34</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Age (years)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Median</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">61.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Range</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">40.4&#x02013;79.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Stage (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;III</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">73</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;IV</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">9</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Grade (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;2</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">18</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;3</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">63</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Chemotherapy (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">71</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Neo-adjuvant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">11</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Residual disease (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;No residual disease</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">16</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x02264;1 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">26</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 1 cm and &#x02264;2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">5</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;&#x0003e; 2 cm</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">25</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Unknown</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">10</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">TP53 (<italic>n</italic>)</td><td rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Wild type</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">6</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">&#x02003;Mutant</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">76</td></tr></tbody></table><table-wrap-foot><fn><p>OS = overall survival; PFS = progression-free survival.</p></fn></table-wrap-foot></table-wrap></sec><sec><title><italic>TP53</italic> mutations arise at high frequency in exons 2&#x02013;4 and 9&#x02013;11 in HGPSC carcinoma</title><p>We analysed the 119 mutations found in 126 HGPSC cases from the pilot and validation set (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). As expected, the majority of <italic>TP53</italic> mutations were missense mutations (56.3%, <italic>n</italic> = 67/119) occurring in exons 4&#x02013;8 (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The most frequently mutated codon was 273 (<italic>n</italic> = 9/67 cases, 13.4%) comprising R273C, R273H, and R273L mutants. Analysis of exon and splice sites for exons 2&#x02013;4 and 9&#x02013;11, outside the DNA binding domain, showed 12 (10.1%) and 10 (8.4%) mutations, respectively, which taken together comprised 18.5% (<italic>n</italic> = 22/119) of all mutations in our series. Of note, a total of eight mutations affected exon 10 (6.7%) in the tetramerization domain (codons 324&#x02013;356) and all were predicted to cause truncation of the protein. Four of these mutations occurred at g.16915 (codon 342). In 717 serous sub-type ovarian, Fallopian, and primary peritoneal cancer cases in Release 13 of the IARC <italic>TP53</italic> database, 30 (4.2%) had mutations in exons 2&#x02013;4, 18 had mutations affecting exon 10 alone (2.5%), and 20 (2.8%) had mutations in exons 9&#x02013;11. Twenty-two mutations from our series (<italic>n</italic> = 22/119, 18.5%) were not present in the IARC database. With the exception of one, all were insertions or deletions (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The remaining novel mutation in case 434 was at position g.11602_11603GC &#x0003e; AA, creating a unique tandem nonsense mutation.</p></sec><sec><title>Low-stage HGPSC cases have a high frequency of <italic>TP53</italic> mutations</title><p>The very high prevalence of mutation in high-stage cases suggested that <italic>TP53</italic> was an early event in the pathogenesis of HGPSC. From the validation set, 15 cases were stage 1 or 2 HGPSC and 13/15 (86.7%) had <italic>TP53</italic> mutation (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD1\">Table 1</xref>). The negative cases 41307 and 60111 had mixed endometrioid/HGS or grade 1 pathology, respectively. As for high-stage cases, the majority of mutations (<italic>n</italic> = 10/13; 76.9%) were missense mutations in exons 5&#x02013;8. There was one nonsense mutation in exon 10 (7.7%) and two splice junction mutations (15.4%).</p></sec><sec><title>Mutation-negative cases have alternative mechanisms of p53 dysfunction</title><p>We considered the possibility that <italic>TP53</italic> mutations in the seven mutation-negative samples (pilot <italic>n</italic> = 1, validation <italic>n</italic> = 6) were missed because of contamination with normal DNA. Although all samples with significant stroma were needle-dissected prior to sequencing, pathological review of the mutation-negative cases indicated that they did not have increased stroma compared with mutation-positive cases (data not shown). Additionally, array-based comparative genomic hybridization (aCGH) showed that all mutation-negative cases had DNA copy number abnormalities (DCNAs), and the least aberrant, case 533, had distinct loss of chromosome arm 1p (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1A</xref>). No samples showed evidence of homozygous deletion of the <italic>TP53</italic> locus (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1</xref>B).</p><fig id=\"fig01\" position=\"float\"><label>Figure 1</label><caption><p>Characterization of <italic>TP53</italic> mutation-negative cancer samples. (A) Summary plots of whole genome DNA copy number data for seven mutation-negative samples. Red indicates chromosomal gain and blue shows regions of chromosomal loss. (B) High-resolution DNA copy number analysis of <italic>MDM2, MDM4</italic>, and <italic>TP53</italic> loci in each sample. The dotted line indicates the position of the gene within the region. Samples with chromosomal gain or loss are marked with a red or blue asterisk, respectively. (C) Confirmation of <italic>MDM2</italic> and <italic>MDM4</italic> copy number gain using quantitative PCR of tumour DNA. Samples with gain are indicated in red. (D) Immunohistochemical staining of p53 protein in the following selected mutation-negative cases: case 41358; case 60258 (<italic>MDM2</italic> gain); case 22029 (<italic>MDM4</italic> gain); and case 60049 (<italic>MDM4</italic> gain).</p></caption><graphic xlink:href=\"path0221-0049-f1\"/></fig><p>Pathology review of the mutation-negative cases resulted in the re-classification of case 60214 as LGS carcinoma, case 23221 as high-grade carcinoma of uncertain primary site, and case 533 as mixed LGS/HGS type (Supporting information, Supplementary <xref ref-type=\"supplementary-material\" rid=\"SD2\">Table 2</xref>). Furthermore, aCGH analysis of cases 533 and 60214 did not show high-frequency DCNAs that are typical of HGPSC [<xref ref-type=\"bibr\" rid=\"b11\">11</xref>]. The original diagnosis of HGPSC was confirmed in the remaining four cases (22029, 41358, 60049, and 60258). To further exclude the possibility of pathological misclassification of endometrioid, clear cell or LGS tumours in the mutation-negative cases, we also tested for mutations commonly associated with these subtypes in <italic>KRAS</italic> (exon 2), <italic>BRAF</italic> (exon 15), <italic>CTNNB1</italic> (exon 3), and <italic>PIK3CA</italic> (exons 10 and 21). Case 60214 had a missense mutation (G12C) in exon 2 of <italic>KRAS</italic>, consistent with LGS origin. No other mutations were detected (data not shown).</p><p>Other mutation-independent mechanisms of inactivation of the p53 pathway were investigated. p53 is targeted for degradation through the activity of MDM2 protein and is also regulated by the related MDM4 protein [<xref ref-type=\"bibr\" rid=\"b13\">13</xref>,<xref ref-type=\"bibr\" rid=\"b14\">14</xref>]. Amplification of <italic>MDM2</italic> is associated with loss of p53 activity in some solid tumours [<xref ref-type=\"bibr\" rid=\"b15\">15</xref>,<xref ref-type=\"bibr\" rid=\"b16\">16</xref>]. aCGH analysis of the remaining four cases showed copy number gain of <italic>MDM4</italic> in cases 22029 and 60049, and of <italic>MDM2</italic> in case 60258 (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1B</xref>). These observations were confirmed by qPCR (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1C</xref>). Interestingly, both cases with <italic>MDM4</italic> gain showed heterogeneous p53 immunostaining, including cytoplasmic staining (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>). Case 60258 with <italic>MDM2</italic> gain showed strong nuclear staining for p53 protein (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>). Interestingly, the remaining case with no MDM2 or MDM4 gain (41358) showed strong nuclear p53 immunostaining (<xref ref-type=\"fig\" rid=\"fig01\">Figure 1D</xref>).</p><p>In summary, the overall <italic>TP53</italic> mutation rate for selected HGPSC cases in the pilot and validation cohorts was 94.4% (<italic>n</italic> = 119/126). After removing the three mutation-negative cases with atypical or LGS histology, the adjusted overall rate was 96.7% (<italic>n</italic> = 119/123). In the remaining four mutation-negative HGPSC cases, three showed evidence of p53 dysfunction with increased p53 nuclear staining or cytoplasmic mislocalization that was correlated with gains at the <italic>MDM2/4</italic> loci.</p></sec><sec><title><italic>TP53</italic> mutation type is not prognostic in HGPSC</title><p>It has been previously reported that the type of <italic>TP53</italic> mutation may predict outcome in ovarian cancer [<xref ref-type=\"bibr\" rid=\"b17\">17</xref>]. Although our study was not adequately powered to detect small effects, we tested for trends in the data. For this analysis, we used all presumed HGPSC cases from the pilot study and the validation cohort (<italic>n</italic> = 127, <italic>n</italic> = 120 had <italic>TP53</italic> mutation; <xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was no indication of significant association between the frequency of <italic>TP53</italic> mutation or the type of mutation (missense versus not) and progression-free survival or overall survival. Similarly, whether or not the missense mutation affected the DNA binding motifs formed by the L2 and L3 loops (codons 164&#x02013;194 and 237&#x02013;250, respectively) or the LSH motifs (codons 119&#x02013;135 and 272&#x02013;287) [<xref ref-type=\"bibr\" rid=\"b18\">18</xref>] had no significant effect on progression-free survival or overall survival (<xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was also no effect of codon 72 polymorphism (Arg, Pro or heterozygous) on prognosis in any of the HGPSCs with mutations (data not shown) or in tumours with missense mutations (<xref ref-type=\"table\" rid=\"tbl3\">Tables 3</xref> and <xref ref-type=\"table\" rid=\"tbl4\">4</xref>). There was no significant interaction between the type of missense mutation (DNA binding or not) and codon 72 polymorphism (data not shown).</p><table-wrap id=\"tbl3\" position=\"float\"><label>Table 3</label><caption><p>The type of <italic>TP53</italic> mutation does not influence progression-free survival</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" rowspan=\"1\" colspan=\"1\">Index category (<italic>n</italic>)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Comparison (<italic>n</italic>)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Hazard ratio</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">CI</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Log-rank <italic>p</italic> value</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mutant (120)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Wild type (7)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;3.1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.5</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Not missense (52)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Missense (68)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.9</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;1.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.8</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">DBM (44)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">NDBM (24)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;1.7</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr></tbody></table><table-wrap-foot><fn><p>DBM = DNA binding mutations; NDBM = non-DNA binding mutations.</p></fn></table-wrap-foot></table-wrap><table-wrap id=\"tbl4\" position=\"float\"><label>Table 4</label><caption><p>The type of <italic>TP53</italic> mutation does not influence overall survival</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" rowspan=\"1\" colspan=\"1\">Index category (<italic>n</italic>)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Comparison (<italic>n</italic>)</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Hazard ratio</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">CI</th><th align=\"center\" rowspan=\"1\" colspan=\"1\">Log-rank <italic>p</italic> value</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mutant (120)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Wild type (7)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.7</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.6&#x02013;4.6</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.3</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Not missense (52)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Missense (68)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.7&#x02013;1.6</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">DBM (44)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">NDBM (24)</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">1.3</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.7&#x02013;2.4</td><td align=\"center\" rowspan=\"1\" colspan=\"1\">0.4</td></tr></tbody></table><table-wrap-foot><fn><p>DBM = DNA binding mutations; NDBM = non-DNA binding mutations.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>By addressing the limitations of numerous other studies of <italic>TP53</italic> mutation in ovarian cancer, we have demonstrated for the first time that HGPSCs have the highest frequency of p53 mutation of any solid cancer. Approximately two-thirds of mutations occurred in exons 5&#x02013;8, known to be mutation hotspots for <italic>TP53</italic>. By sequencing exons 2&#x02013;4 and 9&#x02013;11, we identified 22 mutations (<italic>n</italic> = 22/126, 17.5%) that would not have otherwise been identified in our series and are poorly represented in previous reports. The previously unreported mutations that we have discovered are mostly insertions/deletions predicted to result in truncated proteins, but it is notable that HGPSC cases have frequent involvement of exon 10 and specifically involvement of position g.16915 (codon 342) in the oligomerization domain of p53. This region also contains a putative nuclear export signal for p53 and a recent study of a novel missense mutation at codon 351 has shown that K351N results in significant loss of p53 tetramerization, reduced BAX activation, and reduced nuclear export of p53 [<xref ref-type=\"bibr\" rid=\"b19\">19</xref>]. Cytosolic export of p53 is required for cisplatin-induced apoptosis in A2780 cells, suggesting that combined loss of tetramerization and nuclear export is critical for platinum resistance.</p><p>Of the mutation-negative cases, approximately half were reclassified on pathological review as unrepresentative of HGPSC, including two tumours that were LGS and associated with borderline tumour. Serous cancers may follow two distinct routes to malignancy [<xref ref-type=\"bibr\" rid=\"b20\">20</xref>]. A minority of so-called type I tumours progress from borderline tumours, whereas the majority of HGS (type II) tumours arise with no evidence of LGS or borderline tumours. Borderline serous tumours and their type I invasive counterparts are generally low grade, have relatively limited genomic DNA copy number change, have frequent activating RAS pathway mutations, and have substantially lower rates of <italic>TP53</italic> mutation compared with type II tumours [<xref ref-type=\"bibr\" rid=\"b20\">20</xref>&#x02013;<xref ref-type=\"bibr\" rid=\"b23\">23</xref>]. Detailed analysis of six cases of HGPSC arising from LGS and borderline tumours showed no <italic>TP53</italic> mutation [<xref ref-type=\"bibr\" rid=\"b24\">24</xref>]. Consistent with this model, mutation-negative case 533 had both LGS and HGS components and a bland aCGH profile.</p><p>Exclusion of LGS cases and mixed high-grade serous cases increased the <italic>TP53</italic> mutation frequency to approximately 97% of HGPSCs. Of the remaining mutation-negative cases, three may have had inactivation of the p53 pathway through chromosomal gain at the <italic>MDM2</italic> or <italic>MDM4</italic> loci or potentially other genes that alter p53 function in <italic>trans</italic> such as <italic>RFWD2</italic> and <italic>RCHY1</italic> [<xref ref-type=\"bibr\" rid=\"b25\">25</xref>,<xref ref-type=\"bibr\" rid=\"b26\">26</xref>].</p><p>We are aware of over 70 publications that have sought to relate <italic>TP53</italic> mutation with clinical outcome in ovarian cancer, with conflicting conclusions about the importance of <italic>TP53</italic> mutations for tumour aggressiveness, response to treatment, and survival. There is no sign that a conclusion is at hand: since 2008, there have been a number of papers relating <italic>TP53</italic> mutation and clinical outcome [<xref ref-type=\"bibr\" rid=\"b27\">27</xref>&#x02013;<xref ref-type=\"bibr\" rid=\"b30\">30</xref>], with evidence presented for [<xref ref-type=\"bibr\" rid=\"b29\">29</xref>] and against [<xref ref-type=\"bibr\" rid=\"b28\">28</xref>] mutation being a significant prognostic factor. A recent meta-analysis of 62 studies concluded that <italic>TP53</italic> mutation had a modest impact on survival in ovarian cancer but the effect was insufficient to support clinical application [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>]. Whilst meta-analyses such as that of de Graeff <italic>et al</italic> [<xref ref-type=\"bibr\" rid=\"b4\">4</xref>] have the potential to detect subtle trends that may be missed in all but the largest individual studies, they are confounded if there is a substantial false-negative rate, as our findings indicate. Given the near ubiquitous occurrence of <italic>TP53</italic> mutation, it difficult to conclude that it can be of significant prognostic or predictive significance in HGPSC. We have not, however, excluded the possibility that specific mutations can influence prognosis or response to therapy, an important consideration given the mounting evidence that some <italic>TP53</italic> mutations have specific neomorphic functions [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. It is thought that inactivation of the p53 pathway is a common, perhaps mandatory, event in all solid cancers [<xref ref-type=\"bibr\" rid=\"b31\">31</xref>]. What is particularly unusual about HGPSC is an almost total reliance on mutation <italic>TP53</italic> itself for pathway inactivation, perhaps reflecting the requirement of certain tissues for neomorphic mutations for their transformation [<xref ref-type=\"bibr\" rid=\"b1\">1</xref>]. Future work will need to address interactions between specific mutations and other loci such as <italic>PTEN</italic> and <italic>CDKN2A</italic> [<xref ref-type=\"bibr\" rid=\"b32\">32</xref>,<xref ref-type=\"bibr\" rid=\"b33\">33</xref>].</p><p>Our findings have important implications for the new understanding of the pathogenesis of HGPSC. p53 immunostaining and mutation appear to be a feature of early-stage Fallopian tube lesions from <italic>BRCA1/2</italic> mutation carriers [<xref ref-type=\"bibr\" rid=\"b7\">7</xref>], suggesting that p53 dysfunction is essential for early tumourigenesis of HGPSC. The notion that <italic>TP53</italic> mutation is required to allow survival of <italic>BRCA</italic>-deficient ovarian precursor lesions is consistent with the extremely high rates of <italic>TP53</italic> mutation in breast cancers arising in <italic>BRCA1</italic> mutant women [<xref ref-type=\"bibr\" rid=\"b34\">34</xref>,<xref ref-type=\"bibr\" rid=\"b35\">35</xref>]. BRCA dysfunction may also occur in sporadic HGPSC via a variety of inactivating mechanisms but the very high rate of <italic>TP53</italic> mutation in our series of sporadic HGPSC cases suggests that most are &#x02018;BRCA-like&#x02019; with deficiencies for <italic>BRCA</italic> or closely related DNA repair pathways [<xref ref-type=\"bibr\" rid=\"b36\">36</xref>].</p><p>It has become increasingly clear that ovarian cancer is a series of distinctly different diseases with different aetiologies [<xref ref-type=\"bibr\" rid=\"b23\">23</xref>,<xref ref-type=\"bibr\" rid=\"b37\">37</xref>] and that the development of reliable biomarkers must be subtype-specific [<xref ref-type=\"bibr\" rid=\"b38\">38</xref>]. For example, several biomarkers that appeared to be prognostic in a cohort of all major subtypes of ovarian cancer were not informative within homogeneous subtypes. Our findings provide another example of the importance of refining the analysis of ovarian biomarkers by focusing on the most clinically significant group, HGPSC.</p><p>The key oncogenic and tumour suppressor genes for HGPSC have not been identified and as it has high rates of genomic instability, many of the alterations described may be passenger mutations. Our results for the prevalence of <italic>TP53</italic> mutation may be conservative as our prospectively determined selection criteria excluded low-stage HGPSC cases (<italic>n</italic> = 15). This was because true low-stage HGPSC is a rare entity and often suggests misdiagnosis of LGS histiotype. However, 13/15 of these cases had <italic>TP53</italic> mutation. Our data are therefore consistent with mutant <italic>TP53</italic> being an essential driver mutation early in the pathogenesis of HGPSC. Future studies will need to focus on studying the biological significance of the different types of <italic>TP53</italic> mutation in HGPSC and developing p53 synthetic-lethal therapies for patients with this disease.</p></sec></body><back><ack><p>We thank Sarah Hyland, Philip Chambers, Christian Bourne, and Nik Matthews for expert technical assistance. We acknowledge the support of the University of Cambridge, NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and Hutchison Whampoa Ltd. AAA holds a CR-UK Clinician Scientist Fellowship. D Bowtell, G Chenevix-Trench, A deFazio, A Green, D Gertig, and P Webb&#x02014;The AOCS Management Group&#x02014;gratefully acknowledge the contributions of the full AOCS Study Group, listed on <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.aocstudy.org\">http://www.aocstudy.org</ext-link>, and express their gratitude to all women who participated in the study. The AOCS was supported by the US Army Medical Research and Material Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the NH&#x00026;MRC. We also gratefully acknowledge Catherine Emmanuel, Catherine Kennedy, and Yoke-Eng Chiew for samples, and data from the Westmead Gynaecological Oncology Tissue Bank, a member of the Australasian Biospecimens Network-Oncology group funded by the NH&#x00026;MRC. This work was funded by Cancer Research UK (CR-UK), the Medical Research Council (MRC), and the National Health and Medical Research Council of Australia (NHMRC).</p></ack><ref-list><title>References</title><p>Note: References 39&#x02013;50 are cited in the Supporting information to this article.</p><ref id=\"b1\"><label>1</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Brosh</surname><given-names>R</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name></person-group><article-title>When mutants gain new powers: news from the mutant p53 field</article-title><source>Nature Rev Cancer</source><year>2009</year><volume>9</volume><fpage>701</fpage><lpage>713</lpage><pub-id pub-id-type=\"pmid\">19693097</pub-id></element-citation></ref><ref id=\"b2\"><label>2</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Davidoff</surname><given-names>AM</given-names></name><name><surname>Kerns</surname><given-names>BJ</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Pence</surname><given-names>JC</given-names></name><name><surname>Dodge</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Overexpression and mutation of p53 in epithelial ovarian cancer</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>2979</fpage><lpage>2984</lpage><pub-id pub-id-type=\"pmid\">2032235</pub-id></element-citation></ref><ref id=\"b3\"><label>3</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Okamoto</surname><given-names>A</given-names></name><name><surname>Sameshima</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Terashima</surname><given-names>Y</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Frequent allelic losses and mutations of the p53 gene in human ovarian cancer</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>5171</fpage><lpage>5176</lpage><pub-id pub-id-type=\"pmid\">1680546</pub-id></element-citation></ref><ref id=\"b4\"><label>4</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>de Graeff</surname><given-names>P</given-names></name><name><surname>Crijns</surname><given-names>AP</given-names></name><name><surname>de Jong</surname><given-names>S</given-names></name><name><surname>Boezen</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>WJ</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis</article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type=\"pmid\">19513073</pub-id></element-citation></ref><ref id=\"b5\"><label>5</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group><article-title>Critical evaluation of p53 as a prognostic marker in ovarian cancer</article-title><source>Expert Rev Mol Med</source><year>2004</year><volume>6</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type=\"pmid\">15147608</pub-id></element-citation></ref><ref id=\"b6\"><label>6</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Ishioka</surname><given-names>C</given-names></name><name><surname>Claustres</surname><given-names>M</given-names></name><name><surname>Beroud</surname><given-names>C</given-names></name></person-group><article-title>Locus-specific mutation databases: pitfalls and good practice based on the p53 experience</article-title><source>Nature Rev Cancer</source><year>2006</year><volume>6</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type=\"pmid\">16397528</pub-id></element-citation></ref><ref id=\"b7\"><label>7</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Nucci</surname><given-names>MR</given-names></name><name><surname>Medeiros</surname><given-names>F</given-names></name><name><surname>Saleemuddin</surname><given-names>A</given-names></name><etal/></person-group><article-title>A candidate precursor to serous carcinoma that originates in the distal Fallopian tube</article-title><source>J Pathol</source><year>2007</year><volume>211</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type=\"pmid\">17117391</pub-id></element-citation></ref><ref id=\"b8\"><label>8</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Ince</surname><given-names>TA</given-names></name><name><surname>Muto</surname><given-names>M</given-names></name><name><surname>Kindelberger</surname><given-names>DW</given-names></name><etal/></person-group><article-title>The distal Fallopian tube: a new model for pelvic serous carcinogenesis</article-title><source>Curr Opin Obstet Gynecol</source><year>2007</year><volume>19</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type=\"pmid\">17218844</pub-id></element-citation></ref><ref id=\"b9\"><label>9</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Jordan</surname><given-names>SJ</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>Whiteman</surname><given-names>DC</given-names></name><name><surname>Moore</surname><given-names>SP</given-names></name><name><surname>Bain</surname><given-names>CJ</given-names></name><name><surname>Gertig</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Serous ovarian, Fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>1598</fpage><lpage>1603</lpage><pub-id pub-id-type=\"pmid\">18058817</pub-id></element-citation></ref><ref id=\"b10\"><label>10</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Herrington</surname><given-names>CS</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name></person-group><article-title>The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis</article-title><source>J Pathol</source><year>2007</year><volume>220</volume><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type=\"pmid\">19882674</pub-id></element-citation></ref><ref id=\"b11\"><label>11</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name></person-group><article-title>Reporting recommendations for tumor marker prognostic studies (REMARK)</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type=\"pmid\">16106022</pub-id></element-citation></ref><ref id=\"b12\"><label>12</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Petitjean</surname><given-names>A</given-names></name><name><surname>Marcel</surname><given-names>V</given-names></name><name><surname>Petre</surname><given-names>A</given-names></name><name><surname>Mounawar</surname><given-names>M</given-names></name><name><surname>Plymoth</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recent advances in p53 research: an interdisciplinary perspective</article-title><source>Cancer Gene Ther</source><year>2009</year><volume>16</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type=\"pmid\">18802452</pub-id></element-citation></ref><ref id=\"b13\"><label>13</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Montes de Oca Luna</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>DS</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type=\"pmid\">7477326</pub-id></element-citation></ref><ref id=\"b14\"><label>14</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Parant</surname><given-names>J</given-names></name><name><surname>Chavez-Reyes</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>NA</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Reinke</surname><given-names>V</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53</article-title><source>Nature Genet</source><year>2001</year><volume>29</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type=\"pmid\">11528400</pub-id></element-citation></ref><ref id=\"b15\"><label>15</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Oliner</surname><given-names>JD</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>George</surname><given-names>DL</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Amplification of a gene encoding a p53-associated protein in human sarcomas</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>80</fpage><lpage>83</lpage><pub-id pub-id-type=\"pmid\">1614537</pub-id></element-citation></ref><ref id=\"b16\"><label>16</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>McCann</surname><given-names>AH</given-names></name><name><surname>Kirley</surname><given-names>A</given-names></name><name><surname>Carney</surname><given-names>DN</given-names></name><name><surname>Corbally</surname><given-names>N</given-names></name><name><surname>Magee</surname><given-names>HM</given-names></name><name><surname>Keating</surname><given-names>G</given-names></name><etal/></person-group><article-title>Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type=\"pmid\">7734324</pub-id></element-citation></ref><ref id=\"b17\"><label>17</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shahin</surname><given-names>MS</given-names></name><name><surname>Hughes</surname><given-names>JH</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name></person-group><article-title>The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>2006</fpage><lpage>2017</lpage><pub-id pub-id-type=\"pmid\">11064359</pub-id></element-citation></ref><ref id=\"b18\"><label>18</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Carrieri</surname><given-names>P</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Klaar</surname><given-names>S</given-names></name><name><surname>Eyfjord</surname><given-names>J</given-names></name><etal/></person-group><article-title>The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type=\"pmid\">16489069</pub-id></element-citation></ref><ref id=\"b19\"><label>19</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Muscolini</surname><given-names>M</given-names></name><name><surname>Montagni</surname><given-names>E</given-names></name><name><surname>Caristi</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Kamada</surname><given-names>R</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>3396</fpage><lpage>3405</lpage><pub-id pub-id-type=\"pmid\">19806023</pub-id></element-citation></ref><ref id=\"b20\"><label>20</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vang</surname><given-names>R</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems</article-title><source>Adv Anat Pathol</source><year>2009</year><volume>16</volume><fpage>267</fpage><lpage>282</lpage><pub-id pub-id-type=\"pmid\">19700937</pub-id></element-citation></ref><ref id=\"b21\"><label>21</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>7273</fpage><lpage>7279</lpage><pub-id pub-id-type=\"pmid\">16243797</pub-id></element-citation></ref><ref id=\"b22\"><label>22</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Meinhold-Heerlein</surname><given-names>I</given-names></name><name><surname>Bauerschlag</surname><given-names>D</given-names></name><name><surname>Hilpert</surname><given-names>F</given-names></name><name><surname>Dimitrov</surname><given-names>P</given-names></name><name><surname>Sapinoso</surname><given-names>LM</given-names></name><name><surname>Orlowska-Volk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>1053</fpage><lpage>1065</lpage><pub-id pub-id-type=\"pmid\">15558012</pub-id></element-citation></ref><ref id=\"b23\"><label>23</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Salani</surname><given-names>R</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Giuntoli</surname><given-names>R</given-names><suffix>2nd</suffix></name><name><surname>Gardner</surname><given-names>G</given-names></name><name><surname>Bristow</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance</article-title><source>Int J Gynecol Cancer</source><year>2008</year><volume>18</volume><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type=\"pmid\">17692090</pub-id></element-citation></ref><ref id=\"b24\"><label>24</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dehari</surname><given-names>R</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Logani</surname><given-names>S</given-names></name><name><surname>Shih</surname><given-names>IeM</given-names></name></person-group><article-title>The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis</article-title><source>Am J Surg Pathol</source><year>2007</year><volume>31</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type=\"pmid\">17592266</pub-id></element-citation></ref><ref id=\"b25\"><label>25</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Leng</surname><given-names>RP</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lemmers</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type=\"pmid\">12654245</pub-id></element-citation></ref><ref id=\"b26\"><label>26</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Dornan</surname><given-names>D</given-names></name><name><surname>Wertz</surname><given-names>I</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Arnott</surname><given-names>D</given-names></name><name><surname>Frantz</surname><given-names>GD</given-names></name><name><surname>Dowd</surname><given-names>P</given-names></name><etal/></person-group><article-title>The ubiquitin ligase COP1 is a critical negative regulator of p53</article-title><source>Nature</source><year>2004</year><volume>429</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type=\"pmid\">15103385</pub-id></element-citation></ref><ref id=\"b27\"><label>27</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bartel</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Bohnke</surname><given-names>A</given-names></name><name><surname>Gradhand</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name><name><surname>Thomssen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type=\"pmid\">18172257</pub-id></element-citation></ref><ref id=\"b28\"><label>28</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Darcy</surname><given-names>KM</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>McBroom</surname><given-names>JW</given-names></name><name><surname>Bell</surname><given-names>JG</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><etal/></person-group><article-title>Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers. A Gynecologic Oncology Group study</article-title><source>Gynecol Oncol</source><year>2008</year><volume>111</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type=\"pmid\">18834621</pub-id></element-citation></ref><ref id=\"b29\"><label>29</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Hogdall</surname><given-names>EV</given-names></name><name><surname>Christensen</surname><given-names>L</given-names></name><name><surname>Hogdall</surname><given-names>CK</given-names></name><name><surname>Frederiksen</surname><given-names>K</given-names></name><name><surname>Gayther</surname><given-names>S</given-names></name><name><surname>Blaakaer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas</article-title><source>APMIS</source><year>2008</year><volume>116</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type=\"pmid\">18452430</pub-id></element-citation></ref><ref id=\"b30\"><label>30</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Kraszewska</surname><given-names>E</given-names></name><name><surname>Ziolkowska-Seta</surname><given-names>I</given-names></name><name><surname>Madry</surname><given-names>R</given-names></name><name><surname>Timorek</surname><given-names>A</given-names></name><name><surname>Markowska</surname><given-names>J</given-names></name><etal/></person-group><article-title>TP53 status and taxane&#x02013;platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study</article-title><source>BMC Cancer</source><year>2008</year><volume>8</volume><fpage>27</fpage><pub-id pub-id-type=\"pmid\">18230133</pub-id></element-citation></ref><ref id=\"b31\"><label>31</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Harvey</surname><given-names>M</given-names></name><name><surname>Slagle</surname><given-names>BL</given-names></name><name><surname>McArthur</surname><given-names>MJ</given-names></name><name><surname>Montgomery</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Butel</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type=\"pmid\">1552940</pub-id></element-citation></ref><ref id=\"b32\"><label>32</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Terzian</surname><given-names>T</given-names></name><name><surname>Suh</surname><given-names>YA</given-names></name><name><surname>Iwakuma</surname><given-names>T</given-names></name><name><surname>Post</surname><given-names>SM</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>GA</given-names></name><etal/></person-group><article-title>The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss</article-title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type=\"pmid\">18483220</pub-id></element-citation></ref><ref id=\"b33\"><label>33</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guessous</surname><given-names>F</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Ibidapo</surname><given-names>O</given-names></name><name><surname>Fuller</surname><given-names>L</given-names></name><etal/></person-group><article-title>PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>1723</fpage><lpage>1731</lpage><pub-id pub-id-type=\"pmid\">18339852</pub-id></element-citation></ref><ref id=\"b34\"><label>34</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Phillips</surname><given-names>KA</given-names></name><name><surname>Nichol</surname><given-names>K</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Knight</surname><given-names>J</given-names></name><name><surname>Done</surname><given-names>SJ</given-names></name><name><surname>Goodwin</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>469</fpage><lpage>473</lpage><pub-id pub-id-type=\"pmid\">10070948</pub-id></element-citation></ref><ref id=\"b35\"><label>35</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Holstege</surname><given-names>H</given-names></name><name><surname>Joosse</surname><given-names>SA</given-names></name><name><surname>van Oostrom</surname><given-names>CT</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name><name><surname>de Vries</surname><given-names>A</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name></person-group><article-title>High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>3625</fpage><lpage>3633</lpage><pub-id pub-id-type=\"pmid\">19336573</pub-id></element-citation></ref><ref id=\"b36\"><label>36</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Hallmarks of &#x02018;BRCAness&#x02019; in sporadic cancers</article-title><source>Nature Rev Cancer</source><year>2004</year><volume>4</volume><fpage>814</fpage><lpage>819</lpage><pub-id pub-id-type=\"pmid\">15510162</pub-id></element-citation></ref><ref id=\"b37\"><label>37</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Zorn</surname><given-names>KK</given-names></name><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Gangi</surname><given-names>L</given-names></name><name><surname>Chandramouli</surname><given-names>GV</given-names></name><name><surname>Awtrey</surname><given-names>CS</given-names></name><name><surname>Gardner</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6422</fpage><lpage>6430</lpage><pub-id pub-id-type=\"pmid\">16166416</pub-id></element-citation></ref><ref id=\"b38\"><label>38</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Palmer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ovarian carcinoma subtypes are different diseases: implications for biomarker studies</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e232</fpage><pub-id pub-id-type=\"pmid\">19053170</pub-id></element-citation></ref><ref id=\"b39\"><label>39</label><element-citation publication-type=\"journal\"><collab>ICON</collab><article-title>Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type=\"pmid\">12241653</pub-id></element-citation></ref><ref id=\"b40\"><label>40</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Etemadmoghadam</surname><given-names>D</given-names></name><name><surname>de Fazio</surname><given-names>A</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Mermel</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1417</fpage><lpage>1427</lpage><pub-id pub-id-type=\"pmid\">19193619</pub-id></element-citation></ref><ref id=\"b41\"><label>41</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Nelstrop</surname><given-names>AE</given-names></name><name><surname>McClean</surname><given-names>P</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>McGuire</surname><given-names>WP</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>1545</fpage><lpage>1551</lpage><pub-id pub-id-type=\"pmid\">8622070</pub-id></element-citation></ref><ref id=\"b42\"><label>42</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1534</fpage><lpage>1535</lpage><pub-id pub-id-type=\"pmid\">10995813</pub-id></element-citation></ref><ref id=\"b43\"><label>43</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Thor</surname><given-names>AD</given-names></name><name><surname>Beauchamp</surname><given-names>R</given-names></name><name><surname>Merritt</surname><given-names>V</given-names></name><name><surname>Edgerton</surname><given-names>SM</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name><etal/></person-group><article-title>p53 gene mutations and protein accumulation in human ovarian cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>4961</fpage><lpage>4965</lpage><pub-id pub-id-type=\"pmid\">8506342</pub-id></element-citation></ref><ref id=\"b44\"><label>44</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Kamoi</surname><given-names>S</given-names></name><name><surname>Amada</surname><given-names>S</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Silverberg</surname><given-names>SG</given-names></name></person-group><article-title>Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up</article-title><source>Cancer</source><year>1998</year><volume>82</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type=\"pmid\">9486579</pub-id></element-citation></ref><ref id=\"b45\"><label>45</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Angenendt</surname><given-names>P</given-names></name><etal/></person-group><article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>1807</fpage><lpage>1812</lpage><pub-id pub-id-type=\"pmid\">18772396</pub-id></element-citation></ref><ref id=\"b46\"><label>46</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Kuo</surname><given-names>KT</given-names></name><name><surname>Mao</surname><given-names>TL</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Veras</surname><given-names>E</given-names></name><name><surname>Ayhan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma</article-title><source>Am J Pathol</source><year>2009</year><volume>174</volume><fpage>1597</fpage><lpage>1601</lpage><pub-id pub-id-type=\"pmid\">19349352</pub-id></element-citation></ref><ref id=\"b47\"><label>47</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Bengtsson</surname><given-names>H</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>B</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Estimation and assessment of raw copy numbers at the single locus level</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type=\"pmid\">18204055</pub-id></element-citation></ref><ref id=\"b48\"><label>48</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Rozen</surname><given-names>S</given-names></name><name><surname>Skaletsky</surname><given-names>H</given-names></name></person-group><article-title>Primer3 on the WWW for general users and for biologist programmers</article-title><source>Methods Mol Biol</source><year>2000</year><volume>132</volume><fpage>365</fpage><lpage>386</lpage><pub-id pub-id-type=\"pmid\">10547847</pub-id></element-citation></ref><ref id=\"b49\"><label>49</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Riemenschneider</surname><given-names>MJ</given-names></name><name><surname>Buschges</surname><given-names>R</given-names></name><name><surname>Wolter</surname><given-names>M</given-names></name><name><surname>Reifenberger</surname><given-names>J</given-names></name><name><surname>Bostrom</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>6091</fpage><lpage>6096</lpage><pub-id pub-id-type=\"pmid\">10626796</pub-id></element-citation></ref><ref id=\"b50\"><label>50</label><element-citation publication-type=\"journal\"><person-group person-group-type=\"author\"><name><surname>Wang</surname><given-names>TL</given-names></name><name><surname>Maierhofer</surname><given-names>C</given-names></name><name><surname>Speicher</surname><given-names>MR</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Digital karyotyping</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>16156</fpage><lpage>16161</lpage><pub-id pub-id-type=\"pmid\">12461184</pub-id></element-citation></ref></ref-list><sec sec-type=\"supplementary-material\"><title>SUPPORTING INFORMATION ON THE INTERNET</title><p>The following supporting information may be found in the online version of this article.</p><p><bold>Supplementary experimental procedures.</bold></p><p><bold>Table S1.</bold> Samples listed by AOCS number with results of somatic <italic>TP53</italic> sequencing.</p><supplementary-material content-type=\"local-data\" id=\"SD1\"><media xlink:href=\"path0221-0049-SD1.pdf\" xlink:type=\"simple\" id=\"d32e3668\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/></supplementary-material><p><bold>Table S2.</bold> Summary of clinical, pathology and molecular review of mutation-negative serous carcinomas.</p><supplementary-material content-type=\"local-data\" id=\"SD2\"><media xlink:href=\"path0221-0049-SD2.pdf\" xlink:type=\"simple\" id=\"d32e3674\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/></supplementary-material><p><bold>Figure S1.</bold> Summary of all cases included in the pilot and validation sets.</p><supplementary-material content-type=\"local-data\" id=\"SD3\"><media xlink:href=\"path0221-0049-SD3.pdf\" xlink:type=\"simple\" id=\"d32e3680\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"pdf\"/><media xlink:href=\"path0221-0049-SD4.doc\" xlink:type=\"simple\" id=\"d32e3681\" position=\"anchor\" mimetype=\"application\" mime-subtype=\"msword\"/></supplementary-material></sec></back></article>'}"
      ]
     },
     "execution_count": 367,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x = articles.find_one({'_id': 'test', 'annotations.disease-ontology-keywords': {'$exists': True}})\n",
    "x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 375,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<pymongo.results.DeleteResult at 0x11ae012d0>"
      ]
     },
     "execution_count": 375,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "articles.delete_one({'_id': \"test\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'iterate_infectious_disease_articles' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-16-5a5cc4bd510a>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0;32mfor\u001b[0m \u001b[0marticle\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minfectious_diseases\u001b[0m \u001b[0;32min\u001b[0m \u001b[0miterate_infectious_disease_articles\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdb\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0marticlesubset\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0marticle\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'_id'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minfectious_diseases\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'iterate_infectious_disease_articles' is not defined"
     ]
    }
   ],
   "source": [
    "for article, infectious_diseases in iterate_infectious_disease_articles(db.articlesubset):\n",
    "    print(article['_id'], infectious_diseases)\n",
    "    print(\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'total_article_count' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-10-c28412185261>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtotal_article_count\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'total_article_count' is not defined"
     ]
    }
   ],
   "source": [
    "total_article_count"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'article_with_body_count' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-11-b7972d653aab>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0marticle_with_body_count\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'article_with_body_count' is not defined"
     ]
    }
   ],
   "source": [
    "article_with_body_count"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'infectious_disease_article_count' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-12-db9743c64222>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0minfectious_disease_article_count\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'infectious_disease_article_count' is not defined"
     ]
    }
   ],
   "source": [
    "infectious_disease_article_count"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
